UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
FACULTY CURRICULUM VITAE

RANK/TITLES:

Professor of Pathology (Tenured-Primary)
Professor of Surgery (Secondary)
Professor of Epidemiology (Secondary)
Director, Translational Anatomic Pathology Section
Co-Director, UAB-Tissue Biorepository
Senior Scientist, UAB-Comprehensive Cancer Center
Senior Scientist, UAB-Minority & Health Disparity Center Senior Scientist, UAB-Nutrition Obesity Research Center

Departments:

Pathology (Primary)
Surgery (Secondary)
Epidemiology (Secondary)

Business Address:

1802 6th Ave S – Physical; 1530 3rd Ave S - Mailing
WTI-420A, UAB Comprehensive Cancer Center
Birmingham, AL 35294

EDUCATION:

Institution	**Degree**	**Year**
Osmania University Hyderabad, India	Ph.D., Biochemistry & Zoology (Parasitology)	1983 – 1987
Osmania University Hyderabad, India	M.S., Zoology (Parasitology)	1981 – 1983
Osmania University Hyderabad, India	B.S., Biology	1978 – 1981
University of Alabama at Birmingham, Birmingham, AL	Certificate Course in Bioinformatics	2002

ACADEMIC APPOINTMENTS:

2010 – Present	*Professor* (*Tenured*), Department of Pathology (Primary), University of Alabama at Birmingham (UAB), Birmingham, Alabama.
2017 – Present	*Director*, Translational Anatomic Pathology Section, UAB
2019 – Present	*Co-Director*, UAB-Tissue Biorepository
2017 - Present	*Professor*, Department of Surgery (Secondary), UAB.
2019 – Present	*Professor*, Department of Epidemiology (Secondary), UAB.
2019 – Present	*Senior Scientist*, Nutrition Obesity Research Center, UAB
2007 – Present	*Senior Scientist*, Comprehensive Cancer Center, UAB.
2007 – Present	*Senior Scientist,* Minority Health and Research Center, UAB
2007 – Present	*Faculty Member* of the UAB-Medical Scientist Training Program
2005 - 2010	*Associate Professor* (*Tenured*), Department of Pathology, UAB.
2004 – 2010	*Faculty Member* of the UAB Graduate Program.
2003- 2007	*Associate Scientist*, Comprehensive Cancer Center UAB.
2003- 2007	*Associate Scientist*, Minority Health and Research Center, UAB
2002 - 2005	*Assistant Professor (tenure track)*, Department of Pathology, UAB.
2001 - 2002	*Research Assistant Professor*, Department of Pathology, UAB.
2000– 2001	*Research Instructor*, Department of Pathology, UAB.
1997– 2000	*Research Associate*, Department of Pathology, UAB.
1995 – 1997	*Post-Doctoral Fellow*, Department of Pathology, UAB.
1992 – 1994	*Senior Research Officer*, School of Microbiology, University of New South Wales, Sydney, Australia.
1990 – 1992	*Research Associate*, Department of Immunology, Malaria Research Center (Indian Council of Medical Research), New Delhi, India.
1987 – 1990	*Postdoctoral Research Fellow*, Department of Immunology, Malaria Research Center, New Delhi, India.
1985 – 1987	*Graduate Teaching Assistant*, Department of Zoology, Osmania University, Hyderabad, India.
1983 Mar– 1983 Aug	*Lecturer*, Depart. of Zoology, Arts & Science College, Hyderabad, India.

ADMINISTRATIVE AND LEADERSHIP APPOINTMENTS

2022 – Present	*Member, the UAB Fostering Interdisciplinarity Committee*, for moving research at UAB, Vice President for Research Advisory Committee
2018 – 2022	*Member, the UAB Cancer Committee*, UAB Medicine
2018 – Present	*Member*, Advisory Board for the Cancer Education & Training Program
2016 – Present	*Member*, *Research Advisory Committee*, UAB Pathology
2015 – 2019	*Member*, *Promotion and Tenure Committee*, UAB Pathology
2015 – Present	*Member, Phase 1 Clinical Trials Working Group*, UAB Cancer Center
2009 – Present	*Member,* the *Cancer Control and Population Science Program* of UAB
2022 – Present	*Member,* the *Breast Cancer Working Group*, UAB OCCC
2017 – Present	*Member,* the *Faculty Recruitment Committee of Pathology*, UAB
2015 – 2022	*Member,* the *Faculty Recruitment Committee of Hematology and Oncology*, UAB
2007 – 2015	*Member*, the *Graduate Admissions Committee* for Cancer Pathobiol. UAB

2006 – Present	*Member*, the *Medical Scientist Training Program (MSTP) Admissions Committee*, UAB
2003 – Present	*Member,* the *GI Working Group*, Comprehensive Cancer Center, and UAB
2012 – 2015	*Member,* the *Interdisciplinary and Creative Innovation Forum*, UAB
2007 – 2016	*Member,* the *Residency Admissions Committee* of UAB-Pathology
2007 - 2014	*Member,* the *Pathology Fellowship Recruitment Committee*, UAB
2007 - 2011	*Member,* the *Committee for the Molecular Testing* for HNPCC and other Lynch Syndromes.
2006-2011	*Member, the Undergraduate Honors Program*, UAB

AWARDS/HONORS:

2018	*The Albert F. LoBuglio Distinguished Faculty Award*, UAB O'Neal Comprehensive Cancer Center (one award per year given for outstanding contributions made to the field of cancer research)
2017	Nominated by UAB SOM for the *2017 Fusion Awards* by the City of Birmingham for making significant contributions to the community
2010	Part of *the US President Cancer Panel* to contribute to 2009-2010 Annual Report on significance of cancer biomarkers in special populations
2010	Innovator/Scientist Award from the *Alabama's Governor's Office and the Alabama India Business Partnership*
2009	*Charles Barkley Excellence in Mentoring Award,* University of Alabama at Birmingham
2008	*Charles Barkley Investigator Award* for contributions made to understand the molecular underpinning of racial disparity at molecular level in cancers
1990	*Foreign Travel Grant Award* to attend a scientific conference in Perth, Australia, Council of Scientific & Industrial Research, India
1983	*Incentive Fillip* - Ministry of Education, Government of Andhra Pradesh, India – for securing distinction (top 5) at post-graduate level
1981-83	*Full Scholarship* – Ministry of Education, Government of Andhra Pradesh, India for securing distinction at undergraduate level (top 5 in the state)
1981	*Merit Scholarship* – Ministry of Human Resources, Government of India – for securing distinction at undergraduate level (top 100 in the nation)

EXTERNAL ADVISORY BOARD/COMMITTEES:

2024-Current	*Chair, External Advisory Board,* P20 program, Baylor College of Medicine, Houston, TX
2017-Current	*External Scientific Advisory Board* member of the Mays Cancer Center, UT Health, San Antonio-MD Anderson Cancer Center, San Antonio, TX
2018-Current	*External Scientific Advisory Board* member of the Wake Forest Baptist Comprehensive Cancer Center, Wake Forest, NC
2017 – 2018	*Expert Facilitator*, the *Online Forum* of the National Research Mentoring Network (NRMN), "*Build Your Own Research Program"*, NIMHD/NIH
2010-2014	*External Advisory Committee* member, NCI-R25E Cancer Epidemiology/ Population Science, Dept. of Epidemiol, University of Michigan, Ann Arbor, MI
2009-2011	*Advisor* of the Faculty Development, Department of Surgery, Morehouse School of Medicine, Atlanta, GA

MAJOR RESEARCH/ACADEMIC INTERESTS, EXPERTISE, AND ACCOMPLISHMENTS:

As Professor of Pathology, Surgery, and Epidemiology; Director of Translational Anatomic Pathology; Co-Director of the UAB Tissue Biorepository; and Principal Investigator of several NIH-National Cancer Institute (NCI) funded projects, I have had extraordinarily rewarding experiences in establishing innovative educational, training, and research programs in an academic setting.

Career Background: Initially, I trained as a basic research scientist. My early research career focused on identifying the alternate glucose metabolism of an endoparasite (tapeworm) that lives in oxygen-depleted conditions. The seminal finding of my graduate research was uncovering that, in this parasite, the hexose monophosphate pathway (HNP-shunt/pentose phosphate pathway), an alternate pathway to glycolysis, is an energy metabolic pathway. My postdoctoral research on T-cell epitome mapping of malaria at the Indian Institute of Malaria, Delhi, India, highlighted immune subversion by the parasite and posed challenges in developing a vaccine against malaria. Further postdoctoral training in *Helicobacter* research at University of New South Wales, Sydney, Australia, resulted in establishing that, with experimental models, therapeutic immunization can eradicate established infections (*Lancet. 1994 Apr 9;343(8902):914-5*).

Current Translational Research: Present efforts are focused on translational research for human neoplasias, with emphasis on colorectal (CRC), pancreas, liver, bile duct, and breast cancers. Particularly the research interests include use of genomics (sequencing of DNA and multiple RNA species), proteomics (NMR, Spectrometry, IHC, Luminex, etc.), development of the models systems (3D cultures, organoids, metastatic models, and PDXs), and experimental therapeutic approaches for identification of therapeutic targets and predictive, prognostic, early detection and risk assessment biomarkers of cancers. Currently, efforts are directed towards investigator-initiated biomarker-based clinical trials (targeting mutant p53, P4HA1, and TRIP13 in CRC and pancreatic cancer) and conducting molecular correlative studies as part of clinical trials. Efforts of the laboratory will aid in the development of molecular biomarkers for early detection, diagnosis, prognosis, and precision cancer medicine.

Some of the major contributions to the translational cancer research field include: 1) Identification of molecular targets for drug development; 2) Developing and applying strategies of NCI for biomarker validation; 3) Cancer Health Disparity – Emphasizing a need for consider race/ethnicity in molecular cancer; 4) Developing large series of well-annotated cancer tissue cohorts of colorectal cancer and breast cancer for translational studies; 5) Identification of cancer-specific comorbidities and their role in determining the eligibility of older patients for recruitment into clinical trials; 6) identifying other chronic diseases as risk for cancer development (e.g. chronic kidney diseases for CRC risk); and 7) Establishing that for evaluating the clinical utility of genetic and phenotypic abnormalities especially in CRC, considering the anatomic location of tumors within the colorectum and with tumor stage, race/ethnicity, age, and gender.

***Research Group*:** My collaborative research group includes experts in the fields of cancer cell biology, molecular biology, clinical oncology, pathology, epidemiology, nutrition scientists, geographers/geo-mapping, statistics, and bioinformatics.

Research Accomplishments: At UAB, I developed a diverse research portfolio including, cancer biology, experimental therapeutics, genetics, molecular target identification, biomarker development and validation, cancer health disparities, molecular epidemiology, population sciences, biorepositories/tissue sciences, bioethics, pre-clinical (organoids/patient-derived xenografts) model development, and clinical trials. In particular, my investigations, which relate to the heterogeneity of cancer, have assessed how admixtures of patient populations with various racial/ethnic backgrounds influence cancer outcomes. In 2009, as part of the ***US President Obama's Cancer Panel***, I addressed how racial/ethnic admixtures affect the findings of molecular biomarker studies relating to cancer outcomes, and I contributed to the President's Cancer Report, which evolved into the ***President's Cancer Moonshot Program***.

I have extensive Grant Administration Experience. I have served as Principal Investigator (PI) on extramurally funded R (multiple R01s, R21s, and R03s), P (P20), and U (U54 and U01) series grants from the NCI of the National Institutes of Health (NIH), and grants from the Komen Foundation and the American Cancer Society. Overall, at UAB, my contributions aided in obtaining ***>$80 million in extramural funding*** and, for the last 17 years, the currently active U54 (competitively renewed thrice) and P20 multi-institutional research and education partnership grants from NCI have had a significant impact on cancer disparity research, community outreach, and in creating a pipeline of investigators to become the next generation of health care providers and academic and industrial leaders (https://www.uab.edu/uabmagazine/component/k2/closing-the-gap). My leadership in these research and community activities were recognized by UAB School of Medicine, and I was nominated for the ***2017 Birmingham Fusion Awards (***https://alabamanewscenter.com/2017/03/21/nominees-birmingham-fusion-awards-announced/***)***. In 2010, I received the ***Innovator/Scientist Award from the Alabama's Governor's Office/the Indo-Alabama Business Council.***

As a *team-builder,* I believe in harnessing the knowledge and skills of others for achieving specific goals. During my career, I have collaborated with faculty in the UAB School of Medicine, the School of Public Health (SOPH), the School of Health Professions (SOHP), the School of Nursing, the School of Engineering, and the College of Arts and Sciences. These collaborations have resulted in numerous joint publications, in submitting joint grant proposals, and in establishing productive partnerships. Additionally, ***my secondary appointments*** in the *Departments of Surgery* and in the *Department of Epidemiology* in the SOPH recognize these collaborations.

I have published 165 manuscripts (152 PubMed covered), 227 abstracts, and 10 book chapters, and I have delivered 177 lectures/seminars across the US and the world. For my research contributions, in 2018, I received the ***Albert F. LoBuglio Distinguished Faculty Award*** from UAB, which is given yearly to a distinguished investigator who has made outstanding contributions to cancer research.

I am a *translational researcher*, and I have been working with the ***biotech industry***. I established contracts and worked with *Almac Diagnostics*, Northern Ireland, UK, for the development and independent validation of a prognostic assay for Stage II colon cancer using FFPE tissue (*J Clin Oncol 2011, 10; 29(35):4620-6*) and with *Genomic Health* (now Exact Sciences, Madison, WI) in developing the ***FDA approved*** 12-gene signature to assess the risk of colon cancer recurrence (ColoOncotypeDx) (*BMC Cancer. 2016;16:368, 1-7*).

Education, Teaching and Mentoring: I have established partnerships with high schools, four-year colleges, and minority-serving institutions in Alabama, Georgia, and Mississippi and have implemented educational programs, increased the resources, and established scholarships, particularly to attract students from the underserved minority communities. I have taught and continue to teach several graduate level courses. Together with a faculty member, I developed a graduate level course (*GBSC-728, Cancer Genomics, Epigenetics, and Therapeutics*) and currently serve as *co-Course Director*. In 2013, I developed a summer research experience program for undergraduate students from UAB and from Historically Black Colleges and Universities (80 students), which has aided numerous students (38) in being admitted into medical school and graduate programs. The efforts of our education programs have contributed to developing a UAB undergraduate degree in Cancer Biology, which is the only one of its kind in the US.

I have *mentored* 108 scholars, including 22 physician-scientists/faculty members; 9 medical students, residents and clinical fellows; 25 post-doctoral fellows; 22 graduate/post-baccalaureate students; 9 rotating graduate students, and 21 honors/undergraduate students. Of the faculty members, I have aided 15 in submitting successful applications for extramural funding (K01, R21, R03, and SC2 awards). These trainees come from the School of Medicine, the School of Public Health, and the College of Arts and Sciences. In 2013, at UAB, I developed a *Summer Research Experience Program* for undergraduate students and till now over 102 undergraduate students are trained. For this program students are coming from several minority-serving institutions (Alabama Stage University, Oakwood

College, Stillman College, Miles College, Fisk University, Jackson State University, Mississippi Medical Center, besides well-established partnerships with Tuskegee University and Morehouse School of Medicine). Majority of these students are from underrepresented minority communities. Additionally, I trained several graduate students and postdoctoral fellows in various research activities. The students/fellows who trained with me are now well placed in residency, postdoctoral, and scientist positions in academics and industry. My mentoring skills were recognized by a ***Sir Charles Barkley Mentoring Excellence Award*** in 2009.

Service to UAB and Leadership, Administrative Experience, Fiscal, and Personnel Management. For UAB, I have served on the Residency Admission Committee, the Research Advisory Board and Promotion and Tenure Committee of the Department of Pathology, the Pilot Funding Program, and the Translational Research Group. I am a member of the UAB Medical Scientist Training Program and the Graduate School. I serve on the UAB Vice President for Research Advisory Committee for Fostering Interdisciplinarity Collaborations. At UAB, I am also a Senior Scientist of the O'Neal Comprehensive Cancer Center, the Nutrition Obesity Research Center, and the Minority Health Disparity Research Center. My additional leadership and administrative appointments on various programs/committees include service on the Advisory Board for Cancer Education and Training, the Phase-I Clinical Trials Working Group, the Cancer Control and Population Sciences Committee, the Faculty Recruitment Committee of several departments, the Graduate Admissions Committee, the Interdisciplinary and Creative Innovation Forum, the Residency Admissions Committee, and the Undergraduate Honors Program.

As *Director of the Translational Anatomic Division*, I oversee faculty research efforts, mentor junior faculty, link junior faculty with senior investigators for collaborations, provide pilot funding opportunities/mechanisms, evaluate the success of pilot research programs, mentor/guide investigators in submitting successful applications for extramural funding. As *co-Director of UAB Tissue Biorepository*, I am responsible for providing administration for staff members, providing oversight for *financial management* that includes monitoring/reviweing monthly revenue generation and expenses, hiring appropriately skilled personnel, managing the staff/technical personnel, and allocating resources and personnel to high-demand areas to accomplish the objectives in a timely manner. Currently, this facility provides services for several Departments and Schools.

For the last 17 years, the currently active U54 multi-institutional research and education partnership grant from NCI has supported more than 52 personnel (scientific, technical, administrative, and community-based support staff). As a contact PI, I have led administration of these grants, and I have been responsible for ***personnel management***, coordination, communication, ***budgetary oversight***, preparing and submitting federal financial reports, and reporting of progress to the funding agencies. Additionally, for more than 26 years, I have been running a productive research laboratory and managing an annual average of 5.5 scientific/technical personnel. This demonstrates my expertise and leadership in providing effective administration and personnel and fiscal management.

Service to Outside Institutions, and Scholarly Activities: I presently serve on ***External Advisory Boards*** of two NCI-designated cancer centers (the Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, and the UT Health San Antonio MD Anderson Cancer Center). I am also a faculty advisor for other institutions. I function as an editor (*Molecular Cancer Biology*), as an Associate Editor (*PLoS ONE* and *BMC Cancer)*, and serve on the editorial boards of various cancer research journals, and I serve on various NIH/NCI Oncology Grant Review Committees (study sections).

Community Engagement: I, together with other colleagues, a part of our NIH funded U54 program project, involved in a variety of community research/education engagement programs. These program are highly impactful in addressing cancer health disparities. I also involved in adult education program, "*Leading the Way in Lifelong Learning*," at the University of Alabama, Tuscaloosa. I worked with others in developing the course and delivered lectures on cancer screening, awareness of cancer risk, and recruitment of minority patients into clinical trials and tissue donations.

RESEARCH RECOGNITION:

2004 *Media coverage* – Our findings published in journal, *Cancer* (*2004;101:66-76*) have received extensive national and international media coverage and were reported in leading national newspapers like, New York Times, Washington Times, Chicago Tribune, Atlanta Constitution, NBC (June 24 and 25th, 2004), and the international media like, London Times, Sunday Telegraph, International Tribune, and Reuters News Agency. These findings were covered by NBC *evening news* on 25th June, 2004. Also, the highlights of these studies were posted on over 3000 web-sites.

2004 *Highlights of NIH/NCI Publications*: The studies from our laboratory were chosen by the Division of Cancer Control and Population of the National Cancer Institute (NIH) to publish on their website (http://epi.grants.cancer.gov/photokey.html).

2004 *Chairing a Session*: Invited to deliver a lecture and chair the session on *Clinical Oncology/Molecular Oncology* – during 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine, Crete, Greece (14-16th, October, 2004).

2009 *Editorial Press Release by Clinical Cancer Research*: The editorial board of this journal has selected our article, "racial differences on the prognostic significance of the *p53* gene and colorectal cancer" as noteworthy to publish in their highlights as well as release to the *Press*. Also, this article was used to promote the journals of the Association for Cancer Research (AACR). Therefore, the journal has decided to publish this article in the issue to coincide with its annual meeting in April.

2009 *Press Release by AACR, highlights*: Our *proof of principle* studies on "microRNAs in colorectal cancer" submitted to present at the annual meeting of AACR has been identified as newsworthy for the AACR 100th Annual Meeting 2009, Denver, Colorado April 18-22, 2009, and invited to participate in its press conference (newspapers, magazines, radio, television and/or trade publications).

2009 *Editorial Press Release by the American Cancer Society-Journal Cancer*: The editorial board of this journal has selected our article, "Effect of Comorbidity and Body Mass Index on the Survival of African-American and Caucasian Patients with Colon Cancer" as noteworthy to publish in their highlights as well as released to the *Press*. Also, this article was used to promote the journals of the ACS. The journal has published this article in the 1st November issue.

2009 *Invitation to Contribute to the US Presidents Cancer Panel, 2009.* The Presidents Cancer Panel has invited to present the experts view on "*biologic differences between ethnic groups and their clinical implications in cancer care*" at a session devoted to address the topic, "America's Demographic and Cultural Transformation: Implications for the Cancer Enterprise." This panel meeting was held on 27th October in Los Angeles, California.

2010 *Press Release by AACR highlights*: "Prognostic value of microRNAs in colorectal cancer-race/ethnicity." Findings that were presented by my graduate student at the 101st annual meeting of AACR has been identified, by Dr. Phillip Sharp (Nobel Laureate), as top five clinical translational studies and newsworthy and invited to present at a press conference of the Annual Meeting of 2010, held in Washington DC, April 17-21, 2010.

2015 *Chair - Workshop* on, "Cancer Biomarker Development and Validation," World Congress on Cancer Prevention Methods. Aug 27-29, Dubai, UAB

2016 *Keynote Speaker*: *"Development of Patient Population-Specific Cancer Molecular Biomarkers,"* 13th International Symposium on Recent Advances in Health Research. Jackson, MS (12th Sept.).

2016 *Keynote Speaker*: "*Translating Basic Research in the Biomedical Sciences to Address Health Disparities in Minority Communities,"* XULA-COP Ninth National Health Disparities Conference-RCMI Symposium of NIMHD/NIH. New Orleans, LA (29th Feb).

2017 Nominee of the *Birmingham Fusion Awards*: The School of Medicine, UAB has nominated for this award. This award recognizes ordinary people who do extraordinary things in the Magic City (Birmingham, AL).

2018 *International Distinguished Lecture*, "*Molecular Biomarkers of Colorectal Cancer: Translational Opportunities*." The National Institute of Immunology, New Delhi, India (6th Dec).

2019 *Chair - Workshop* on, "Cancer Biomarker Development and Validation," US-Egypt Translational Cancer Research Forum. Alexandria, Egypt (May 2-3).

2020 *Distinguished International Speaker*, "*Cancer biomarkers for individualized cancer care*," Indo-American Cancer Institute, Hyderabad, India (31st Jan).

2023 *Keynote Speaker*, *International Global Cancer Consortium Conference*, Manipal Comprehensive Cancer Care Center, Kasturba Medical College, Manipal, India (Jan 7th).

GRANT SUPPORT

CURRENTLY ACTIVE:

1. **2U54-CA118948 -15** NIH-NCI - (**U. Manne, Lead PI**) 09/01/2006-08/31/26
   Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership

   The primary objectives of this project are to maintain progress in establishment of effective cancer research programs at Morehouse School of Medicine and Tuskegee University and to conduct cancer health disparities research at UAB. The overall objective of this Partnership is to reduce and eliminate cancer health disparities.

2. **DoD W81XWH2110100** (L Wang, PI **Manne U-Co-I**) 05/01/21-04/30/25
   Title: Role of TUBB4A in Racial Disparities, Tumor Metastasis, and Chemotherapy Resistance

   This project focuses on identifying molecular mechanisms underlying TUBB4A in chemoresistance of prostate cancer.

3. **4U54-CA118948** -S**16** NIH-NCI - (**U. Manne, Lead PI**) 088/01/22-08/31/25
   Morehouse School of Medicine/Tuskegee University/UAB CCC Partnership

   Career Development Supplement, Dr. Andrea Gillis, a minority faculty of UAB Surgery Department

   The primary objectives of this project are to maintain progress in establishment of effective cancer research programs at Morehouse School of Medicine and Tuskegee University and to advance the career of a surgeon scientist by conducting cancer health disparities research at UAB.

PENDING

1. **1 R01 CA292672-01** NIH/NCI **(Manne U, PI)** 04/01/25 – 03/30/30
   Mechanisms of targeting AAA ATPase TRIP13 with DCZ0415 to block the FGFR4/STAT3 axis in colorectal cancer

   The goal of this project is to pharmacologically block TRIP13 and to elucidate the mechanisms of actions in reducing CRC growth and metastasis and develop TRIP13 as a novel therapeutic target in colorectal cancer.

2. **1 R01 CA00000-01** NIH/NCI **(Manne U, MPI,** A Singh, PI**)** 04/01/25 – 03/30/30
   KRAS-Claudin2 Signaling: A Novel Regulator of Colon Cancer Disparity

   The goal of this project is to develop claudin2 (Cldn2) as prognostic biomarker for African American patients to detect aggressiveness of colorectal cancer and to evaluate the role of Cldn2 in promoting KRAS-mediated oncogenic growth and resistance to the EGFR-therapy in KARS-mutant colorectal cancer.

3. **1R01 CA293094-A1** NIH/NCI (**Manne U, MPI**, S. Varambally, PI) 04/01/25 – 03/30/30
   Evaluation of AAA ATPase enzyme TRIP13 as prognostic biomarker and investigation of its functions in aggressive breast cancers

   The goal is to establish TRIP13 as a marker of risk and prognosis in breast cancer.

4. **1R01 CA00000-01** NIH/NCI (**Manne U, Co-I**, S. Varambally, PI) 04/01/25 – 03/30/30
   A platform development for multi-dimensional cancer proteogenomic and epigenetic data analysis and visualization

   The goal is to incorporate disparate cancer sequencing, proteomics, and other omics data to the UALCAN platform by introducing new integrative analyses with interactive visualization features to select and validate new molecular targets.

5. **DoD CA0000-01 –** DoD **(**S. Gupta PI, **Manne U, Sub award-PI)** 07/01/24 – 06/30/27
   Race based prognostic classifier for prostate cancer

   This primary goal of this project is to identify a gene expression profile of prostate cancers collected from non-Hispanic Caucasians, and African Americans patients.

RESUBMISSION

6. **1R01 CA262387-01 –** NIH/NCI **(**Varambally, PI, **Manne U, MPI)** 08/01/22– 07/31/27
   Investigating the functional role of de novo purine metabolic enzyme PAICS in prostate cancer and targeting

   Proposed investigations of this project will characterize in detail the expression of PAICS, mechanism of its action and targeting PAICS both in vitro and in pre-clinical models to evaluate it as a valuable therapeutic target. (Not fundable, resubmitting in Nov, 2024).

7. **1R21 CA292766-01** NIH/NCI (**Manne** U, PI) 07/01/24 – 06/30/26
   Elucidating relationships between TP53 SNPs, race, obesity, tumor immune microenvironment, and colorectal cancer progression

   The goal of this project is to assess the p53 72 codon polymorphism in colorectal cancer and establish the risk obesity, TME and prognosis in colorectal cancer.

8. **R01 CA0000-01 –** NIH/NCI **(**S. Gupta PI, **Manne U, Sub award-PI)** 07/01/24 – 06/30/29
   Prognostic-predication classifier for prostate cancer

   This primary goal of this project is to identify a gene expression profile of prostate cancers collected from Caucasians, and African Americans patients. (Resubmitted in Nov'2024)

9. **1R21 CA263261-01** NIH/NCI **(**Palle, PI, **Manne U, MPI)** 04/01/23– 03/31/28
Rational combination to treat BRCA proficient triple negative breast cancer

This project is aimed to identify RAD51 as a potential biomarker for TNBC patients of AA ethnicity, and test rational drug combinations to reduce the racial disparity for TNBCs. (Not fundable, resubmitting in early 2025)

10. **1 R01 CA250327-01 –** NIH/NCI/NIDDK **(Manne U, PI)** 04/01/22 – 03/31/27
P4HA1, a Biomarker of Aggressive Colorectal Cancer: Developing into a Precision Biomarker and Targeting with a Small Molecule Inhibitor

This project proposes to develop P4HA1 as biomarker of colorectal cancer to elucidate the role of this enzyme in CRC growth and metastasis, and to use a small molecule inhibitor to treat animals bearing diverse models (PDX and xenograft models) (Not fundable, resubmitting).

11. **U2CCA272015 –** NIH/NCI **(**S. Sen PI, **Manne U, Sub award-PI)** 07/01/24 – 06/30/29
Liquid Biopsy Biomarkers for Early Detection of Bladder Cancer

This primary goal of this project is to develop a tiered screening strategy for patients with early-stage, non-muscle-invasive bladder cancer. This involves liquid biopsies, non-invasive biomarker assays, and metabolome evaluations to stratify those needing referral for cystoscopy. An additional goal is to develop candidate surveillance biomarkers of bladder cancer for Hispanics, non-Hispanic Caucasians, and African Americans.

12. **1R01CA264823-01 –** NIH/NCI **(**Palle, PI, **Manne U, MPI)** 04/01/24– 03/31/29
Defining epigenetic regulators that contribute to racial disparity in triple-negative breast cancer

Proposed studies expected to determine the biological and mechanistic underpinnings, and identify prognostic biomarkers for disparity in TNBC, and aid in developing therapeutic interventions to reduce this disparity in TNBC outcomes

COMPLETED RESEARCH SUPPORT

1. **R01CA213987-NIH/NCI (**Rao CV, PI; **Manne U, Sub-award**) 12/15/16 – 11/31/23
Safer Approaches to CRC Chemoprevention (NEC)

The purpose of this project is to develop a potential early intervention using a novel, efficacious, and safer drug, mPGES-1/5-LOX inhibitor, CDPDPA that we discovered for colorectal cancer (CRC) prevention.

2. **NAS 2000007148 (**M. Fouad, PI; U. **Manne, Project Lead)** 10/01/16 – 12/30/22
(No-Cost Extension)
US-Egypt Science & Technology Development Fund of the National Academy of Sciences Transdisciplinary Collaborative Center (TCC) for Colorectal Cancer Research

The objective of this project, proposed by the University of Alabama at Birmingham (UAB) and the University of Alexandria, Faculty of Medicine (UAFM), is to establish the Transdisciplinary Collaborative Center for Colorectal Cancer Research in Egypt to reduce the high morbidity of colorectal cancer in the Egyptian population.

3. **R01CA219187-NIH/NCI)** (K. Palle, PI; **Manne U, Sub-award**) 04/01/19 – 03/31/21
Hedgehog/Gli1- mediated signaling mechanisms in ovarian cancer health disparities

The objective of this supplement award is to develop rationally designed novel therapeutic combinations to prevent and treat acquired chemoresistance and disease recurrence to improve overall and progression free survival of the ovarian cancer patients.

4. **P30CA013148** – NCI/NIH - (Manne, U , Subproject PI) 03/28/97 – 03/31/22
Cancer Center Core Support Grant – Tissue Procurement Core Facility

This Tissue Procurement (TP) Core Facility is funded to provide human tissues for research to members of the UAB Cancer Center. It is not funded to provide tissues to investigators outside UAB.

5. **1P20 CA192973-02 -** NIH/NCI **(Manne, U., Lead PI)** 10/23/14 – 9/31/2019
The Alabama State University/UAB Comprehensive Cancer Center Partnership

6. This application is to establish a Partnership between Alabama State University (ASU) and the UAB Comprehensive Cancer Center (UAB CCC) The Partnership, located in the heart of the Southeast, a region with a large, historically underserved African American population, has goals of attaining excellence in research focused on cancer health disparities.

7. **1P20CA192973-02 -** NIH/NCI **(Manne, U., PI of a Project)** 10/23/14 – 9/31/2019
The Alabama State University/UAB Comprehensive Cancer Center Partnership: Project-I BZW2 in the progression of colorectal cancers.

The primary goal of this preclinical translational proposal is to determine the role of BZW2 in tumor progression and to establish its clinical utility in colorectal cancers.

8. **Elkus Eminent Scholar Research Program in GI** (Pilot) 04/1/2018-03/31/2019
Therapeutic Value of Navitoclax based on the Expression status of miR-181b and miR-21and PDCD4 in Colon Cancer.
This project was focused on assessing the efficacy of a novel anti-Bcl-2 family inhibitor, Navitoclax.

9. UAB O'CCC and NCTN-LAPS Pilot Project 01/01/20 – 12/31/20
(**Manne U, MPI**; Kennedy C, MPI)
The Aryl Hydrocarbon Receptor (AHR) in Colorectal Cancer (CRC) Chemosensitivity

The objective of this project is to develop CRC tissue microarray resources and to evaluate the predictive value of AHR in CRC.

10. **3U54 CA118948-10S1 -** NIH/NCI **(Manne, U., PI)** 09/01/14 – 08/31/17
(*Supplement to support the career development of Dr. Esther Suswam, a minority faculty member of UAB Pathology Department)*

Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership

This supplement is to support a minority faculty member for her career development. The studies proposed in this application will evaluate the modulatory role of the TTP/Lin28/let-7 signaling axis in CRC progression (prognostic) and treatment (predictive) outcomes in CRCs of AA and CA patients, by analyzing genetic and phenotypic profiles of these molecules in samples derived from colorectal patients.

11. **3U54CA118948-10S2-**NIH/NCI**-(Manne, U., PI)** 09/01/15 – 08/31/17
(*Supplement to support the efforts of UAB to develop PDX)*

This Administrative Supplement to the currently funded *Morehouse School of Medicine/Tuskegee University/UAB CCC Partnership* grant will support the acquisition of blood and surgical specimens from patients with GI malignancies (colon and pancreas) and for development of a patient-derived xenograft model (PDX) repository at the University of Alabama at Birmingham.

12. **3U54 CA118948-09S1 -** NIH/NCI **- (Manne, U., PI)** 09/01/15 – 08/31/17
(*Supplement to support the Evaluation Core of the MSM/TU/UABCCC Partnership)*

Morehouse School of Medicine/Tuskegee University/UAB CCC Partnership

The goal of this supplement to U54 CA 118948 is to build on the current evaluation and better understand the factors that contribute to the success of the MSM-TU-UAB CCC Partnership's Community Outreach Program, Increasing Minority Participation in Clinical Trials (IMPaCT), and thus on what will make the program easily implemented in new settings.

13. UAB-CCC Cancer Prev. & Control/Basic Research Grant 10/01/15-09/30/17
(2-year Pilot project, **Manne U,** and J. Posey (R. Paluri**, MPI**)

Clinical and Molecular Assessment of Men at High Risk for Esophageal Disorder

The proposed prospective work will identify cumulative and progressive clinical and molecular factors. Through measurements performed on an at-risk population, we anticipate identifying esophageal disorders at an early stage to prevent their progression to esophageal adenocarcinomas.

14. UAB-CCC Cancer Prev. & Control/Basic Research Grant 10/01/16-09/31/18
(2-year Pilot project, **Manne U**, **MPI** and S. Sudarshan**,** MPI)
Metabolic remodeling in colorectal and renal cancers

The proposed, prospective work will identify the role of PGC-1alpha in the TCA cycle of colorectal and renal cell carcinomas, and identify novel transcriptional regulators of energy metabolism.

15. 3U54 CA118948-09S3 - NIH/NCI 09/01/14 – 08/31/16
(Manne, U., PI) (*Supplement to support the efforts of NCI to develop PDX)*

Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership

This Administrative Supplement grant will support acquisition of biological (blood) samples at the University of Alabama at Birmingham (UAB) for development of a patient-derived xenograft model (PDX) repository at NCI. Blood samples will be collected from active cancer patients (with solid or hematological malignancies).

16. R21 CA17251-02 NIH/NCI (Bumpers, H) 10/01/14 – 08/31/16
(H. Bumpers PI, **U. Manne, Co-Investigator/Sub-Contract**)

Effects of NefM1 apoptotic peptide on primary and metastatic colorectal cancer Xenografts

The goal of this proposal is to determine the extent to which NefM-1 peptide inhibits growth of primary tumors, angiogenesis and metastasis of xenografts of patient-derived colorectal cancers implanted in mice.

17. 2R01-CA098932 - NIH-NCI - (**U. Manne, PI**) 04/01/03-09/31/9
Prognostic Molecular Markers of Colorectal Adenocarcinoma (with 2 yrs. NOC)

The studies proposed in this project focused on identification of potential prognostic phenotypic molecular markers of African-American and Caucasian patients who have undergone surgery for sporadic colorectal.

18. 3R01-CA098932-S1- NIH/NCI - (**U. Manne, PI**) 10/01/09-09/31/11
(AARA-Supplement)
Prognostic Molecular Markers of Colorectal Adenocarcinoma

The studies proposed in this supplemental project were to complete the tasks listed in the original application of R01 (2R01-CA098932-08). Also, this supplement aided in maintaining the large databases created during the funding period. The goal of the original proposal was to discover

and develop prognostic (disease recurrence and survival) value of phenotypic (IHC) expression of p53, Bcl-2, MUC1, MUC4, and several other markers in colorectal adenocarcinomas tissues.

19. 1CA139629 - NIH/NCI - (**U. Manne, PI**) 09/01/09 -08/31/11
Predictive Molecular Markers of Colorectal Cancer
The studies proposed in this project were to determine the predictive value (therapy efficacy) of aberrant phenotypic expression of nuclear accumulation of p53, Bcl-2, Bax, TP, DPD, TS in sporadic stage II & III CRCs, collected only from non-Hispanic Caucasian patients treated with 5FU-based adjuvant therapies.

20. Charles Barkley Foundation- UAB-MHRC 10/01/13 – 09/31/15
(Jesus Salazar, PI) (2-year Pilot project, **Manne U,** Mentor)
Retrotransposon element profiling in colorectal cancer racial disparities.
The goal of this pilot study is to determine if structural variants of retrotransposon insertional polymorphisms (RIPs) are present in the TP53 gene and if such RIPs show genetic differences in colorectal cancers of African Americans and Caucasians.

***21.* UO1–CA086389**-NIH-NCI-(H. Lynch, PI; **U. Manne, Co-I**) 03/01/09 – 7/28/12 *EDRN Clinical Epidemiology & Validation Centers*
The pilot studies proposed in this project have evaluated value of some of the potential candidate molecular markers identified in sporadic CRCs (p53, Bcl-2, MUC1) in Lynch Syndromes (familial CRCs).

22. 2U24 CA086359-10 NIH/NCI (W.Grizzle, PI; **U. Manne, Co-PI**) 04/01/01– 03/31/11
Early Detection Research Network (EDRN): Biomarker Validation Laboratories
This effort was to provide immunopathological support to aid the NCI in validation of molecular markers for early detection and prognostic characterization of common epithelial malignancies (e.g., prostate and colon). Candidate molecular markers were assigned to this laboratory based upon reviews by the NCI.

23. Charles Barkley Foundation- UAB-MHRC 10/01/10 – 09/31/12
(L. Council, PI) (2-year Pilot project, **Manne U,** Mentor)
Molecular Basis for Chronic Hepatitis C Related Liver Disease and Hepatocellular Carcinoma in African American Patients
These studies were to determine if epigenetic disarray or genetic mutational profiles of the p53 gene are distinctly different and contribute to the progression of HCV-associated cirrhotic lesions to hepatocellular carcinomas (HCCs) and the aggressive progression of HCCs in African-American and non-Hispanic Caucasian patients.

24. 1U54CA153719-01 NIH/NCI 09/01/10–08/31/12
(J. Cannon, PI) (2-year Pilot project, **Manne U,** Mentor)
Colorectal Cancer Screening in the Metro-Birmingham Area
This work focuses on collecting data on colorectal cancer screening in populations living in the metro-Birmingham area and on analyzing the data based on race/ethnicity.

25. Charles Barkley Foundation- UAB-MHRC 10/01/11 – 09/31/13
(Shantel Hebert-Mageel, PI) (2-year Pilot project, **Manne U,** Mentor)
Prognostic and Therapeutic Significance of p53 Codon 72 Polymorphism in Triple Negative Breast Cancer in African American Women
This pilot study should determine if the Pro/Pro polymorphism in p53 is a risk factor for the development of triple negative breast cancers and a potential prognostic factor in AA women. The findings obtained will be utilized for future extramural funding applications.

26. POP138306 -SGK- (Manne U, PI) 05/01/06 – 04/31/08 (Susan G. Komen Breast Cancer Foundation)
Rabphillin-3A-Like Gene Alterations in Breast Cancer

In this project, breast cancer tissues were evaluated for the mutational status of Rabphillin-3A-Like, a potential tumor suppressor gene, and the genetic abnormalities were correlated with disease progression and clinical outcomes.

27. 1R03-CA097542-01 - NIH-NCI - **(U. Manne, PI)** 09/23/02-08/31/04
Molecular Markers of Colon Cancer: Racial Differences

This proposal was focused on identification of variations in immunophenotypic expression levels of molecular markers and correlated the variations with the aggressive forms of colorectal adenocarcinomas of African-American and Caucasian patients.

28. ACS-IRG-UAB Comprehensive Cancer (U. Manne, PI) 09/23/02-08/31/04
p53 Mutations in Colorectal Cancer: Racial Differences

This proposal identified underlying variations in genetic lesions within the p53 gene that are associated with the aggressive forms of colorectal adenocarcinomas of African-American and Caucasian patients.

29. 1 P50 11910-03S1 NIH/NIDR (J. Engler, PI; **Mann U. Co-I**)) 9/30/96 - 12/31/01
Tobacco and oral cancer

This project investigates the effect of smoking and alcohol abuse on changes in biomarker expression and in cytomorphometric parameters. In addition, vitamin levels will be evaluated in the same epithelium. Changes in vitamin levels will be correlated to determine if smoking and tobacco abuse modulate biomarkers as part of the pathogenesis of oral cancer.

30. Young Scientist Award, **Manne U** (PI) 10/1/90 – 5/31/92
University Grants Commission, New Delhi, India
Anti-Malarial Effect of Cyclosporine-A on rodent malaria models, Plasmodium berghei & Plasmodium cyanomalgi

This project assessed the effect of anti-parasitic effect of Cyclosporine-A on two mouse models of malarial parasites.

PATENTS:

1) **Title:** "Treating Helicobacter, esp. *H. pylori*, infections – by oral administration of vaccine containing Helicobacter antigens, e.g. for treating peptic ulcers or gastritis."

Patent No.: WO9503824A. International Patent Class: A61K–039/02; A61K–039/108.
***Note*:** I am one of the investigators of the project for which the patent has been granted to the University of New South Wales, Sydney, Australia.

2) **Title:** "Novel missense mutations and single nucleotide polymorphisms in the *Rabphillin-3A-Like* gene and uses thereof."

Patent No.: WO/2006/099259. International Application No.: PCT/US2006/008830
Note: I am the Principle Investigator of the studies for which the patent has been granted to the University of Alabama at Birmingham, Birmingham, AL, USA.

PUBLICATIONS: A total of ***173 manuscripts*** (159 appear in PubMed and the remaining 14 are not yet covered by PubMed), 10 books/book chapters, and 234 published abstracts.

Peer-Reviewed Manuscripts:

1. **Manne U**, Bhargavi G.Y, Rama Krishna GV: Histochemical localization of phosphatase in *Raillietina echinobothrida* (cestoda). Pro. Int. Acad. Parasitol., 1985; 6(1&2): 43-46.
2. **Manne U**, Rama Krishna G.V. Bhargavi G.Y: The Neuroanatomy of *Dipylidium canninum*(cestoda),. Ind. J. Parasitol., 1985; 9(2): 181-182.
3. Rama Krishna G.V, **Manne U**, Bhargavi G.Y: Staining and characterization of esterases of osmoregulatory system in *Avitellina centripunctata* (cestoda). Pro. Int. Acad. Parasitol., 1985; 6(1&2): 29-31.
4. Bhargavi G.Y, **Manne U**: Distribution of phosphatases in the metacercaria of *Euclinostomum heterostomum (trematoda).* Pro. Int. Acad. Parasitol., 1985 6(2): 33-37.
5. **Manne U**, Saxena Q.B: Effect of Cyclosporin - A Antimalarial drug, on the lymphocyte proliferation of Balb/C mice in vitro. J. Expt. Biol., 1990; 28: 880-882.
6. **Manne U,** Saxena Q.B: Humoral and cellular response to merozoite surface antigens 1 (MSA1) of *Plasmodium vivax* and *P. falciparum* in acute and clinically immune malaria donors. J Malariology, 1991; 93-100.
7. Biswas S, Saxena Q.B, **Manne U:** Antimalarial effect of cyclosporin-A on murine *P.berghei* and human *P.falciparum.* Ind. J. Malarial., 1991; 28: 1-8.
8. Doidge C., Gust I, Lee A, Buck F, Hazell S, **Manne U:** Therapeutic immunization against *Helicobacter* infection. The Lancet, 1994; 343: 914-915.
9. **Manne U**, Myers RB, Srivastava S, Grizzle WE. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 89(8):585-586, 1997.
10. **Manne U**, Myers RB, Moron C, Poczantek RB, Stockard CR, Weiss H, Brown D, Srivastava S, Grizzle WE. Prognostic significance of Bcl-2 protein expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer, 1997; 74:346-358.
11. Grizzle WE, Myers RB, **Manne U**. The use of biomarker expression to characterize neoplastic processes. Biotechnic & Histochemistry, 1997; 72(3):96-104.
12. **Manne U**, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S, Grizzle WE. Nuclear accumulation of p53 in Colorectal Adenocarcinomas: Prognostic importance differs with race and location of the tumor. Cancer, 1998; 83:2456-2467.
13. Myers RB, Oelschlager DK, Coan PN, Frost AR, Weiss HL, **Manne U**, Pretlow TG, Grizzle WE. Changes in Cyclin Dependent Kinase Inhibitors p21 and p27 during the Castration Induced Regression of the CWR22 Model of Prostatic Adenocarcinoma. J. Urololgy, 1999; 161: 945-949.
14. Urban D, Myers RB, **Manne U**, Weiss H, Mohler J, Perkins D, Markiewicz, Lieberman R, Kelloff G, Marshall M, Grizzle WE. Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur. Urology, 1999; 35 (5-6):429-438.
15. Myers RB, Oelschlager D, **Manne U**, Coan PN, Grizzle WE. Androgenic Regulation of Growth Factor and Growth Factor Receptor Expression in the CWR22 Model of Prostatic Adenocarcinoma. Int. J. Cancer, 1999; 82 (3), 424-429.
16. Poczantek R B, Myers R B, **Manne U**, Oelschlager D, Weiss H, Bostwick D G, Grizzle W E: Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol, 1999; 162 (4), 1462-1466.
17. Piyathilake CJ, Frost AR, Weiss H, **Manne U**, Heimburger DC, Grizzle WE. The expression of Ep-CAM (17-A) in Squamous cell cancers of the lung. Hum Pathology, 31 (4), 482-487, 2000.

18. **Manne U**, Weiss H, Grizzle WE. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int. J. Cancer (Pred. Oncol.), 2000; 89: 423-30.

19. **Manne U**, Weiss H, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin. Cancer Research, 2000; 6:4017-25.

20. Piyathilake CJ, Frost AR, **Manne U**, Bell WC, Weiss H, Heimburger DC, Grizzle WE. The Expression of Fatty Acid Synthease (FASE) is an Early Event in the Development and Progression of Squamous Cell Carcinoma of the Lung. Human Pathol, 2000; 31(9):1068-73.

21. Piyathilake CJ, Johanning GL, Frost AR, Whiteside MA, **Manne U**, Grizzle WE, Heimburger DC, Niveleau A. Immunohistochemical Evaluation of Global DNA Methylation: Comparison with in Vitro Radiolabeled Methyl Incorporation Assay. Biotechnic & Histochem, 2000; 5(6):251-8.

22. Grizzle WE, **Manne U**, Jhala N, Weiss H: The molecular characterization of colorectal neoplasia in translational research. Arch. Pathol & Lab. Medicine, 2001; 125(1):91-98.

23. Gibbons MD, **Manne U**, Carroll WR, Peters GE, Weiss HL, Grizzle WE: Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands. The Laryngoscope 2001; 111:1373-8.

24. **Manne U**, Gary BD, Oelschlager DK, Frost AR, Weiss H, Grizzle W E: Altered sub-cellular localization of Suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas. Clinical Cancer Research 2001;7(11):3495-503.

25. Grizzle WE, **Manne U**, Weiss HL, Jhala N, Talley LI. Molecular Staging of Colorectal Cancer in African-American and Caucasian Patients Using Phenotypic Expression of p53, Bcl-2, MUC-1 and $p27^{kip-1}$. Int. J. Cancer 2002; 97(3):403-409.

26. Miller CR, Gustin AN, Vickers SM, **Manne U**, Grizzle WE, Buchsbaum DJ, Diasio RB, Johnson, MR. Quantitation of cytosine deaminase mRNA by real time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-Flurocytosine toxicity in vitro. Analytical Biochemistry 2002; 3.1 (2):189-199.

27. Piyathilake CJ, Frost AR, **Manne U**, Weiss H, Bell WC, Heimburger DC, Grizzle WE. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clinical Cancer Research 2002, 734-744.

28. Piyathilake CJ, Frost AR, **Manne U**, Weiss H, Heimburger DC, Grizzle WE. Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers. Chest. 2003, 123(1):181-6.

29. Alvarez RD, Conner MG, Weiss H, Klug PM, Niwas S, **Manne U**, Bacus J, Kagan V, Sexton KC, Grubbs CJ, Eltoum IE, Grizzle WE. The Efficacy of 9-Cis-Retinoic Acid (Aliretinoin) as a Chemopreventive Agent for Cervical Dysplasia: Results of a Randomized Double-Blind Clinical Trial. Cancer Epidemiology Biomarkers Prev. 2003; 12(2):114-119.

30. Chhieng DC, Benson E, Eltoum I, Eloubeidi M, Jhala N, Jhala D, Siegal GP, Grizzle, WE, and **Manne U**. MUC1 expression in diagnosing pancreatic ductal carcinoma obtained by fine needle aspiration. Cancer (Cytopathol.) 2003, 25; 99(6):365-371.

31. **Manne U,** N. Jhala, J. Jones, H. L. Weiss, C. Chatla, Meleth, S. Suarez-Cuervo C., Grizzle W. E. Prognostic significance of $p27^{kip-1}$ expression in colorectal adenocarcinomas is associated with tumor stage. Clinical Cancer Research 2004, 10: 1743-1752.

32. Alexander D, Chatla C, Funkhouser E, Meleth S, Grizzle WE, **Manne U**. Post-surgical disparity in survival between African-Americans and Caucasians with colonic adenocarcinomas. Cancer 2004, 101:66-76.

33. **Manne U**, Chatla C, Alexander D. Impact of comorbidity on survival disparity in African-Americans and Caucasians with colorectal cancer. Cancer 2004, 101 (12):2899-2900.

34. Liu D, Sprague A, **Manne U.** JRV: An interactive tool for data mining visualization. Proc Assoc Comp Machinery 2004, 42: 442-447.

35. Liu D, Sprague A, **Manne U**. Dynamically constructing classification rules with visualization techniques. Proc Inform Knowledge Eng 2004, 29: 49-54.

36. Alexander D, Nirag Jhala, Chatla C, Funkhouser E, Coffey C, Grizzle WE, **Manne U**. High grade tumor differentiation is a poor prognostic indicator of African Americans with colonic adenocarcinomas. Cancer 2005, 103:2163-2170.

37. Grizzle WE, Semmes OJ, Bigbee W, Malik G, Miller E, Manne B, Oelschlager DK, Zhu L, **Manne U.** Use of high throughput mass spectrographic methods to identify to identify disease processes. Molecular Diagnostics 2005, 17: 211-222.

38. **Manne U**, Srivastava RG, Srivastava S. Keynote review: Recent advances in biomarker application in cancer diagnosis and treatment. Drug Discovery Today 2005, 10: 965-976.

39. Grizzle WE, Semmes OJ, Bigbee W, Zhu L, Malik G, Oelschlager DK, Manne B, **Manne U.** The need for the review and understanding of SELDI-MALDI data prior to analysis. Cancer Informatics 2005, 1(1):86-97.

40. Chatla C, Alexander D, Katkoori VR, Jhala NC, Katholi CR, Grizzle WE, **Manne U**. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinomas. Cancer Biomarkers 2005, 1:241-250.

41. Verma M, **Manne, U**. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Reviews in Hematol and Oncol 2006, 60 (1): 9-18.

42. Jhala NC, Jhala D, Vickers SM, Eltoum I, Batra S, **Manne U**, Eloubeidi M, Jones J, Grizzle WE. Biomarkers in diagnosis of pancreatic carcinoma on fine needle aspirates: A translational research application. Amer J Clin Pathol 2006, 126 (4):12-19.

43. Baker AC, Eltoum I, Curry RO, Stockard CR, **Manne U**, Grizzle WE, Chhieng D. Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med 2006, 130(10):1510-5.

44. Benavides MA, Oelschlager DK, Zhang HG, Stockard CR, Vital-Reyes VS, Katkoori VR, **Manne U**, Wang W, Bland KI, Grizzle WE. Methionine inhibits cellular growth dependent upon the p53 status of cells. Amer Journal Surgery 2007, 193:274-283.

45. Meleth S, Chatla C, Venkat Katkoori Anderson B, Hardin MJ, Al Bartolucci, Grizzle WE, **Manne U**. A comparison of proportional hazards regression to linear discriminant analysis. Cancer Informatics 2007, 2: 1-8.

46. **Manne, U**. Understanding the racial disparity in colorectal cancer will aid in individualized medicine. *Editorial*. Future Medicine (Oncology Series) 2007 3(3):235-41.

47. Alexander D, Waterbor J, Hughes T, Funkhouser E, Grizzle WE, **Manne U**. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source**:** An epidemiologic review**.** Cancer Biomarkers 2007, 3:301-313.

48. Chhieng D, Hardin M, Anderson B, **Manne U**. Predicting 5-year survival of colorectal carcinoma patients using data mining methods. Am Med Informatics 2007, 11:907-910.

49. Matthews KS, Rocconi RP, Estes JM, Conner MG, **U Manne**, Shanmugam CK, Whitworth JM, Huh WK, Alvarez RD, Straughn JM, Barnes MN. Endometrial Cancer and Risk of Hereditary Non-Polyposis Colorectal Cancer in Women Less than 50 Years of Age. Obstetrics & Gynecology 2008, 111(5):1161-6.

50. Katkoori VR, Chatla C, Jia X, Kumar S, Ponnazhagan S, Callens T, Messiaen L, Grizzle WE, **Manne U**. Clinical significance of a novel single nucleotide polymorphism in the 5'

untranslated region of the Rabphillin-3A-Like Gene in colorectal adenocarcinoma. Frontiers in Biosciences 2008, 13, 1050-1061.

51. Shanmugam SK, Katkoori VR, Jhala NC, Grizzle WE, Siegal GP, **Manne U**. p53 nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior. J Histochem & Cytochem 2008, 56(3):305-312.
52. Shanmugam SK, Katkoori VR, Jhala NC, Grizzle WE, **Manne U**. Immunohistochemical expression of Rabphillin-3A-Like (Noc2) in human endocrine pancreas and islet cell tumors. Biotech Histochem 2009, 84(2):39-45.
53. Otali D, Stockard CR, Oelschlager DK, Wan W, **Manne U**, Watts SA, Grizzle WE. Combined effects of formalin fixation and tissue processing on immunorecognition**.** Biotech Histochem 2009, 84(3):1-25.
54. Katkoori VR, Jia X, Shanmugam CK, Wan W, Meleth S, Bumpers H, Grizzle WE, **Manne U**. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clinical Can Res 2009, 15(7):2406-2416.
55. Harrington W, Bond V, Huang MB, Powell M, Lillard J, **Manne U**, Bumpers H. HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor Induced Spleens and Hepatic Metastasis. Mol & Cell Pharmacol 2009, 1(2):85-91.
56. Hines R, Chatla C, Bumpers HL, Waterbor JW, McGwin G, Funkhouser E, Coffey CS., Posey J, **Manne U**. Predictive capacity of three comorbidity indices in estimating mortality following surgery for colon cancer. J Clinical Oncology 2009, 27(26):4339-4345.
57. Koya S, Shanmugam CK, Katkoori VR, **Manne U**, Posey JA. Furthering the evidence-based management of dermatologic effects of EGFR inhibitor therapy. Current Colorectal Cancer Reports, 2009, 5(4): 179-181.
58. Hines R, Shanmugam C, Waterbor JW, McGwin G, Funkhouser E, Coffey CS, Posey J, **Manne U.** Effect of comorbidity and body mass index on colon cancer survival of African American and Caucasian patients. Cancer, 2009, 115(24):5798-5806.
59. Wang CW, **Manne U**, Reddy VB, Kapoor R. Quantitative estimation of interleukins in serum/plasma samples using a rapid and cost-effective fiber-optic dip-probe. J. SPIE (Society of Photographic Instrumentaion Engineers), 2010, 28(1):7559-7563.
60. Papageorgis P, Lambert A, Ozturk S, Gao F, Pan H, **Manne U**, Alekseyev Y, Thiagalingam A, Abdolmaleky H, Lenburg M, Thiagalingam S. Smad signaling is required for maintenance of epigenetic gene silencing during breast cancer progression. Cancer Res. 2010, 70(3):968-78.
61. Anderson B, Hardin JM, Alexander D, Meleth S, Grizzle WE, **Manne U**. Comparison of the predictive qualities of three prognostic models built on a molecular biomarker dataset of colorectal cancer. Frontiers in Biosciences, 2010, E2; 849-56.
62. Shanmugam C, Jhala NC, Katkoori VR, Wan W, Meleth S, Grizzle WE, **Manne U**. Prognostic value of MUC4 expression in colorectal adenocarcinomas. Cancer. 2010, 116(15):3577-86.
63. **Manne U,** Shanmugam C, Katkoori VR, Bovell L, Bumpers HL, miRNAs as Biomarkers for Management of Patients with Colorectal Cancer. Biomarkers in Medicine (Future Medicine-Review), 2010; 4(5):22-31.
64. Atha DH, **Manne U**, Grizzle WE, Wagner PD, Srivastava S, Reipa V. Standards for immunohistochemical imaging: A protein reference device for biomarker quantitation. J. Histochem & Cytochem 2010; 58(11):1005-1014.

65. Wang CW, **Manne U**, Reddy VB, Oelschlager DK, Katkoori VR, Grizzle WE, Kapoor R. Development of combination tapered fiber-optic biosensor dip-probe for quantitative estimation of interleukin-6 in serum samples. J Biological Sensors Journal of Biomedical Optics 2010, 15(6), 067005.

66. Katkoori VR, Suerez-Curvo C, Shanmugam C, Bumpers, H, Posey J, Grizzle, WE, **Manne U**. Bax expression is a prognostic and predictive marker in colorectal cancer. J. Gastrointestial Oncol 2010, 1:76-89. PMC3397579

67. Shanmugam C, Hines RB, Jhala NC, Katkoori VR, Zhang B Bumpers HL, Posey J, Bumpers HL, Grizzle WE, Eltoum IE, Siegal GP, **Manne U.** Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer. J. Hematol & Oncol 2011, 4:25-34.

68. Kennedy RD, Davison T, Kerr P, Black JM, Bylesjo M, Kay E, Ahdesmaki M, Farztdinov V, Goffard N, Hey P, Holt R J, McDyer F, Mulligan K, Mussen J, O'Brien E, Oliver G, Proutski V, Walker SM, Wilson C, Winter A, O'Donoghue D, Mulcahy H, O'Sullivan J, Sheahan K, Hyland J, Dhir R, Bathe O, Winqvist O, **Manne U**, Shanmugam CK, Ramaswamy S, Smith W, McDermott U, Wilson R, Longley D, Marshall J, Cummins R, Sargent DJ, Johnston PG and Harkin PD. Development and independent validation of a prognostic assay for Stage II colon cancer using formalin fixed paraffin embedded tissue. J Clin Oncol 2011, 10; 29(35):4620-6.

69. **Manne U**, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark. 2011;9(1-6):235-65.

70. Grizzle WE, Srivastava S, **Manne U**. The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark. 2011;9(1-6):21-39.

71. Grizzle WE, Srivastava S, **Manne U.** Translational pathology of neoplasia. Cancer Biomark. 2011; 9(1-6):7-20.

72. Bovell L, Shanmugam CK, Katkoori VR, Zhang B, Vogtmann E, Grizzle WE, **Manne U**. microRNAs are Stable in Formalin-Fixed Paraffin-Embedded Archival Tissue Specimens of Colorectal Cancers Stored for up to 28 Years. Front BioSci (Elite Ed). 2012; 4:1937-40.

73. Samuel T, Fadlalla K, Mosley L, Katkoori V, Turner T, **Manne U**. Dual-mode interaction between Quercetin and DNA-damaging drugs in cancer cells. Anticancer Res. 2012; 32(1):61-71.

74. Bowman E, Oprea G, Okoli J, Rizzo M, Gabram-Mendola S, **Manne U**, Smith G, Pambuccian S, Bumpers HL. Pseudoangiomatous stromal hyperplasia (PASH) of the breast: A series of 24 patients. Breast J Breast J. 2012: 18(3):242-7.

75. Tuupanen S, Yan J, Turunen M, Gylfe1 AE, Kaasinen E, Li L, Eng C, Culver DA, Kalady MF, Pennison MJ, Pasche B, **Manne U**, de la Chapelle A, Hampel H, Henderson BE, Le Marchand L, Hautaniemi S, Askhtorab H, Smoot D, Sandler R S, Keku T, Kupfer SS, Ellis NA, Haiman CA, Taipale J, Aaltonen LA. Characterization of the colorectal cancer associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genetics 2012; 205(1-2):25-33.

76. Katkoori VR, Shanmugam C, Jia X, Vitta SP, Sthanam M, Callens T, Messiaen L, Chen D, Zhang B, Bumpers HL, Samuel T, **Manne U**. Prognostic significance and gene expression profiles of p53 mutations in microsatellite-stable stage III colorectal adenocarcinoma. PLoS ONE, 2012: 7(1): e30020. doi:10.1371/journal. pone.0030020.

77. Katkoori V, Manne K, Vital-Reyes V, Rodríguez-Burford C, Shanmugam C, Sthanam M, **Manne U**, Chatla C, Abdulkadir S, Grizzle W. Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech Histochem. 2013: 88(1):38-46.

78. McNally L, **Manne U**, Grizzle W. Post-transcriptional processing of genetic information and its relation to cancer. Biotech Histochem. 2013: 88(7):365-72.

79. Vogtmann E, Shanmugam C, Katkoori R, Waterbor J, **Manne U.** Socioeconomic status, p53 abnormalities, and colorectal cancer, J Gastrointestinal Oncol 2013: 4(1):40-44.

80. Bovell L, Putcha BDK, Samuel T, and **Manne U**. Clinical Implications of MicroRNAs in Cancer, Biotech Histochem Biotechnic & Histochemistry 2013: 8897): 388-96.

81. Gales D, Clark C, **Manne U**, Samuel T. The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN Oncology, 2013; 859154; 1-8.

82. Bumpers H, Huang MB, Katkoori V, **Manne U**, Bond V.Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer. J Cancer Ther. 2013; 4(4):898-906.

83. Bovell, L, Katkoori VR, Shanmugam CK, Grizzle WE, **Manne U**. Prognostic Value of microRNAs Varies with Patient Race/Ethnicity and Stage in Colorectal Cancers. Clin Cancer Res 2013; 19(14); 3955–65.

84. Tabatabai MA, Kengwoung-Keumo JJ, Eby WM, Bae S, **Manne U**, Fouad M. Singh KP. A new robust method for nonlinear regression. J Biomet Biostat 2014; 5: 211. doi:10.4172/2155-6180.1000211.

85. Tabatabai MA, Li H, Eby WM, Kengwoung-Keumo JJ, **Manne U**, Bae S, Fouad M and Singh KP. Robust logistic and probit methods for binary and multinomial regression. *Biomet Biostat* 2014; 5:202.

86. Karthikeyan C, Lee C, Moore J, Mittal R, Suswam EA, Abbott KL, Pondugula SR, **Manne U**, Narayanan NK, Trivedi P, Tiwari AK. IND-2, a pyrimido [1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells. *Bioorg Med Chem.* 2015; 23(3):602-11.

87. Tabatabai MA, Kengwoung-Keumo J-J, Eby WM, Bae S, Guemmegne JT, **Manne U**, Fouad M, Partridge EE, Singh KP. Disparities in cervical cancer mortality rates as determined by the longitudinal hyperbolastic mixed-effects type II model. *PLoS ONE*. 2014; 9(9):e107242.

88. Samuel T, Fadlalla K, Gales D, Putcha BDK, **Manne U**. Variable NF-κB pathway responses in colon cancer cells treated with 1 chemotherapeutic drugs. *BMC Cancer* 2014; 14(1):599.

89. Fadlalla K, Elgendy R, Gilbreath E, Pondugula S, Yeshualaeshet T, Mansour M, Serbessa T, **Manne U**, Samuel T. 3-(2-Bromoethyl)-indole inhibits the growth of cancer cells and NF-κB activation. *Oncology Reports* 2015; 34(1):495-503.

90. Bumpers HL Janagama DG, **Manne U**, Basson MD, Katkoori VR. Nanomagnetic levitation 3-D cultures of breast and colorectal cancers. *J Surgical Res* 2015; 194(2):319-26.

91. Narayanan NK, Kunimasa K, Yamori Y, Mori M, Mori H, Nakamura K, Miller G, **Manne U**, Tiwari AK, and Narayanan B. Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in a colon- 26 tumor- bearing mouse model in vivo. *Cancer Medicine*. 2015, 4(11):1767-80.

92. Katkoori VR, Basson M D, Bond VC, **Manne U**, Bumpers HL. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers. *Oncotarget* 2015; 6(29):27763-77.

93. Putcha B-D K, Jia X, Katkoori VR, Salih C, Shanmugam CK, Jadhav T, Bovell L, Behring MP, Callens T, Messiaen L, Bae S, Grizzle WE, Singh KP, **Manne U**. Clinical implications of Rabphillin-3A-Like gene alterations in breast cancer. *PLoS ONE* 2015;10(6):e0129216.

94. Kumar S, Stokes J, Singh UP, Gunn KS, Acharya A, **Manne U**, Mishra M. Targeting tumorigenic Hsp70: A possible future therapy for cancer, mini review. *Cancer Letters* 2016; 374:156–166.

95. Krishn SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, Lo W-C, Fan L W-T, **Manne U** and Batra SK. Mucins and associated glycan signature in colon adenoma-carcinoma sequence. *Cancer Letters* 2016; 374(1):156-66.

96. Govindarajan R, Posey JP, Chao CY, Lu Ruixiao, Jadhav T, Javed AY, Javed A, Mahmoud FA, Osarogiagbon RU, **Manne U**. A Comparison of 12-Gene Colon Cancer Assay Gene Expression in African American and Caucasian Patients with Stage II Colon Cancer. *BMC Cancer*. 2016;16:368, 1-7.

97. **Manne U**, Jhadav T, Putcha B-DK, Suswam EA. Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. Current Colorectal Cancer Report. *Curr Colorectal Cancer Rep*, 2016; 12:332–344.

98. Council, LN, Shanmugam CK, Suswam EA, Katkoori VR, Heslin MJ, Hanna A, Jhala NC, Varambally S, **Manne U**. Association between Hepatitis C Virus Infection, P53 Phenotypes and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. *J Dig Dis Hepatol*. 2016;(5). JDDH-121 (online).

99. Kumar S, Stokes J III , Eroglu E, Scissum-Gunn K, Saldanha S, Singh U, **Manne U**, Ponnazhagan S, Mishra M. Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. *Oncotarget*, 2017; DOI: 10.18632/oncotarget.14947.

100. Kaye S, Zeng Z, Sanders M, Chittur K, Koelle PM, Lindquist R, **Manne U**, Lin Y, Wei J. Label-Free Detection of DNA Hybridization with A Compact LSPR-based Fiber-Optic Sensor. *Analyst*, 2017, 142(11):1974-1981.DOI: 10.1039/C7AN00249A.

101. Zhang W, Zhang B, Vu T, Yan G, Zhang B, Chen X, **Manne U**, Datta PK. Molecular characterization of pro-metastatic functions of ß4-integrin in colorectal cancer. Oncotarget, 2017, 27;8(54):92333-92345. doi: 10.18632/oncotarget.21290.

102. Chowdhury R, Gales D, Valenzuela P, Miller S, Yehualaeshet T, Manne U, Francia G, Samuel T. Bromoethylindole (BEI-9) redirects NF-κB signaling induced by camptothecin and TNFα to promote cell death in colon cancer cells. Apoptosis. 2017; 22(12):1553-1563. doi: 10.1007/s10495-017-1427-6.

103. Katkoori VR, **Manne U**, Chaturvedi L, Basson M, Haan P, Coffey D, Bumpers HL. Functional consequence of the p53 codon 72 polymorphism in colorectal cancer. *Oncotarget*, 2017, Aug 29;8(44):76574-76586. doi: 10.18632/oncotarget.20580.

104. Kumar S, Stokes J III , Singh UP, Scissum-Gunn K, **Manne U**, Mishra M. Prolonged exposure of resveratrol induces reactive superoxide species-independent apoptosis in murine prostate cells. Tumor Biology, 2017; 1-20, DOI: 10.1177/1010428317715039.

105. Chakravarthi BVSK, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, Jing X, Wang R, Mehra R, Asangani IA, Chinnaiyan AM, **Manne U**, Sonpavde G, Netto GJ, Gordetsky J, Varambally S. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Mol Cancer Res. 2017, DOI: 10.1158/1541-7786.MCR-17-0230.

106. Koo DH, Singh B, Jiang J, Friebe B, Gill BS, Chastain PD, **Manne U**, Tiwari HK, Singh KK. Single molecule mtDNA fiber FISH for analyzing numtogenesis. *Anal Biochem.* 2017, pii: S0003-2697(17)30131-8.

107. Zhang W, Zhang B, Vu T, Yuan G, Zhang B, Chen X, Manne U, Datta PK. Molecular characterization of pro-metastatic functions of β4-integrin in colorectal cancer. Oncotarget. 2017;8(54):92333-92345.

108. Jia X, Shanmugam C, Paluri RK, Jhala NC, Behring MP, Katkoori VR, Sugandha SP, Bae S, Samuel T, **Manne U**. Prognostic Value of Loss of Heterozygosity and Sub-Cellular Localization of SMAD4 Varies with Tumor Stage in Colorectal Cancer. *Oncotarget*, 2017; 8:20198-20212.

109. Kumar S, Singh R, Malik S, **Manne U**, Mishra M. Prostate cancer health disparities: An immuno-biological perspective. Cancer Lett. 2018;414:153-165.

110. Kumar S, Gurshaney S, Adagunodo Y, Gage E, Qadri S, Sharma M, Malik S, **Manne U**, Singh UP, Singh R, Mishra MK. Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer. Front Biosci (Landmark Ed). 2018; 23:1987-2000.

111. Kouba E, Ford A, Brown CG, Yeh C, Siegal GP, **Manne U**, Eltoum IE. Detection of BRAF V600E mutations with next-generation sequencing in infarcted thyroid carcinomas after fine-needle aspiration. Am J Clin Pathol. 2018;150(2):177-185.

112. Chakravarthi BVSK, Chandrashekar DS, Hodigere Balasubramanya SA, Robinson AD, Carskadon S, Rao U, Gordetsky J, **Manne U**, Netto GJ, Sudarshan S, Palanisamy N, Varambally S. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. Prostate. 2018;78(16):1311-1320.

113. Behring M, Shrestha S, **Manne U**, Cui X, Gonzalez-Reymundez A, Grueneberg A, Vazquez AI. Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma. Oncotarget. 2018;9(96):36836-36848.

114. Hasan S, Jacob R, **Manne U**, Paluri R. Advances in pancreatic cancer biomarkers Article. Oncology Reviews. 02/2019; 13(1), 410.

115. Bedi D, Henderson H, **Manne U**, Samuel T: Camptothecin induces PD-L1 and immunomodulatory cytokines in colon cancer cells. Medicines (Basel) 2019; 6(2).

116. Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li XB, Oprea-Ilies G, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis IO, Cantuaria G, Gupta M, **Manne U**, Agboola J, Baskovich B, Janssen EAM, Callagy G, Walsh EM, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada HA, Omonisi A, Ahmed SA, Rakha EA, Rida P, Aneja R. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers (Basel). 2019; 11(7).

117. Agarwal S, Behring M, Hale K, Al Diffalha S, Wang K, **Manne U***, Varambally S. MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer. Transl Oncol. 2019; 12(11):1461-1467. *Shared Senior Authorship.

118. Behring M, Vazquez AI, Cui X, Irvin MR, Ojesina AI, Agarwal S, **Manne U**, Shrestha S. TP53 somatic mutations are associated with immune-rich breast tumors. Molecular Genetics & Genomic Medicine. 2019:e1001. doi: 10.1002/mgg3.1001.

119. Hebert-Magee S, Yu H, Behring M, Jadhav T, Shanmugam C, Frost A, Eltoum IE, Varambally S, **Manne U**. The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype. PLoS One. 2019; 14(2):e0211734.

120. Behring M, Hale K, Ozaydin B, **Manne U.** Inclusiveness and Ethical Considerations for Observational, Translational, and Clinical Cancer Health Disparity Research. Cancer (ACS). 2019;14(2):e0211734. doi: 10.1371/journal.pone.0211734.

121. Mittal K, Toss MS, Wei G, Kaur J, Choi DH, Melton BD, Osan RM, Milligy IM, Green AG, Janssen EAM, Søiland H, Gogineni K, **Manne U**, Rida P, Rakh EA, Aneja R. A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ. Clin Cancer Res 2020; pii: clincanres.1272.2019.

122. Varambally S, Chandrashekar DS, Chakravarthi B, Robinson A, Anderson J, Agarwal S, Balasubramanya SA, Eich M-L, Bajpai AK, Davuluri S, Guru M, Guru A, Naik G, Manna DD, Acharya KK, Carskadon S, **Manne U**, Crossman D, Ferguson J, Grizzle WE, Palanisamy N, Willey CD, Crowley M, Netto G, Yang Y, and Sonpavde G. Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression. Oncogene. 2020, Mar 30. https://doi.org/10.1038/s41388-020-1275-7

123. Chandrashekar DS, Chakravarthi BVSK, Robinson AD, Anderson JC, Agarwal S, Balasubramanya SAH, Eich ML, Bajpai AK, Davuluri S, Guru MS, Guru AS, Naik G, Della Manna DL, Acharya KK, Carskadon S, **Manne U**, Crossman DK, Ferguson JE, Grizzle WE, Palanisamy N, Willey CD, Crowley MR, Netto GJ, Yang ES, Varambally S, Sonpavde G. Therapeutic actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene. 2020 Mar 30. doi: 10.1038/s41388-020-1275-7.

124. Agarwal S, Chakravarthi BVSK, Behring M, Kim H-G, Chandrashekar DS, Gupta N, Bajpai P, Elkholy A, Balasubramanya SAH, Hardy C, Al Diffalha S, Varambally S, and **Manne U**. PAICS, a purine nucleotide metabolic enzyme, is involved in tumor growth and the Metastasis of colorectal cancer. Cancers (Basel). 2020 Mar 25;12(4): pii: E772. doi: 10.3390/cancers12040772.

125. Agarwal S, Chakravarthi BVSK, Kim H-G, Gupta N, Hale K, Balasubramanya SAH, Oliver PG, Thomas DG, Eltoum IE, Buchsbaum D, **Manne U***, Varambally S*. PAICS, a de novo purine biosynthetic enzyme, is overexpressed in pancreatic cancer and is involved in its progression. Translational Oncology 2020;13(7):100776. doi: 10.1016/j.tranon. 2020.100776. Epub 2020 May 15. *Co-Correspondence

126. Davis M, Martini R, Newman L, Elemento O, White J, Verma A, Datta I, Adrianto I, Gardner K, Kim H-G, Colomb WD, Eltoum IE, Frost AR, Grizzle WE, Sboner A, **Manne U*** and Yates C*. Identification of distinct heterogenic subtypes and molecular signatures associated with African ancestry in triple negative breast cancer using quantified genetic ancestry models in admixed race populations. Cancers (Basel) 2020 May 13; 12(5):1220. doi: 10.3390/cancers12051220. *Co-Correspondence.

127. Agarwal S, Behring M, Kim H-G, Bajpai P, Chakravarthi BVSK, Gupta N, Elkholy A, Al Diffalha S, Varambally S, and **Manne U**. Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. Translational Oncology. 2020 Mar 18;13(4):100754. doi: 10.1016/j.tranon.2020.

128. Xiong M-J, Patel C, **Manne U**, Al Diffalha S. Cirrhotomimetic Hepatocellular Carcinoma: Experience of a Single Institution and Review of Literature. Hepatic Oncology. 2020 Aug 21;8(1):HEP28. doi: 10.2217/hep-2020-0015.

129. Mishra NK, Niu M, Southekal S, Bajpai P, Elkholy A, **Manne U**, Guda C. Identification of prognostic markers in cholangiocarcinoma using altered DNA methylation and gene expression profiles. Front Genet. 2020;11:522125. doi: 10.3389/fgene.2020.522125. eCollection 2020.

130. Gibson JT, Orlandella RM, Turbitt WJ, Behring M, **Manne U**, Sorge RE, Norian LA. Obesity-associated myeloid-derived suppressor cells promote apoptosis of tumor-infiltrating CD8 T cells and immunotherapy resistance in breast cancer. *Front Immunol.* 2020 Oct 6;11:590794. doi: 10.3389/fimmu.2020.590794. eCollection 2020.

131. Memon RA, Granada CNP, Patel C, **Manne U**, Heslin MJ, Harada S, Al Diffalha S. Gastric Sclerosing Epithelioid Fibrosarcoma harboring a rare FUS-CREM fusion. I*nt J Surg Pathology.* 2021 Aug;29(5):565-570. doi: 10.1177/1066896920961174.

132. Espinoza I, Agarwal S, Reddy A, Shenoy V, Subramony C, Sakiyama M, Fair L, Poosarla T, Zhou X, Orr SW, Lahr C, Bae S, Al Diffalha S, **Manne U***, Gomez CR.* Expression of Trefoil Factor 3 is decreased in colorectal cancer. Oncology Reports 2021 Jan;45(1):254-264. doi: 10.3892/or.2020.7829. Epub 2020 Oct 30. (*co-Corresponding Authors).

133. Agarwal S, Behring M, Kim H-G, Chandrashekar DS, Chakravarthi BVSK,, Gupta N, Bajpai P, Elkholy A, Al Diffalha S, Datta PK, Heslin MJ, Varambally S, and **Manne U**. TRIP13 promotes tumor formation and metastasis of colorectal cancer cells. *Mol Oncol.* 2020. doi: 10.1002/1878-0261.12821.

134. Stokes Iii J, Vinayak S, Williams J, Malik S, Singh R, **Manne U**, Owonikoko TK, Mishra MK. Optimum health and inhibition of cancer progression by microbiome and resveratrol. *Front Biosci (Landmark Ed)*. 2021 Jan 1; 26:496-517.

135. Shanmugam CK, Behring M, Luthra V, Leal Sixto M Jr., Al Diffalha, S, Varambally S, Netto GJ, **Manne U**. Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic. *MedRxiv.* 2021 Jan 20:2021.01.16.21249937. doi: 10.1101/2021.01.16.21249937.

136. Saleh M, Chandrashekar DS, Shahin S, Agarwal S, Kim H-G, Behring M, Shaikh AJ, Moloo Z, Eltoum I-E A, Yates C, Varambally S, **Manne U**. Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian women. *Transl Oncol.* 2021 Apr 8;14(7):101086.

137. Robinson AD, Chakravarthi BVSK, Agarwal S, Chandrashekar DS, Davenport ML, Chen G, **Manne U,** Beer DG, Edmonds MD, Varambally S. Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma. *Transl Oncol.* 2021 May 25;14(8):101128.

138. Behring M, Ye Y, Elkholy A, Bajpai P, Agarwal S, Kim H-G, Ojesina A, Wiener H, **Manne U***, Shrestha S*, Vazquez A*. Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent. *Cancer Medicine* 2021 Aug; 10(16):5712-5720 (co-Correspond).

139. Whitaker DE, Snyder FR, Miguel-Majors SLS, Bailey LO, Acevedo-Fontanez AI, Adams T, Adeyanju T, Arredondo E, Barajas C, Boozer-Yeary RS, Briant KJ, Brooks ME, Bruff C, Bryant BE, Cadet DL, Cannady K, Carlisle VA, Carrizosa-Ramos M, Carter VL, Cortes C, Cortez-Weir J, Dang JHT, DeJesus J, desai N, Diaz-Mendez M, Erwin DO, Escobar B, Fleming K, Flores A, Ford ME, Fredrick C, Ganey K, Garcia M, Gatson J, Grossman B, Guerra EC, Hardy CM, Hauser L, Hillyer GC, Holland J, Holt CL, Inada MK, Jones BA, Kim K, Kinney AY, Lam H, Landa V, Lang J, Lopez AM, Lopez J, De La Torre CL, **Manne U**, McNeill LH, Mitchell CL, Monge M, Morales J, Moseley M, Mummert AG, Navas-Nacher EL, Nervi L, Prabhu S, Reyes A, Rogers ML, Schifano K, Schiffelbein J, Schmitt KM, Scott T, Sempasa D, Serrano M, Sondgeroth K, Vadgama JV, Vanderpool RC, Alamo CV, Vines A, Hooper MW, Widman C, Wilkins CH, Wong C, Zabora J, Springfield SA. Screen to Save: NCI National Consortium for Colorectal Cancer Outreach and Screening Initiative to Promote Awareness and Knowledge of Colorectal Cancer in Racial/Ethnic and Rural Populations. Cancer Epidemiology, Biomarkers & Prevention (S2S NCI's research consortium) *Cancer Epid Biomark Prev*. 2020 May; 29(5):910-917.

140. Chandrashekar DS, **Manne U**, Varambally S. Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells *Scientific Reports. Sci Rep*. 2021 Aug 10;11(1):16212. doi: 10.1038/s41598-021-95733-w.

141. Burkett A, McElwee S, Margaroli C, Bajpai P, Elkholy A, **Manne U**, Wille K, Benson P. Positive Retrospective SARS-CoV-2 testing in an Alabama Autopsy case of Acute Respiratory Distress Syndrome. *Case Rep Pulmonol*. 2021 Aug 28;2021:5484239. doi: 10.1155/2021/5484239. eCollection 2021.

142. Orandi BJ, Li G, Dhall D, Bajpai P, **Manne U**, Arora N, Lu A, Coronado AC, Kassel R, Pinninti S, Lewis CE, Chapleau C, Locke JE, Gutierrez Sanchez LH. Acute Liver Failure in a Healthy Young Female with COVID-19. *J Ped Gastroenterol Nutrition.* JPGN Reports. 2021, 2:3(e108).

143. Espinoza I, Agarwal S, Reddy A, Shenoy V, Sakiyama M, Shenoy V, Fair L, Orr SW, Al Diffalha S, Prizment A, **Manne U***, Gomez CR.* Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancer (*Shared senior authorship). *Front Biosci (Landmark Edition*) 2021 Oct 30;26(10):765-776. (*co-Corresponding Authors).

144. Malik S, Davuljigari CB, Stokes James III, Musa H, Habtu B, **Manne U**, Singh R, Mishra MK. The biological clocks and cancer. *Cancer Lett.* 2022 Feb 28;527:80-94. doi: 10.1016/j.canlet.2021.12.006.

145. Mani C, Tripathi K, Omy TR, Reedy M, **Manne U**, Palle K. GLI1-Targeting Drugs Induce Replication Stress and Homologous Recombination Deficiency and Synergize with PARP-Targeted Therapies in Triple Negative Breast Cancer Cells. *BBA - Molecular Basis of Disease*. 2022 Feb 1;1868(2):166300. doi: 10.1016/j.bbadis.2021.166300.

146. Haynes T, **Manne U**, Singh S, and Mir H. Distinct Metabolism and Profiles of Pineal Hormones in Race/Ethnic Groups Leading to Colorectal Cancer Health Disparities. *Transl Oncol.* 2022 Jan 3;16:101330. doi: 10.1016/j.tranon.2021.101330.

147. Vu T, Datta A, Banister C, Jin L, Yuan G, Samuel T, Bae S, Eltoum IE, **Manne U**, Zhang B, Welner RS, Mitra K, Buckhaults P, Datta PK. STRAP is a Critical Mediator of APC Mutation-Induced Intestinal Tumorigenesis through a Feed-Forward Mechanism. 2022 Jan;162(1):193-208. doi: 10.1053/j.gastro.2021.09.010.

148. Chandrashekar DS, Karthikeyan SK, Korla PR, Athar M, Netto GJ, **Manne U**, Crieghton C, Varambally S. UALCAN: An update to the integrated cancer data analysis platform. *Neoplasia* 2022 Jan 22;25:18-27. doi: 10.1016/j.neo.2022.01.001.

149. Burkett AE, Sher SB, Patel CR, Eltoum I, Dhall D, Margaroli C, Peter S, Lee G, Bajpai P, Benson PV, **Manne U,** Al Diffalha S. Gastrointestinal Manifestations of COVID-19 Infection: Clinicopathologic Findings in Intestinal Resections Performed at Single Institution. *Front Med* (Lausanne) (section Pathology). 2022 Feb 14;9:811546. doi: 10.3389/fmed.2022.811546.

150. Shanmugam CK, Behring M, Luthra V, Leal Sixto M Jr., Al Diffalha, S, Varambally S, Netto GJ, **Manne U**. Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic. *BMJ Open.* 2022 Apr 21;12(4):e053912. doi: 10.1136/bmjopen-2021-053912.

151. Agarwal S, Afaq F, Bajpai P, Kim H-G, Elkholy A, Behring M, Chandrashekar DS, Diffalha SA, Khushman M, Sugandha SP, Varambally S, **Manne U**. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits the EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt-β/catenin pathway in colorectal cancer. *Oncol Mol Oncol.* 2022 16(8):1728-1745. doi: 10.1002/1878-0261.13201.

152. Rehman H, Chandrashekar DS, Chakravarthi BVSK, Shelton A, Nepal S, Eich ML, Robinson AD, Ma A-H, Agarwal S, Balasubramanya SAH, Naik G, **Manne U**, Netto GJ, Miller CR, Pan C-X, Sonpavde G, Varambally S, Ferguson III JE. ARID1A-deficient Bladder Cancer is Dependent on PI3K Signaling, and can be Targeted via EZH2 and/or PI3K Pharmacologic Inhibition: Therapeutic Implications. *JCI Insights.* 2022 Jul 19:e155899. doi: 10.1172/jci.insight.155899.

153. Martini R, Delpe P, Chu TR, Arora K, Lord B, Verma A, Bedi D, Karanam B, Elhussin I, Chen Y, Gebregzabher E, Oppong JK, Adjei EK, Jibril A, Awuah B, Bekele M, Abebe E, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Chitale d, Bensenhaver JM, Nathanson SD, Jackson L, Petersen LF, Proctor E, Stonaker B, Gyan KK, Gibbs L, Monojlovic Z, Kittles R, White J, Yates Clayton, **Manne U**, Gardner K, Mongan N, Cheng E, Ginter P, Hoda S, Elemento O, Robine N, Sboner A, Carpten J, Newman L, Davis MB. African ancestry-associated gene expression signatures and functional pathways in triple negative breast cancer underlie diverse tumor biology linked to adverse clinical outcomes, a comparison across women of African descent. *Cancer Discovery* 2022 Nov 2;12(11):2530-2551. doi: 10.1158/2159-8290.CD-22-0138.

154. Wells GA, Glasgow JN, Nargan K, Lumamba K, Rajhmun M, Maharaj K, Perumal L, Matthew M, Hunter RL, Pacl H, Lever JEP, Stanford D, Singh S, Bajpai P, **Manne U**, Benson P, Rowe SM, le Roux S, Sigal A, Tshibalanganda M, Wells C, du Plessis A, Msimang M, Naidoo T, Steyn AJC. A high-resolution 3D atlas of the spectrum of tuberculous and COVID-19 lung lesions. *EMBO Molecular Medicine* 2022 Nov 8;14(11):e16283. doi: 10.15252/emmm.202216283.

155. Behring M, Agarwal S, Bajpai P, Elkholy A, Kim H-G, Wei S, Shrestha S, **Manne U**. Age-dependent heterogeneity of lymph node metastases and survival identified by analysis of a national breast cancer registry. *J Pharmacy and Pharmacol Res*, 2022;6(3):147-157. doi: 10.26502/fjppr.060.

156. Obuya S, Elkholy Amr, Avuthu N, Behring M, Bajpai P, Kim H-G, El-Nikhely N, Akinyi P, Orwa J, Afaq F, Abdalla M, Micheal A, Farouk M, Bateman LB, Fouad M, Saleh M, Guda C, **Manne U***, Arafat W*. A signature of *Prevotella copri* and *Faecalibacterium prausnitzii* depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients. *J Gastrointestinal Oncol*,| 2022 Oct; 13(5):2282-2292. https://dx.doi.org/10.21037/jgo-22-116. (*co-Corresponding Authors).

157. Bajpai P, Banerjee NS, Moore DW, Kim H-G, Afaq F, Contreras CM, Heslin MJ, Reddy VB, Peter S, Varambally S, Diffalha SA, **Manne U**. Developing 3D organoid raft cultures from patient-derived xenografts as rapid models to screen efficacy of experimental Therapeutics. *Int. J. Mol. Sci.* 2022, 23(22):14392.

158. Karthikeyan SK, Nuo X, Ferguson JE III, Rais-Bahrami S, Qin ZS, **Manne U**, Netto GJ, Chandrashekar DS, Varambally S. Identification of androgen response-related lncRNAs in prostate cancer. *Prostate.* 2023 May;83(6):590-601. doi: 10.1002/pros.24494.

159. Dhall D, Makhoul E, Taguibao R, Waters K, Zhang W, Vail E, Lee G, Diffalha SA, Patel C, **Manne U**, Behring M, Chopra S, Harada S. Molecular Characterization of Visible Low Grade Dysplastic lesions in Patients with Inflammatory Bowel disease. *Hum Pathol.* 2023 May;135:108-116. doi: 10.1016/j.humpath.2023.01.009.

160. Mani C, Acharya G, Ochola D, Mereddy N, Pruitt K, **Manne U** and Palle K. Racial differences in RAD51 expression is regulated by miRNA-214-5P and its inhibition synergizes with olaparib in Triple-Negative Breast Cancer. *Breast Cancer Research.* 2023 Apr 20;25(1):44. doi: 10.1186/s13058-023-01615-6.

161. Southekal S, Mishra N, Shakyawar SK, Bajpai P, Elkholy A, **Manne U**, Guda C. Molecular subtyping and survival analysis of osteosarcoma reveals prognostic biomarkers and key canonical pathways. *Cancers,* 2023 Apr 4;15(7):2134. doi: 10.3390/cancers15072134.

162. Patel C, Behring M, Al Diffalha S, Dhall D, Lee G, Shanmugam CK, Grizzle WE, **Manne U**. Immunophenotypic Profiles and Prognosis for Colorectal Mucinous Adenocarcinomas are Dependent on Anatomic Location. *Cancer Medicine.* 2023; doi: 10.1002/cam4.5803.

163. Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, Xiu J, Korn WM, Berger MD, Lenz H-J, Puccini A, Fontana E, Shields AF, Marshall JL, Hall M, El-Deiry W, Hsieh D, Tabernero J, Pichler R, Khushman M, **Manne U**, Lou E, Wolf D, Sokolova V, Wimmer K, Schnaiter S, Zeimet AG, Gulhati Pat, Widmann G, Seeber A. Genomic context of PBRM1 mutations in biliary tract cancer reveals therapeutic vulnerabilities to agents targeting DNA damage repair targeting drugs. *NPJ Precision Oncology.* 2023 Jul 3; 7(1):64.

164. Elkholy A, Avuthu N, Behring M, Abdalla M, Behring M, Bajpai P, Kim H-G, Header D, Abo Elwafa RAH, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W, **Manne U**. Microbiome Diversity in African American, European American, and Egyptian Colorectal Cancer Patients. *Heliyon*. 2023 Jul 7; 9(7):e18035.

165. Agarwal S, Bajpai P, Behring M, Kim H-G, Afaq F, Elkholy A, Chandrashekar DS, Chakravarthi BVSK, Gupta N, Diffalha SA, Sugandha SP, Varambally S, **Manne U**. BZW2 expression, regulated by miR98, c-MYC, and EZH2, activates WNT/β-catenin signaling and promotes metastasis of colorectal cancer. *Mol Cancer Res* 2023 Jul 5; 21(7):698-712.

166. Yamada HY, Xu C, Jones KL, O'Neill PH, Venkateshwar M, Chiliveru S, Kim HG, Doescher M, Morris KT, **Manne U***, Rao CV*. Molecular disparities in colorectal cancers of White Americans, Alabama African Americans, and Oklahoma American Indians. *NPJ Precision Oncology.* 2023 Jul 3; 7(1):64. (*Co-Corresponding authors).

167. Paluri RK, Haris H, Li P, Gbolahan O, Jacob R, **Manne U.** Role of Chemoradiation in Gallbladder Cancer – A Single Institution Retrospective Analysis. *J Gastrointest Oncol*, 2023 Oct 31; 14(5):2212-2220.

168. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer. Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry KL, Holmes T, Wang J, Huang CH, Ward AB, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Ganji PN, Maxuitenko Y, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponenko V, Abdelkarim H, Mitra AK, Boyd MR, **Manne U**, Bae S, El-Rayes BF, Piazza GA. bioRxiv. 2024 Jan 24:2023.05.17.541233. doi: 10.1101/2023.05.17.541233.

169. Dhasmana S, Dhasmana A, Rios S, Enriquez-Perez IA, Khan S, Afaq F, Haque S, **Manne U**, Yallapu MM, Chauhan S. An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. *Comput Struct Biotechnol J.* 2023 Nov 17;21:5765-5775.

170. Gunturu D, Hassan M, Bedi D, Datta P, **Manne U**, Samuel T. Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision Medicine. *Current Oncol*. 2024;31(3):1195-1206. doi: 10.3390/curroncol31030089.

171. Afaq F, Agarwal S, Bajpai P, Kim H-G, Behring M, Elkholy A, Chandrashekar DS, Diffalha SA, Sugandha SP, Khushman M, Paluri R, Samuel T, Varambally S, **Manne U**.

Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. *Neoplasia*. 2024 Jan;47:100951. doi: 10.1016/j.neo.2023.100951.

172. Khushman M, Toboni M, Xiu J, **Manne U**, Farrell A, Lou E, Shields A, Philip P, Salem M, Abraham J, Spetzler D, Marshall J, Jayachandran P, Hall M, Lenz H-J, Sahin I, Seeber A, Powell M. The differential response to immune check point inhibitors according to different mismatch repair alterations. *Clin Cancer Res*. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-23-3004.

173. Bajpai, P, Agarwal S, Afaq F, Diffalha SA, Chandrashekar DS, Kim H-G, Bash R, Miller CR, Singh SK, Singh R, Varambally S, Ganji PR, Manne A, Paluri R, Khushman M, **Manne U**. A novel drug combination with dual JAK/HDAC inhibitor to reduce regorafenib toxicity in colorectal cancer. *J Exp Clinical Cancer Res* (In Press).

Manuscripts Submitted (In Review)

1. Bajpai, P, Agarwal S, Jadhav T, Chen D, Sugandha SP, Al Diffalha S, Varambally S, and **Manne U**. Distinct Gene Expression Profiles of Colorectal Cancer: Race/Ethnicity (In Review).
2. Yamada HY, Rout M, Xu C, O'Neill PH, Afaq F, Moris K, Sanghera D, **Manne U***, Rao CV*. Mutational Disparities in Survival Critical Genes in Colorectal Cancers of White Americans, Alabama African Americans, and Oklahoma American Indians (In Review).
3. Chandrashekar DS, Afaq F, Karthikeyan SK, Athar M, Shrestha S, Singh R, **Manne U**, Varambally S. Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cells (In Review).
4. Kim S, Itani M, Liu X, Sun L, Krysiak K, Fox N, Firwana B, Al Diffalha S, **Manne U**, Seeber A, Molly K, Frank M, Stubblefield H, Pedersen K, Lim K, Abushukair H, Khushman M. The treatment sequence for patients with colorectal cancers harboring TRK fusion and microsatellite instability-high. A Case Report and Literature Review (In Review).
5. Ghandour F, Green KD, Bajpai P, Patel CR, **Manne U**, Al-Diffalha S. New Ganglion Cell Marker B3GNT6: Advancing Hirschsprung's Disease Diagnosis (In Review).
6. Ghandour F, Cannon R, MD, Patel CR, Akce M, Galgano S, **Manne U**, Gbolahan, Khushman M, Al-Diffalha S. Diagnostic Complexity and Management Dilemmas in Solid Tubulocystic Variant of Intrahepatic Cholangiocarcinoma: Case series (In Review).
7. Ghandour F, Zein-Sabatto Bassel, Joao L, Patel CR, Dhall D, **Manne U**, Al-Diffalha S. Exploring Fibronodular Hepatocellular Carcinoma: A Case Series Investigating Histopathological and Clinical Characteristics, and its Potential Association with Cirrhosis (In Review).
8. Foote, J, Mattox T, Keeton A, Chen X, Smith F, Berry K, Holmes T, Wang J, Wang C-H, Ward A, Hardy C, Fleten K, Flatmark K, Yoon K, Sarvesh S, Ganji P, Maxuitenko Y, Valiyaveettil J, Carstens J, Bushsbaum D, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponeko V, Abdelkarim H, Mitra A, Boyd M, **Manne U**, Bae S, El-Rayes B, Piazza G. A novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer (In Review).
9. Amara CS, Kamal AHM, Hassan MK, Piyarathna DWB, Ambati CSR, Gangnus T, Putluri V, Arun AK, Seeley EH, Liu X, **Manne U**, Kim H_G, Netto GJ, Gassman NR, Villanueva H, Bollag RJ, Parsawar K, Terris MK, Eberlin LS, Lerner SP, Creighton C, Lotan Y, Putluri

N. Cigarette smoke promote the tumor progression via FASN in bladder cancer and rewiring the fatty acid metabolism (In Review).

10. Manne A, Esnakula A, Sheel A, Amir S, **Manne U**, Paluri R, He K, Yang W, Sohal D, Kasi A, Noonan A, Mittra A, Hays J, Malalur P, Roychowdhury S, Rahman S, Jin N, Cloyd J, Tsai S, Ejaz A, Pitter K, Miller E, Hasanov E, Dillhoff M, Yu L. Clinical Significance of Mature MUC5AC Expression In Resected Pancreatic Ductal Adenocarcinoma (In Review).
11. Manne A, Boa Y, **Manne U**, Paluri RK, Kasi, A, Thanikachalam K, Sheel A, Sara A, He K, Noonan AM, Esnalula A. Hays JL, Mittra A, Malalur P, Rahman Sm Roychowdhury S, Elkatib R, Jin N, Cloyd JM, Dillhoff M, Yu L, and Yang W. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Before Resection (In Review).
12. Gillis, A, Herring B, Guenter R, Chen, W, Chen D, Chen, H, Rose B, **Manne U**, Bhatia S. Validity of geographic-level social determinant of health metrics in pancreatic neuroendocrine tumors (In Review).
13. Kumar R, Duyar-Ayerdi S, Sundaresan A, Srinivasasainagendra V, Pedamallu CS, Behring M, Chandrashekar DS, Eltoum I-E, Varambally S, Lefkowitz E, Tiwari HK, Shrestha S, Chaudhary LN, Kirby JR, Yates C, **Manne U***, Ojesina AI.*(*co-Corresponding Authors).
14. Manne A, Esnakula A, Sheel A, Sara A, **Manne U**, Paluri RK, He K, Yang W, Sohal DP, Kasi A, Noonan AM, Mittra A, Hays J, Roychowdhury S, Malalur P, Rahman S, Jin N, Cloyd JM, Tsai S, Aslam E, Pitter K, Miller E, Thanikachalam K, Dillhoff M, Yu L. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts the Treatment Response and Outcomes (In Review).
15. Nagaraju GP, Saddala MS, Foote JB, Khaliq AM, Masood A, Golivi Y, Bandi DSR, ; Sarvesh S, Reddy SP, Switchenko J, Carstens JL, Akce M, Herting C; Alese OB, Yoon KJ, **Manne U,** Bhasin MK; Lesinski GB, Sukhatme VP, El-Rayes B. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine: A single-cell RNA analysis (In Review).

BOOKS/BOOK CHAPTERS:

1. Grizzle WE, Myers RB, **Manne U**, Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. John Walker's Methods in Molecular Medicine - Tumor Marker Protocols, (Eds. Hanausek, Walaszek Z). The Humana Press Inc, Totowa, NJ: 143-160, 1998.
2. Grizzle WE, Myers RB, **Manne U**, Srivastava S. Factors affecting immuno-histochemical evaluation of biomarker expression in neoplasia. John Walker's Methods in Molecular Medicine - Tumor Marker Protocols, (Eds. Hanausek, Walaszek Z). The Humana Press Inc, Totowa, NJ: 161-179, 1998.
3. Grizzle WE, Shibata D, **Manne U**, Myers RB, Frost AR. Molecular and histopathologic changes in the development of colorectal neoplasia. In: Molecular Pathology of Early Cancer, (Eds. S. Srivastava, D. E. Henson & A. Gazdar), IOS press, Van Diemenstratt, Amsterdam, Netherlands. Chapter 10, pp. 135-170, 1999.
4. Grizzle WE, Semmes OJ, Bigbee WL, Malik G, Miller E, Manne B, Oelschalger DK, Zhu L, **Manne U**. Use of mass spectrographic methods to identify and characterize disease processes with emphasis on high throughput methods. In: *Molecular Diagnostics*. (Eds. G. Patrinos, W. Ansorg). 2007.

5. **Manne U**, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and Progression of Colorectal Neoplasia. In: *Translational Pathology of Early Cancer,* (Eds. WE Grizzle, S Srivastava), (Eds. Hanausek, Walaszek Z). The IOS Press, Amsterdam, the Netherlands: 2010.
6. Grizzle WE, Srivastava S, **Manne U**. Translational Pathology of Neoplasia. In: *Translational Pathology of Early Cancer.* (Eds. S Srivastava, WE Grizzle) IOS Press BV, Amsterdam, The Netherlands; 2012;7-20.
7. Grizzle WE, Srivastava S, **Manne U**. The biology of incipient, pre-invasive or intraepithelial neoplasia. In: *Translational Pathology of Early Cancer*, (*Eds.* S Srivastava, WE Grizzle), IOS Press BV, Amsterdam, The Netherlands; 2012;21-39.
8. **Manne U**, Shanmugam C, Katkoori VR, Grizzle WE. Development and progression of colorectal neoplasia. *In: Translational Pathology of Early* Cancer, (Eds. S Srivastava, WE Grizzle), IOS Press BV, Amsterdam, The Netherlands; 2012;235-265.
9. **Manne U,** *Editor of a special issue* of the journal *Molecular Cancer Biology*, *Molecular Disparities in Cancer Biology,* and Published by the *eOpen Access* Publishing, Lithonia, GA, USA; 2014.
10. **Manne U,** Putcha BDK, Samuel T, Srivastava S. Book Chapter, *Prognosis and Predictive Biomarkers: Colorectal Cancer. Chapter-13.* In: Biomarkers in Cancer Screening and Early Detection (Ed. S Srivastava), (ISBN: 978-1-118-46880-7).Wiley Oxford, UK; 2017.

PUBLISHED ABSTRACTS/PODIUM PRESENTATIONS (***A total of 241 published abstracts***):

1. Rama Krishna GV, **Manne U** & S. S. Simha: Studies on the cercarial emergence pattern from two snail hosts, *Lymnea luteola* and *Melanoides tuberculatus* IV National Congress of Parasitology, Pant Nagar, U.P. India, 8-9 March, 1985.
2. Rama Krishna GV, **Manne U** & S. S. Simha: The neuroanatomy and esterase distribution in the cercaria of *Echinochasmus* (trematoda) - Ibid.
3. **Manne U**, Biswas S & Saxena QB: Effect of cyclosporin-A on the immune system of normal mice and mice infected with *Plasmodium berghei* in vitro: 57th Annual Meeting of the SBC (I) October 9-12, 1988 at New Delhi, India.
4. **Manne U** & Saxena QB: Effect of cyclosporin-A on the immune system of BALB/C mice infected with *P.berghei* in vivo: 26th Annual Scientific Meeting of Australian Society for Parasitology. 8-11 August 1990, at Fremantle, Perth, Australia.
5. **Manne U**, Kabilan L, Saxena SK, Biswas S, Roy A, Saxena QB & Good MF: T-cell proliferation responses to merozoite surface antigen - 1 (MSA1) of *P.falciparum* & *P.vivax*. XVII Annual Conference of Indian Immunology Society, 7-9 October 1991, at N Delhi, India.
6. Roy A, Kabilan L, Biswas S, Saxena SK, Roy A, **Manne U**, Yadav R.P.S & Ghosh SK: Antibodies to the ring infected erythrocyte surface antigen peptides and the circum sporozoite peptide of *P.falciparum* in Rourkela, Orissa -Ibid
7. Kabilan L, Biswas S, Roy A, Saxena SK, **Manne U,** Ghosh SK & Yadav R.P.S: Absence of antigenic diversity in Pf155/RESA among Indian isolates. - Ibid.
8. Buck F, Doidge C, Lee A, Hazell S, **Manne U**, Gust I: Effective protection against *Helicobacter felis* infection in mice with *H. pylori* antigens. Beginning the Second Decade and the VIIth Workshop of the European *Helicobacter Pylori* Study Group, September 30 - October 1, 1994, Houston, Texas, USA. American Journal of Gastroenterology, 89 (8): 1285-1422 (Abstract # 201), 1994.

9. Doidge C, Lee A, Buck F, Hazell S, **Manne U**, Gust I: Therapeutic immunization against *Helicobacter pylori*. American Journal of Gastroenterology, 89 (8): 1285-1422 (Abstract # 339), 1994 - Ibid.
10. **Manne U**, Myers R B, Moron C, Srivastava S, Grizzle W E: Racial distribution of p53 mutations in colorectal adenocarcinoma. 1996 Annual Meeting of the United States and Canadian Academy of Pathology. Modern Pathology. 9, (1): 62 A (Abstract # 347), 1996.
11. **Manne U**, Myers R B, Moron C, Srivastava S, Grizzle W E: p53 and Bcl-2 protein expression in colorectal cancer. 1996 Annual Meeting of the United States and Canadian Academy of Pathology. Modern Path. 9, (1): 62 A (Abstract # 348), 1996.
12. **Manne U**, Brown D, Myers R B, Perucho M, Srivastava S, Moron C, Grizzle W E: Racial distribution and p53 abnormalities in mucinous and non-mucinous colorectal adenocarcinomas. Eighty-Seventh Annual Meeting of the American Association for Cancer Research. Proc Amer Assoc Cancer Res 37: 253A, (Abstract # 1724), 1996.
13. Myers R B, **Manne U**, Grizzle W E, Deshane J, Wright M, Curiel DT: Intracellular antibody mediated down-regulation of p 185^{erbB-2} expression in malignant prostatic cells. 1996 Eighty-Seventh Annual Meeting of the American Association for Cancer Research. Proc Amer Assoc Cancer Res 37: 342A, (Abstract # 2334), 1996.
14. **Manne U**, Shibata D, Tsao J, Srivastava S, Grizzle W E: p53 nuclear accumulation (p53NA), Bcl-2 expression and clinicopathological characteristics of primary colorectal adenocarcinomas (CAC) with microsatellite instability (MSI). Proc Amer Assoc Cancer Res 38: (Abstract #1003), 1997.
15. Grizzle WE, Myers RB, **Manne U**, Beenken SW, Urban DA, Alvarez RD, Barnes S: Use of biomarkers in nutritional studies of neoplastic processes. International Conference on Nutrition and Cancer, July 16-19, Irvine, CA, 1997.
16. Roland P, Myers R B, Conner M G, **Manne U**, Alvarez R D, Grizzle W E: CD44 expression in cervical dysplasia. Proc Amer Assoc Cancer Res 38: (Abstract #721), 1997.
17. Poczantek R B, Myers R B, **Manne U**, Bostwick D G, Grizzle W E: Expression of the 17-1-A tumor-associated antigen in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Proc Amer Assoc Cancer Res 38: (Abstract #2861), 1997.
18. **Manne U**, Myers RB, Oelschlager D, Weiss HL, Perucho M, Grizzle WE. Association between the Amount of mucin and p53 Abnormalities in Colorectal Adenocarcinomas. Proceedings American Association for Cancer Research (Abstract #3734) 39:549, 1998.
19. **Manne U**, Myers RB, Sekar CM, Grizzle WE. Differential Growth Inhibitory Effects of Inositol Hexophosphate on Colon Cancer Cell Lines. Proceedings American Association for Cancer Research (Abstract #4078) 39:599, 1998.
20. Myers RB, **Manne U**, Frost AR, Grizzle WE, LeBoeuf RD. Expression of Suppressin in Neoplasia of the Breast. Proceedings American Association for Cancer Research (Abstract #4241) 39:623, 1998.
21. **Manne U**, Oelschlager D, Grizzle WE, LeBoeuf RD. Expression of Suppressin, a Candidate Tumor Suppressor Gene, in Colorectal Adenocarcinomas. Proceedings American Association for Cancer Research (Abstract #4242) 39:623, 1998.
22. Beenken SW, Manne U, Myers RB, Weiss H, Krontiras H, Malone W, Peters GE, Kelloff GJ, **Grizzle WE**. Increased Expression of Transforming Growth Factor-Alpha, Epidermal Growth Factor Receptor, erbB-2 and erbB-3 in Dysplastic Leukoplakia. Amer Soc Clin Oncol, Los Angeles, CA, May 16-19, 1998.
23. Piyathilake CJ, **Manne U**, Heimburger DC, Weiss H, Frost AR, Grizzle WE. TGF-α Expression in Epithelial Hyperplasia/Dysplasia and Invasive Squamous Cell Carcinoma

(SCC) in the Human Lung. American Society of Preventive Oncology, Annual Meeting, Bethesda, MD, March 4-6, 1998.

24. Pederson LC, Beenken SW, **Manne U**, Myers RB, Weiss H, Malone W, Peters GE, Kelloff GJ, Grizzle WE. Changes in the expression of p185erbB-2 in dysplastic Leukoplakia. Fifth Research Workshop on the Biology, Prevention and Treatment of Head and Neck Cancer, August 28-30, 1998.
25. **Manne U**, Oelschlager DK, Gary BD, Frost AR, Weiss HL, LeBoeuf RD, Grizzle WE. Altered subcellular localization of Suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas. Proceedings American Assoc. for Cancer Research (Abstract # 4613) 40: 1999.
26. Gibbons MD, **Manne U**, Carroll WR, Peters GE, Weiss HL, Grizzle WE. Phenotypic expression of p185erbB-2 in malignant salivary gland tumors. Proceedings American Assoc. for Cancer Research (Abstract # 1269) 40: 1999.
27. Urban D, Myers R, **Manne U**, Weiss HL, Mohler J, Poulin N, Grubbs C, Lieberman R, Kellof G, Grizzle WE. Evaluation of biomarker modulation by fenretinide (4-HPR) in prostate cancer patients. Proceedings American Association for Cancer Research (Abstract # 2849) 40: 1999.
28. **Manne U**, Weiss HL, Grizzle WE. Bcl-2 expression is associated with improved prognostiis in African-Americans and Caucasians with colorectal adenocarcinomas. Proceedings American Assoc. for Cancer Research (Abstract # 3789) 41: 2000.
29. Piyathilake CJ, Johanning GL, Frost AR, Whiteside MA, **Manne U**, Grizzle WE, Heimburger DC, Niveleau A. Immunohistochemical evaluation of global DNA methylation: Comparison with *in vitro* radiolabelled methylation incorporation assay. Proceedings of American Association for Cancer Research (Abstract # 3174) 41: 2000.
30. Piyathilake CJ, Frost AR, Weiss H, **Manne U**, Heimburger DC, Grizzle WE. The expression of Ep-CAM (17-1A) is associated with progression of squamous cell carcinoma of the lung. Proceedings of American Association for Cancer Research (Abstract # 4391) 41: 2000.
31. **Manne U**, Jhala N, Jones J, Weiss H, Grizzle WE. Prognostic Markers of Colorectal Adenocarcinoma - Nuclear Accumulation of p53, Expression of Bcl-2, MUC1 and Suppressin: Effect of Ethnicity and Anatomic location. Proceeding of the Early Detection Network Meeting, Chicago, IL, September 26 – 28, 2000.
32. Gustin A, **Manne U**, Myers RB, Weiss H, Peters GE, Perloff M, Malone W, Grizzle WE, Beenken SW. Increased Expression of Transforming Growth Factor-Alpha, Epidermal Growth Factor Receptor, erbB-2 and erbB-3 in Dysplastic Oral Leukoplakia. American Association for Cancer Research Annual Meeting, San Francisco, CA, April 1-5, 2000.
33. Frost A, Myers R, **Manne U**, Weiss H, Urist M, Heslin M, Grizzle W, Beenken SW. Evaluation of erbB-2, TGF-Alpha and PCNA Expression in a Study of Difluromethylornithine (DFMO) in Patients with Breast Ductal Carcinoma *In Situ*. American Society for Clinical Oncologists Annual Meeting, 2000.
34. Piyathilake CJ, Frost AR, **Manne U**, Weiss H, Heimburger DC, **Grizzle WE**. Elevated Expression of Fatty Acid Synthase (FASE) in Squamous Cell Cancer of the Lung. FASEB: Experimental Biology 2000, Vol. 14(4), Abstract #552.1, March 15, 2000
35. Gibbons MD, **Manne U**, Carroll WR, Peters GE, Weiss HL, Grizzle WE: Molecular Differences in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Major Salivary Glands. Annual Meeting of Head and Neck Surgeons, 2001.
36. **Manne U**, Hardin JM, Sprague AP, Jones WT, Grizzle WE. Use of Artificial Intelligence (AI) and Computational Statistical (CS) Methods in Predicting the Clinical Outcome of Colorectal Cancer (CRC) Patients. AACR Meeting, 2001; Vol. 41, Abstract # 1534.

37. Jhala NC, **Manne U**, Gary B, Talley L, Weiss HL, Grizzle WE. Nuclear Accumulation of p53 in Colorectal Adenocarcinoma: Prognostic Importance Differs with Race, Age and Location of the Tumor. AACR Annual Meeting, 2001; Vol. 41, Abstract # 2692.
38. Piyathilake CJ, Frost AR, **Manne U**, Weiss H, Heimburger DC, Grizzle WE. Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers. FASEB J 15 (4): A249-Part 1 MAR 7 2001.
39. Piyathilake CJ, Frost AR, **Manne U**, Weiss H, Bell WC, Heimburger DC, Grizzle WE. Differential Epression of Growth Factors in Squamous Cell Carcinoma and Pre-cancerous Lesions of the Lung. AACR Annual Meeting, 2001; Vol. 41, Abstract # 2790.
40. Steinhauer JR, **Manne U**, Jhala N, Grizzle WE. Heterogeneity of differentiation in colorectal adenocarcinomas. Annual meeting of the United States and Canadian Academy of Pathology, 2002. Abstract # 308.
41. **Manne U**, Hardin M, Sprague A, Jones WT, Grizzle WE. Validation of prognostic value of molecular markers of colorectal Adenocarcinoma (CRC) using data mining tools. Fifth Steering Committee Meeting of EDRN of NCI-NIH, Houston TX, Feb 3-5, 2002.
42. **Manne U**, Bell W, Jones J, Talley L, Said-Al-Naief N, Grizzle, WE. Expression of TGF-a, EGF receptor, erbB-2 and erbB-3 in squamous cell dysplasia and carcinoma of the tongue. Amer Assoc Cancer Res Annual Meeting, 2002; Vol. 42, Abstract # 5018.
43. **Manne U**, Gary B, Jones, J, Jhala N, Chatla C, Grizzle WE. Differences in the mutational spectra of the p53 gene in colorectal adenocarcinomas of African-Americans and Caucasians. Amer Assoc Cancer Res Annual Meeting, 2002; Vol. 42, Abstract # 5018.
44. Nirag C Jhala, **Manne U**, Jones J, Oelschlager DK, Vasudevan V, Weiss HL, Grizzle, WE. Prognostic significance of p27kip-1 expression in colorectal adenocarcinomas is associated with tumor stage. Amer Assoc Cancer Res Annual Meeting, 2002; Vol. 42, Abstract # 1083.
45. **Manne U**, Jhala N, Vasudevan V, Jones JL, Weiss HL, Grizzle WE. Molecular changes in adenomatous colorectal lesions in patients with existing colorectal Adenocarcinoma. AACR, Frontiers in Cancer Prev Research, Boston, MA October 14-18, 2002; Abstract # B322.
46. Chhieng DC, Benson E, Eltoum IA, Eloubeidi MA, Jhala NC, Jhala D, Siegal GP, Grizzle WE, **Manne U**. MUC1 expression in diagnosing pancreatic ductal carcinoma obtained by fine needle aspiration biopsy. USCAP 2003.
47. Drake RR, **Manne U,** Adam BL, Ahn C, Cazares L, Semmes OJ, Bigbee WL, Grizzle WE, Johnson DA, SELDI-TOF-MS profiling of serum for early detection of CRC. AACR 2003.
48. Jhala N, **Manne U**, Chatla C, Meleth S, Jones J, Grizzle WE. Molecular phenotypic expression in adenomas and colorectal adenocarcinomas. Gordon Res Conference "New Frontiers in Cancer Detection & Diagnosis" meeting, August 17-22, 2003, Andover, NH.
49. **Manne U,** Jhala N, Vasudevan V, Chatla C, Jones J, Suarez-Cuervo C, Meleth S, Grizzle WE. Molecular phenotypic changes in adenomatous components of colorectal adenocarcinomas. Annual meeting of AACR 2003, Vol. 44, Abstract #1877.
50. Singh R, **Manne U,** Gary B, Abdulkadir S, Mahasreshti P, Grizzle WE. Role of p53 in COX-2 mediated apoptosis in prostatic adenocarcinoma. Annual meeting of AACR 2003, Vol. 44, Abstract #LB-153.
51. Alexander D, Chatla C, Funkhouser E, Grizzle WE, **Manne U**. Racial differences in colorectal cancer survival. International Conference of Epidemiology, Ontario, Canada.
52. Liu D, Sprague A, **Manne U.** JRV: An interactive tool for data mining visualization. 2003 Annual Meeting of Association for Computing Machinery, Nov 13-14, Gatlinburg, TN.

53. Grizzle WE, **Manne U**, Jhala N, Suarez-Cuervo C, Meleth S, Alexander D. (invited presentation) The molecular staging of colorectal cancer. Presented at the Society of Toxicology Meeting, March 21-25, 2004, Baltimore, MD.
54. Thomas RD, Grizzle WE, **Manne U**, McLean VA. Predicting clinical prognosis in colorectal cancer patients using molecular profile data and bioinformatics technologies. Presented at the Society of Toxicology Meeting, March 21-25, 2004, Baltimore, MD.
55. Vital-Reyes V, Rodriguez-Burford C, Oelschlager DK, Suarez-Cuervo C, Manne U, Grizzle, WE. The COX-2 inhibitor, Celecoxib, inhibits differentially the cellular growth of ovarian, prostate and colon carcinoma cell lines independent of p53 status. Presented at the 12th SPORE Investigators' Workshop, Baltimore, MD, July 10-13, 2004.
56. Gandham M, Katkoori VR, Soong R, Diasio RB, Suarez-Cuervo C, Meleth S, Shibata DK, Grizzle WE, **Manne U**. Analysis of microsatellite instability in colorectal adenocarcinomas of African-Americans and Caucasians. Annual meeting of AACR 2004 (Abstract # 918).
57. Katkoori VR, Gandham M, Jhala NC, Soong R, Diasio RB, Meleth S, Grizzle WE, **Manne U**. Differences in the mutational spectra of the p53 gene in proximal colonic adenocarcinomas of African-Americans and Caucasians. AACR 2004 (Abstract # 4023).
58. Suarez-Cuervo C, Herring C, Jhala NC, Posey J, Grizzle WE, Meleth S, **Manne U.** Predictive molecular markers of 5-FU treatment of colorectal cancer. AACR 2004 (Abstract # 1145).
59. Chatla C, Alexander D, Katkoori VR, Jhala NC, Katholi CR, Grizzle WE, **Manne U**. Bcl-2 expression and p53 nuclear accumulation are the indicators of tumor recurrence and patient survival in colorectal adenocarcinoma AACR 2004 (Late breaking Abstract # 213).
60. Liu D, Sprague A, **Manne U**. JRV: An interactive tool for data mining visualization. Association of Computing Machinery, Southeast Conference, April 2-3, 2004.
61. Liu D, Sprague A, **Manne U**. Dynamically constructing classification rules with visualization techniques. International Conference on Information and Knowledge Engineering, Las Vegas, NE, June 21-24, 2004.
62. Alexander D,Chatla C, Nirag C. Jhala, Funkhouser E, Grizzle WE, **Manne U**. Racial differences in survival based on tumor differentiation and stage in patients who have undergone surgery for colon cancer. ASCO 2004, Abstract 3609.
63. Carroll A, Herring C, Suarez-Cuervo C, Chatla C, Jhala N, Grizzle WE, **Manne U**. Detection of p53 mutations by a panel of monoclonal antibodies and their clinical implications in colorectal adenocarcinoma. PREP program of pathology, July 23, 2004.
64. Meleth S, Hardin M, **Manne U.** Determining approaches to develop outcome predictive models for human malignancies. M2004, the 7th Annual Datamining Technology Conference, Las Vegas, NE, October 18-20, 2004, (Submitted).
65. **Manne U,** Grizzle WE, Jhala N, Sreelatha M, Chatla C, Hardin M. Clinical implications of molecular markers of colorectal cancer differ with tumor location, stage and ethnicity. 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine, Crete, Greece, 2004, Abstract 414.
66. Benavides MA, Stockard SR, Oelschlager DK, Vital-Reyes VS, Katkoori VR, **Manne U**, Grizzle WE. Methionine inhibits the growth of MCF-7 (breast) and LNCaP (prostate) cancer cell line but not DU-145 prostate cancer cells. AACR 46: (Abstract 1577), 2005.
67. Herring C, Chatla C, Katkoori VR, Jhala NC, Oelschlager DK, Grizzle WE, **Manne U.** Detection of p53 mutations by a panel of monoclonal antibodies and their clinical implications in colorectal adenocarcinoma. AACR 46: (Abstract 1262), 2005.

68. Katkoori VR, Jia X, Chatla C, Ponnazhagan S, **Manne U.** An alteration in the 5'UTR of Rabphillin-3A-like (RPH3AL) gene is associated with nodal metastasis in colorectal adenocarcinoma. AACR 46: (Abstract 2816), 2005.
69. Katkoori VR, Chatla C, Jia X, Grizzle WE, **Manne U.** Mutations in the L3 loop of zinc-binding domain of the p53 are poor prognostic indicators of Caucasians with colorectal adenocarcinomas. AACR 46: (Abstract 2548), 2005.
70. Jia X, Katkoori VR, Chatla C, Cao X, **Manne U.** Identification of a novel *Smad4* mutation in colorectal adenocarcinoma. AACR 46: (Abstract 1928), 2005.
71. Chatla C, Neelagiri V, Jain V, Jhala NC, Grizzle WE, **Manne U.** African-American patients with high grade proximal colonic adenocarcinomas are at increased risk of short survival. AACR 46: (Abstract # 474), 2005.
72. Jhala NC, Chatla C, Katkoori V, Herring C, Grizzle WE, **Manne U**. Usefulness of molecular phenotypic expression in colorectal adenocarcinomas based on tumor stage, differentiation and histologic type. Proc GI Cancers Symposium of ASCO (Abstract 228), 2005.
73. Benavides MA, Oelschlager DK, Zhang H-G G, Stockard CR, Vital-Reyes VS, Katkoori VR, **Manne U,** Bland KI, Grizzle WE. Methionine inhibits celluar growth dependent upon the p53 status. AACR 47: (Abstract 2639), 2006.
74. Jia X, Katkoori VR, Jhala NC, Callens T, Messiaen L, Herring CB, Posey J, Grizzle WE, **Manne U.** Molecular and immunohistochemical analysis of Smad4 in colorectal cancer. AACR 47: (Abstract 912), 2006.
75. Katkoori VR, Jia X, Chen D-T, Grizzle WE, **Manne U**. Differential gene expression profiles of colorectal adenocarcinomas in relation to a single nucleotide polymorphism at -25 of the 5' untranslated region of the RPH3AL gene. AACR 47: (Abstract 96), 2006.
76. Meleth S, Anderson B, Hardin MJ, Chatla C, **Manne U.** The optimal cut point determination of prognostic molecular biomarkers of colorectal cancer by a novel statistical technique. AACR 47: (Abstract 5326), 2006.
77. Goli R, Katkoori VR, Callens T, Messiaen L, Jhala NC, Grizzle WE, **Manne U.** Higher incidence of single nucleotide polymorphisms at codon 72 of the p53 gene are associated with poor prognosis of African-American patients with high grade colorectal adenocarcinomas. AACR 47: (Abstract 391), 2006.
78. Katkoori VR, Jia X, Chatla C, Kumar S, Selvarangan P, Grizzle WE, **Manne U**. A novel single nucleotide polymorphism in the 5'untranslated region of the Rabphillin-3A-like gene is associated with nodal metastasis, early recurrence and poor survival of patients with colorectal adenocarcinoma. AACR 47: (Abstract 5728), 2006.
79. **Manne U**, Suarez-Cuervo C, Jhala N. C, Posey J, Herring CB, Meleth S, Grizzle WE. Phenotypic expression of Bax is a predictive marker of 5-fluorouracil treatment in colorectal cancer. Proc ASCO, J Clin Oncology, Abstract 3605, 2006.
80. Chhieng D, Hardin M, Anderson B, **Manne U**. Predicting 5-year survival of colorectal carcinoma patients using data mining methods, Proc Amer Med Informatics Assoc 2007.
81. Jia X, Katkoori VR, Callens T, Messiaen L, Grizzle WE, **Manne U**. Correlation between the abnormalities of p53 and Rabphillin-3A-Like genes in colorectal carcinoma, AACR 48: (Abstract 4555), 2007.
82. Katkoori VR, Goli RR, Jia X, Callens T, Messiaen L, Jhala NC, Grizzle WE, Meleth S, **Manne U**. Prognostic value of molecular alterations in high grade colorectal adenocarcinomas varies in African-Americans and Caucasians, AACR 48: (Abs141), 2007.

83. Shanmugam CK, Katkoori VR, Jia X, Jhala NC, Grizzle WE, **Manne U**. Allelic variants of the Rabphillin-3A-Like gene and their association with aggressive phenotypic features of colorectal adenocarcinomas, Proc Amer Assoc Cancer Res 48: (Abstract 5306), 2007.
84. Jia X, Katkoori VR, Callens T, Messiaen L, Shanmugam CK, Jhala NC, Messiaen L, Grizzle WE, **Manne U**. Immunohistochemical staining patterns of Smad4 expression based on 18q deletions in colorectal adenocarcinomas, AACR 48: (Abstract 205), 2007.
85. Katkoori VR, Jia X, Callens T, Kumar S, Selvarangan P, Messiaen L, Grizzle WE, **Manne U**. Rabphillin-3A-Like gene is a candidate tumor suppressor in colorectal adenocarcinoma, AACR 48: (Abstract 3650), 2007.
86. Reddy VB, Oelschlager DK, Nolan JS, Taylor KL, Post J, Grizzle WE, **Manne U**. Cytokine expression profiles of patients with acute myelogenous leukemia (AML) and non-hodgkin lymphoma (NHL) detected by Luminex-based multiplex assay, ASCO 25: (Abstract 18530), 2007.
87. **Manne U**, Grizzle WE, Alexander DD, Katkoori VR. Racial Differences in Colorectal Cancer: The Need to Educate Clinicians and Researchers for Improved Patient Care. Proc. Amer Assoc Cancer Education, 2007 (Abstract 147).
88. Grizzle WE, Talley LI, Stockard CR, Steciuk MR, Otali D, McGauley CL, Shanmugam CK, Parker SB, Adams AL, Chhieng CF, Hameed O, Johnson MR, Manne U, Frost AR. Racial differences in ductal carcinomas of the breast and DCIS. AACR-Science of Cancer Health Disparities Conference, 2007 (Abstract A74).
89. Katkoori VR, Jia X, Callens T, L Messiaen, Grizzle WE, **Manne U**. Prognostic Importance of p53 codon 72 polymorphism differs with Race in Microsatellite Stable Colorectal Adenocarcinoma, AACR- Cancer Health Disparities Conference, 2007 (Abstract A26).
90. Jia X, Shanmugam CK, Katkoori VR, Callens T, Messiaen L, Callens T, Grizzle WE, **Manne U**. Loss of Heterozygosity at 17p13.3 and 17p13.1 Loci is Associated with Poor Survival of African Americans with Colorectal Adenocarcinomas. AACR-Science of Cancer Health Disparities Conference, 2007 (Abstract 243).
91. **Manne U**. Molecular Advances in Colorectal Cancer: The Need to Educate Researchers and Clinicians for Improved Patient Care. IACRCON, Gujarat, India -2008.
92. **Manne U**. Prognostic and Predictive Molecular Biomarkers of Colorectal Cancer 5th International Symposium on Genetics, Health and Diseases. Guru Nanak Dev University, Amritsar, India -2008.
93. Grizzle WE, Talley LI, Stockard CR, Steciuk MR., Otali D, McGauley CB, Shanmugam CK, Parker SB, Adams AL, Chhieng CF, Hameed O, Johnson MR., Manne U, Frost AR. Racial differences in DCIS and carcinoma of the breast. AACR-2008 (Abstract 5485).
94. Shanmugam CK, Jhala NC, Meleth s, Junker W, Batra SK, Grizzle WE, **Manne U**. Aberrant Phenotypic Expression of MUC17 is Associated with Aggressive Behavior of Colorectal Adenocarcinomas. AACR-2008 (Abstract 987).
95. Katkoori VR, Bovell L, Singh S, **Manne U**. Identification and Differential Expression of Novel Genetic Variants of the *RPH3AL* Gene in Colorectal Adenocarcinoma. AACR-2008 (Abstract 4248).
96. Jia X, Shanmugam CK, Mcgauley CL, Callen T, Messiaen L, Chhieng DC, **Manne U**. Molecular Analysis of the *Rabphillin 3A-Like* Gene in Breast Cancer. AACR-2008 (Abstract 203).
97. Katkoori VR, Jia X, Shanmugam CK, Ponnazhagan S, Lin H-Y, Grizzle WE, **Manne U**. Down regulation of the *Rabphillin-3A-Like* gene, located on 17p 13.3, is associated with the metastasis of colorectal adenocarcinoma. AACR-2008 (Abstract 334).

98. **Manne U**. Prognostic Biomarkers of colorectal cancer. Sydney Cancer Conference, Sydney, Australia – 2008 (Abstract 114).
99. Koya S, Katkoori VR, **Manne U**, Posey JA. Association between IGR-1R expression and p53 mutational status in colorectal cancers. AACR-2009 (Abstract# 1647).
100. Grizzle WE, Talley L, Stockard CR, Steciuk MR, Otali D, Shanmugam CK, Parker SB, Chhieng CF, Hameed O, Johnson MR, Manne KB, **Manne U**, Meleth S, Frost AR. Analysis by Race of p53 and Bcl-2 Interaction in DCIS. AACR-2009 (Abstract# 3441).
101. Bovell L, Katkoori VR, Davis DE, **Manne U**. MicroRNA profiles of colorectal adenocarcinomas – racial disparity. AACR-2009 (Abstract# 549).
102. Jia X, Shanmugam CK., Callen T, Messiaen L, Grizzle WE, **Manne U**. Molecular analysis of the *Rabphillin-3A-Like g*ene in breast normal and tumor cell lines and tissues. AACR-2009 (Abstract # 5328).
103. Jia X, Katkoori VR, Shanmugam CK, Callen T, Messiaen L, Jhala NC, Posey J, **Manne U**. Distinct clinical Implications of Allelic Variations and Aberrant Expression of SMAD4 in Colorectal Adenocarcinoma. AACR-2009 (Abstract # 4458).
104. Katkoori VR, Jia X, Callen T, Messiaen L, Bumpers H, Meleth S, **Manne U**. p53 mutations predict aggressiveness of stage II microsatellite stable sporadic colorectal adenocarcinomas. AACR-2009 (Abstract#1637).
105. Shanmugam CK, Katkoori VR, Jhala NC, Wan W, Meleth S, Junker W, Batra SK, Grizzle WE, **Manne U**. Increased expression of MUC4 is associated with poor survival of patients with early stage colorectal adenocarcinoma. AACR-2009 (Abstract# 2726).
106. Katkoori VR, Shanmugam CK, Brittnee LL, Batra SK, Grizzle WE, Siegal GP, **Manne U**. MUC17 is a potential tumor suppressor gene in colorectal adenocarcinoma. AACR-2009 (Abstract# 4362).
107. Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum I, **Manne U**, Siegal, GP. Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis. ASCO 2009 (Ab# 6027).
108. Posey JA, Koya S, Katkoori VR, Davis DE, **Manne U**. Prognostic significance of VDR, DKK-1, and DKK-4 expression in colorectal cancer. ASCO 2009 (Abstract # e15047).
109. Bumpers HL, **Manne U**. Predictive and prognostic molecular markers of colorectal cancer of African-American patients. Minority Institution/Cancer Center Partnership Scientific Meeting of NCI, 2009 (Abstract #4).
110. Shanmugam CK, Hines RB, Jhala NC, Grizzle WE, **Manne U.** Clinical significance of lymph node extraction in Stage II and III colon cancers, UAB-CCC-Annual Retreat, October-2009.
111. Salih C, Jia X, Shanmugam CK, Katkoori VR, Callens T, Messiaen LM, Hameed O, **Manne U.** Clinical implications of Rabphillin-3A-Like (RPH3AL) gene alterations in breast cancers. UAB-CCC-Annual Retreat, October-2009.
112. Bovell L, Katkoori VR, Shanmugam CK, Lee C-H, Sreelatha Meleth, Bumpers HL, Grizzle WE, **Manne U.** The prognostic value of microRNAs in colorectal cancer varies with patient race/ethnicity. UAB-CCC-Annual Retreat, October-2009.
113. Katkoori VR, Shanmugam CK, Chen D, Bumpers HL, **Manne U.** Gene expression signatures associated with p53 mutations in microsatellite-stable Stage III colorectal adenocarcinoma. UAB-CCC-Annual Retreat, October-2009.
114. Shanmugam CK, Hines RB, Jhala NC, Posey J, Bumpers HL, Birdsong G, Manne. Clinical Relevance of Lymph Node Evaluation in Stage II and III Colon Cancers. AACR-2010 (Abstract# 846).

115. Katkoori VR, Shanmugam CK, Chen D, Bumper HL, Collens Tom, Messiaen L, **Manne U**. Gene Expression Signatures of Microsatellite-Stable Stage III Colorectal Adenocarcinomas based on the p53 Status. AACR-2010 (Abstract# 4655).
116. Chura S, Jia X, Shanmugam CK, Katkoori VR, Collens T, Messiaen L, Hameed O, **Manne U**. Clinical Implications of Rabphillin-3A-Like (RPH3AL/NOC2) Gene Alterations in Breast Cancer. AACR-2010 (Abstract# 4647).
117. Bovell L, Katkoori VR, Shanmugam C, Lee CH, Meleth S, Bumpers HL, Grizzle WE, **Manne U.** Higher Expressions of miR-21, miR-106a, miR-181b, and miR-203 are Associated with Poor Prognosis in Colorectal Cancer Patients. AACR-2010 (Ab# 4037).
118. Atha DH, Tona A, **Manne U**, Grizzle WE, Wagner P, Srivastava S, Elliott JT. Development of an In-Vitro System for Performance Characterization of p53 Antibodies. AACR-2010 (LB-238).
119. Vogtmann E, Shanmugam CK, Waterbor J, Bumpers HL, **Manne U**. Factors associated with colorectal cancer survival vary between males and females. AACR-2010 (LB-418).
120. Bumpers HL, Debeatham W, **Manne U,** Goud JD. Development of in vitro tumorigenic models as 3-D cultures using hydrogels and nanomagnetic levitation, Submitted to the Society of Black Academic Surgeons meeting, 2011.
121. Bumpers HL, Huang M-B, Harrington W, Goud JD, **Manne U,** Bond VC. Exploitation of the CXCR-4 receptors on human breast cancers using a novel apoptotic peptide (Nef-M1). Era of Hope meeting sponsored by the DoD, 2011.
122. Bumpers H L, Goud JD, DeBeatham WL**, Manne U.** Nanomagnetic levitation based 3-D cultures of breast and colon cancer cells for high throughput drug screening and xenograft studies. AACR-2011 (Abstract # 4298).
123. Shanmugam CK, Salih C, Katkoori VR, Bovell L, Callens T, Messiaen LM, Hameed, Grizzle WE, **Manne U**. Single Nucleotide Polymorphism in p53 Codon 72 is Associated with Grade III Tumors in African Americans with Breast Carcinoma. AACR-2011 (Abstract # 2271).
124. Vogtmann E, Shanmugam CK, Katkoori V, Waterbor J, **Manne U**. Association between socioeconomic status and p53 abnormality among colorectal cancer patients AACR-2011 (Abstract # 1923).
125. Bovell L, Shanmugam CK, Katkoori VR, Salih C, Grizzle WE, **Manne U**. MicroRNAs are Stable in Formalin-Fixed Paraffin-Embedded Archival Tissue Specimens of Colorectal Cancer Stored for More than 20 Years. AACR-2011 (Abstract # 1167).
126. Ahluwalia S, Shanmugam CK, Katkoori VR, Jhala NJ, Peter S, Grizzle WE, **Manne U**. The Prognostic Value of p53 Abnormalities in Colorectal Cancers Varies Based on Detection Methods. AACR-2011 (Abstract # 2262).
127. Katkoori VR, Salih C, Sthanam M, Shanmugam CK, Callens T, Messiaen LM, Grizzle WE, Bumpers HL, Birdsog G, **Manne U**. Prognostic Significance of the Low Microsatellite Instability Phenotype Differs with Race in Colorectal Adenocarcinoma. AACR-2011 (Abstract # 2261).
128. Butler AR, Katkoori VR, Choudhary S, Ather M, **Manne U**. Interaction between Rabphillin-3A-Like Gene and Phosphorylation of Mammalian Target of Rapamycin (mTOR) in Colon Cancer. Summer Institute, 2011, MSM/TU/UAB.
129. Katkoori VR, Shanmugam C, Sthanam M, Callens T, Messiaen LM, Bumpers H L, Birdsong G, Samuel T, **Manne U**. Clinical Value of Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in African American and non-Hispanic Caucasian Colorectal Cancer Patients (AACR-2012, Abstract # 1152).

130. Council1 LN, Shanmugam C, Katkoori VR, Sthanam M, Hanna A, **Manne U**, Clinical Significance of p53 Codon 72 Polymorphism in HCC (AACR-2012, Abstract # 1158).
131. Katkoori VR, Choudhary S, Butler AR, Shanmugam C, Samuel, Athar M, Manne U. Interaction between the Rabphillin-3A-Like Gene and Phosphorylation of Mammalian Target of Rapamycin (mTOR) in Colorectal Cancers (AACR-2012, Abstract # 4156).
132. Samuel T, Fadlalla K, Katkoori V, Khazal K, Turner T, **Manne U**. Co-treatment of cancer cells with DNA damaging drugs and quercetin suppresses cell growth independent of p21 and Bax induction (AACR-2012, Abstract # 4664).
133. Hébert-Magee S, Eltoum I, Frost AR, McBride C, **Manne U**. Higher incidence of triple negative breast cancer in African-American and young women is independent of BMI, poverty, or potential carcinogenic exposure. UAB Health Disparity Res Symposium, 2012.
134. Sims WD, Hébert-Magee S, **Manne U**. The p53 codon 72 polymorphisms in African-American women with Triple-Negative Breast Cancer. Scientific Symposium at Summer Institute, MSM/TU/UAB, 2012.
135. Patterson Z, Fadlalla K, Benjamin S, Yehualaeshet T, Turner T, Manne U, Samuel T. The activity of indole-derivative compounds on colon cancer cells. Annual Biomedical Research Symposium, Atlanta, 2012.
136. Samuel T, Patterson Z, Fadlalla K, Putcha BDK, Posey J, **Manne U**. The NF-kB–CXCL8 axis as a modifier of drug response in colon cancer cells. UAB OCCC Retreat, 2012.
137. Salazar-Gonzalez JF, Salazar MG, Putcha BDK, **Manne U**. PCR Amplification and sequencing of 19 Kb of the TP53 gene from DNA extracts of colorectal cancers. UAB Cancer Center Retreat, 2012.
138. Council LN, Shanmugam C, Katkoori VR, Hanna A, **Manne U**. Association between HCV infection, p53 phenotypes, and APC variants in hepatocellular carcinomas. UAB Cancer Center Retreat, 2012.
139. Gangrade A, Putcha BDK, Jadhav T, Bovell L, Hebert-Magee S, **Manne U**. Expression Profiles of miRNAs in Breast Cancer: Histologic Type and Patient Race. UAB Graduate School Scientific Symposium, 2013.
140. Van Dyke ME, Eltoum I, Frost AR, **Manne U**, Hébert-Magee S. Rare Histologic Subtypes, Race, and Survival in the UAB Breast Consortium Study. National Scientific Symposium of UAB MHRC, 2013.
141. Katkoori VR, **Manne U**, Basson MD, Bumpers HL. Progressive expression of n-cadherin and epidermal growth factor receptor in colorectal adenocarcinoma (AACR, 2013: Abstract #2620).
142. Bovell L, Putcha BDK, Devadasan D, Bae S, Grizzle WE, **Manne U.** Evaluation of the prognostic value of miRNA-181b and its target identification and validation in colorectal cancers (AACR, 2013: Abstract #1944).
143. Jadhav T, Chen D, Putcha BDK, Samuel T, Posey J, Heslin MJ, **Manne U.** Distinct gene expression profile of recurrent Stage II colorectal cancers in African American and Caucasian American Patients (AACR, 2013; Abstract #4031).
144. Putcha B-DK, Jadhav T, Bovell L, Hebert-Magee S, Frost A, Eltoum I-E, Bae S, **Manne U**. Expression Profiles of miRNAs in Breast Cancer: Histologic Type and Patient Race. The 2013 San Antonio Breast Cancer Symposium, 2013 (Accepted).
145. Bumpers HL, Goud JD, **Manne U**, Basson M, Katkoori VR. Development of Magnetic Levitation 3-D Cultures of Breast and Colon Cancer Cells Using Carbon Encapsulated Cobalt Magnetic Nanoparticles. American Society of Surgery, 2013 (Accepted).

146. Paluri R, Posey J, **Manne U**, Putcha B-DK, Jadhav T, Council L. The influence of vitamin D and receptor status in colorectal cancer. ASCO-GI, 2013 (Accepted, Abstract #122938).
147. Bumpers HL, Katkoori VR, Chen D, Manne U. The Role of BetaB2-Crystallin in Progression of Breast and Colorectal Cancers in African Americans. AACR Health Disparity Meeting, Atlanta, GA, 2013 (Abstract# C56).
148. Suswam EA, Putcha B-DK, Walker KD, Johnson LJ, Howard J, Partridge E, Fouad MN, Bae S, **Manne U**. Tristetraprolin Suppression is Associated with Advanced Stage Colorectal Cancer. AACR Health Disparity Meeting, Atlanta, GA, 2013 (Abstract# C77).
149. Salazar-Gonzalez JF, Salazar MG, Putcha B-DK, Partridge E, Fouad MN, **Manne U**. Genetic alterations in the *TP53* genomic region of African American and Caucasian colorectal cancers. AACR Health Disparity Meeting, Atlanta, GA, 2013 (Abstract# C61).
150. Putcha B-DK, Holt BM, Bovell L, Jadhav T, **Manne U**. Overexpression of miR-181b and Underlying Molecular Mechanisms in Aggressive Progression of African American Colorectal Cancers. AACR Health Disparity Meeting, Atlanta, GA, 2013 (Abstract# C22).
151. Putcha B-DK, Jadhav T Hebert-Magee S, Bae JH, Frost A, Eltoum I-E, Bae S, **Manne U**. Prognostic value of miRNAs in Breast Cancer: Molecular Type and Patient Race. AACR Health Disparity Meeting, Atlanta, GA, 2013 (Abstract# C21).
152. Samuel, T, Fadlalla, K, Elgendy, R, Putcha, B.D.K, Posey, J, **Manne, U**. Differential activation of NF-kB signaling and CXCL8 secretion in colon cancer cells treated with chemotherapeutic drugs. AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics, Boston, MA, 2013 (Abstract #B70).
153. Pennison MJ, Zeng Q, Bellam N, Zimmerman JW, Moore-Smith L, Wang M, Henegan JC, Buckhaults PJ, Sadim M, Kaklamani V, Lindor N, Hopper JL, Marchand LL, Gallinger S, Newcomb PA, Haile R, Baron JA, Stram DO, Zhang H-T, Absher D, **Manne U**, Jadhav T, Edberg JC, Kimberly RP, Xu J, Zhang K, Yi N, Pasche B. Dual role of TGFBR1 as a modifier of colorectal cancer risk ASCO – GI Conference -2014 (Abstract #140530).
154. Suswam EA, Putcha BDK, Walker KD, Johnson LJ, Howard J, Partridge EE, Fouad MN, Bae S, **Manne U**. Molecular profiles of tristetraprolin and growth factors in colorectal cancers of African Americans and Caucasian Americans. CPACHE-MICP-NIH, 2014.
155. Katkoori VR, Basson MD, **Manne U**, Bumpers HL. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis by attenuating AKT and mitogen-activated protein kinase signaling in colon cancer. AACR, 2014 (Abstract# 1027).
156. Jadhav T, Narang S, Bae J, Schultz M, Eltoum I-E, Bellis S, Bae S, **Manne U**. Expression of ST6Gal-1 in colorectal cancer and patient prognosis. AACR, 2014 (Abstract 3820).
157. Putcha BDK, Hebert-Magee S, Jadhav T, Frost AR, Eltoum I-E, **Manne U**. Racial disparity in the TP53 mutation spectra in triple-negative breast cancers: Validation with TCGA data. AACR, 2014 (Abstract LB-287).
158. Suswam, EA, Putcha BDK, Bae S, **Manne U**. Tristetraprolin, a candidate tumor suppressor, involved in colorectal cancer progression. EDRN Scientific Symposium, Washington DC, August, 2014.
159. Behring MP, **Manne U**, Shrestha S, Azrad M, Vazquez AI. Association of inter-tumor copy number variation and lymph node invasion in ductal breast cancer. UAB Comprehensive Cancer Center Retreat, Oct 2014.
160. Jadhav T, Salazar-Gonzalez JF, Hebert-Magee S, Behring MP, Frost AR, Eltoum I-E, Bae S, Manne U. Codon 72 and Intron-3 Polymorphisms in *TP53* are Risk Factors for Breast Cancer. UAB Comprehensive Cancer Center Retreat, Oct 2014.

161. **Manne U**. Evidence-Based Cancer Care Requires Development of Patient Population-Specific Molecular Biomarkers." Athens, Greece, October, 2014.
162. Paluri RK, Posey J, Council L, Putcha BDK, Jadhav T, **Manne U**. The influence of vitamin D and vitamin D-receptor status in colorectal cancer. ASCO-2014 (Abstract #122938).
163. Govindarajan R, Posey J, Chao C, Lu R, Bailey H, Krishnakumar J, Jadhav T, Javed AY, Javed A, Mahmoud FA, Osarogiagbon RU, **Manne U**. Recurrence Score Result Distributions in Stage II Colon Cancers of African American and Caucasian Patients. ASCO – GI -2015 San Francisco, CA (Abstract # 613).
164. Putcha B-DK, Jadhav T, Behring MP, Bae S, Frost AR, Eltoum I-E, Chen L, Weiss H, Grizzle WE, **Manne U**. Prognostic value of miRNAs in breast cancer varies with patient race and molecular subtype. AACR-2015 (Abstract 4004).
165. Suswam EA, Putcha B-DK, Tiwari A, Jadhav T, Walker, KD, Harkins L, Amer S, Eltoum I-E, Bae S, **Manne U**. Molecular and cellular localization profiles of tristetraprolin in colorectal cancer: implications for tumor progression in diverse patient populations. AACR-2015 (Abstract 4953).
166. Jadhav T, Salazar-Gonzalez JF, Hebert-Magee S, Behring MP, Putcha B-DK, Bae JH, Frost AR, Eltoum I-E, Bae S, **Manne U**. Codon 72 and Intron-3 Polymorphisms in *TP53* are Risk Factors for Breast Cancer. AACR-2015 (Abstract 2776).
167. Paluri R, Behring M, Posey JP, **Manne U**. Nuclear Accumulation of p53 is a Prognosticator for Young White Patients with Proximal Colon. ASCO- GI Symposium, 2016 (Ab# 559).
168. Chen Yeh, **Manne U**. Clinical validation of a next-generation sequencing assay specifically for blood-drop liquid biopsy. AACR-2016 (Abstract 3148).
169. Suswam EA, Kumar G, Kim H-G, Osmar M, el Kouni MH, **Manne U**. In vitro characterization of PTAU and FU interactions in colon cancer cells. AACR-2016 (Abstract-2159).
170. **Manne U**. Development of Patient Population-Specific Cancer Molecular Biomarkers-13th International Scientific Symposium on Recent Advances in Environmental Health, Jackson, MS (Abstract 28).
171. Mishra MK, 1 Scissum-Gunn K, Scarinci I, **Manne U**. Building a Collaborative Partnership in Cancer Research and Education between Alabama State University and the University of Alabama at Birmingham Comprehensive Cancer Center: A P20 Initiative. PACHE, NCI, Bethesda, MD (Sept, 2016).
172. Lillard JW, Troy RM, **Manne U**. Morehouse School of Medicine/Tuskegee University/ University of Alabama at Birmingham Comprehensive Cancer Center Partnership: An U54 Initiative. PACHE, NCI, Bethesda, MD (Sept, 2016).
173. Williams S, Samuel T, Jones-Wonni B, Bae S, **Manne U**, Suswam EA. Silencing mutant p53 downregulates growth factor expression in metastatic colon cancer cells, SW620. ABRCMS, Orlando, FL (Nov, 2016).
174. Lin Y, Wei J, Chittur K, Lindquist R, **Manne U**. A LSPR Fiber Optic Biosensor for Point-of-Care Diagnostics. SPIE BiOS, San Francisco, CA (Jan 2017).
175. Katkoori VR, Manne U, Bumpers HL. Functional consequence of the p53 codon 72 polymorphism in Colorectal Cancer. AACR, 2017
176. Kumar S, Stoke III J, Malik S, Singh UP, Gunn KS, **Manne U**, Ponnazhagan S, Mishra MK. Gr1-MDSCs and Tregs modulate the prostate cancer progression. AACR-217, Washington, DC (Abstract 2955)
177. Govindarajan R, Posey J, Chao CY, Baily H, Turner M, Stopper M, **Manne, U**. Comparison of the distribution of 12-gene assay results between right and left sided lesions in Stage II colon cancer. CAP annual meeting, 2017 (2017-A-1684-USCAP).

178. Kumar S, Malik S, Singh UP, Ponnazhagan S, Gunn KS, **Manne U**, Mishra MK. PD-1 expression on Foxp3+ Treg cells modulates CD8+ T cell function in prostatic tumor microenvironment. American Assoc Immunologists, 2017, Washington DC (Abstract 115.11) (J Immunol, 189, 1 suppl)
179. Varambally, S, Chakravarthi BVSK, Sonpavde G, Pena M R, Gordetsky J, Agarwal S, Chandrashekar DS, Chinnaiyan A, Netto G, **Manne, U**, Kunju LP, and Beer D. Beyond precision medicine: Targeting cancers with various aberrations by blocking de novo purine biosynthetic enzyme PAICS. UAB Cancer Center Retreat (Oct, 2017).
180. Huffman B, Agarwal S, Saldana S, Grey M, Behring M, Guo R, Kim H-G, Varambally S, Mishra M, **Manne U**. Overexpression of BZW2 in Colorectal Cancers, Summer Institute of UAB/MSM/TU Partnership, 2017.
181. Ozaydin B, **Manne U**, Feldman S. Design of a colorectal cancer data warehouse. TREO talk paper. 24th American Conference on Information Systems, New Orleans, LA, 2018 (Abstract 297).
182. Mittal K, Bhattarai S, Klimov S, Krishnamurthi U, Li X, Wetherilt CS, Aleskandaran MA, Green AA, Rakha EA, Ellis IO, Cantuaria G, Wei G, Osan RM, Gupta MV, **Manne U**, Rida PCG, and Aneja R. beta-Catenin overexpression underlies the aggressive disease course in African American triple-negative breast cancer patients who lack androgen receptor. Published Abstract of AACR Cancer Health Hisparities Meeting, Can Epi Biomar & Prev. 2018, 27(7); 44-45.
183. Wang K, **Manne U**, Eltoum, IE, Guo R. Re-evaluating Utility of the immunohisto-chemistry for detecting H. Pylori infection. USCAP-2018, Vancouver, Canada (Abstract 509), (Modern Path, 2018, 31: 797-797).
184. Kumar S, Stoke III J, Malik S, Singh UP, Ponnazhagan S, Manne U, Mishra MK. FoxP3+T cells program/re-program the prostatic tumor microenvironment, AACR-2018, Chicago, IL (Abstract 4690).
185. Katkoori VR, Manne U, Bumpers HL. Nef-M1 peptide inhibits CXCR4 driven Wnt/β-catenin signaling in breast cancer, AACR-2018, Chicago, IL (Abstract 4799).
186. Agarwal S, Chakravarthi BV, Chandrashekar D, Guo R, Datta P, Varambally S, **Manne U**. TRIP13, a target of miR-192, facilitates colorectal cancer progression through WNT/β-catenin signaling. AACR-2018, Chicago, IL (Abstract 3495).
187. Lillard JW, Rivers BM, Troy RM, Yates C, Scarinci I, **Manne U.** Comprehensive Cancer Research Partnerships. Center for Advance Cancer Health Equity Program, NCI, Bethesda, MD (Abstract 15).
188. Bhattarai S, Klimov S, Mittal K, Krishnamurthi U, Li X, Wali D, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis O, Gupta M, McCullough LE, **Manne U**, Agboola J, Baskovich Brett, Janssen EA, Callagy G, Mehta A, Shet T, Rakha EA, Rida PCG, Ritu A. Prognostic role of Androgen Receptor in TNBC: A global multi-institutional experience. AACR Cancer Health Disparities, 2018, New Orleans, LA (Abstract C101 A).
189. Wang K, Manne U, Eltoum I-E, Guo R. Re-evaluating utility of the immunohistochemistry for detection of H. pilori infection. USCAP 2018, Vancouver, BC (Abstract 509).
190. Wang K, Tracht JM, Manne U, Eltoum I-E, Guo R. Is Immunohistochemistry Over-Utilized in Detection of CMV in Cases Suspected of CMV Colitis? A Retrospective Correlational Study. USCAP 2019, Baltimore, MD (Abstract 94).
191. Behring M, Hale K, Ozaydin B, Manne U. Ethical Considerations for Observational Cancer Health Disparity Research. National Bioethical Conference, 2019, Tuskegee University, AL (Abstract 16).
192. Stokes J III, Berry E II, Singh R, **Manne U**, Mishra MK. PD-1 modulates CD8+ T cell function in prostate tumor microenvironment. AACR-2019, Atlanta, GA (Abstract 2792).

193. Katkoori VR, Anderson Z, **Manne U**, Bumpers H. Inhibition of CXCR4 driven colorectal cancer progression by Nef-M1 peptide. AACR-2019, Atlanta, GA (Abstract 3879).
194. Agarwal S, Chakravarthi BVS, Behring M, Kim H-G, Hale K, Alsubaie AM, Diffalha SA, Sugandha SP, Varambally S, **U. Manne**. MicroRNA-124 modulated collagen-prolyl hydroxylase P4HA1 expression regulates colon cancer progression. AACR-2019, Atlanta, GA (Abstract 851).
195. Behring M, Ozaydin B, **Manne U**. Codon 72 polymorphisms of p53 are associated with obesity, diabetes, and race in breast cancer. AACR-2019, Atlanta, GA (Abstract 4209).
196. Paluri R, **Manne U,** Williams G, Rose B, Heslin M, Reddy S, Baig K, Vickers S, Gbolahan O, Smith C, Jacob, R. Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer. GI ESMO-2019, Barcelona, Spain (Abstract 559).
197. Paluri R, Behring M, Jacob R, Al-Diffalha S, Manne U. Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma – A single center experience. GI ESMO-2019, Barcelona, Spain (Abstract 537).
198. Bajpai P, Elholy A, Behring M, Chen D, Hale K, Agrawal S, Kim H-G, Jadhav T, Samuel T, **Manne U.** Inter-ethnic Differential Gene Expression in Stage II Recurrent Colorectal Cancers. AACR Health Disparity Meeting, San Francisco, CA, 2019 (Abstract C044 I).
199. Xiong M-J, Patel CR, **Manne U**, Al Diffalha S. Cirrhotomimetic Hepatocellular Carcinoma: A Single Institution Experience. USCAP, 2020 (Virtual Poster).
200. Patel CR, Behring M, D Sameer Al, Jhala N, Dhall D, **Manne U**. Prognosis of colorectal mucinous adenocarcinomas is dependent on anatomic location. USCAP, 2020 (Virtual Po).
201. Agarwal S, Behring M, Kim H-G, Gupta N, Chandrashekar DS, Diffalha SA, Varambally S, **U. Manne**. TRIM29 mediates metastasis though hypoxia regulated proteins in microsatellite stable and p53 mutated colorectal cancer. AACR-2020, San Diego, CA (Virtual Poster).
202. Bajpai P, Elkholy A, Agarwal S, Kim H-G, Behring M, **Manne U**. Navitoclax (ABT-263) induces apoptosis in colon cancer cells by upregulating caspase 3 through inhibition of Bcl-2 family members. AACR-2020, San Diego, CA. (Virtual Poster).
203. Elkholy A, Mohsen M, Behring M, Bajpai P, Embaby A, Hedar D, Haleem RA, Saeed H, Fouad M, Arafat W, **Manne U**. Absence of *Mitsuokella multacida* is associated with early onset of colorectal cancer. AACR-2020, San Diego, CA. (Virtual Poster).
204. Al Diffalha S, Patel CR, Bajpai P, Elkholy A, Behring M, Choi J, Shelton A, Smith Berger E, Lee G, Dhall D, Netto GJ, Xiong M-J, Worthey E, Miller R, **Manne U**. Somatostatin Receptor 5 is a Candidate Diagnostic Biomarker of Cirrhotic-Like Hepatocellular Carcinoma. USCAP, 2021 (Virtual Poster).
205. Obuya S, Elkholy A, Avuthu N, Behring M, Bajpai P, Agarwal S, Kim H-G, El-Nikhely N, Akinyi P, Orwa J, Abdalla M, Micheal A, Mostafa M, Bateman LB, Fouad M, Saleh M, Guda C, **Manne U***, Waleed Arafat2*. Gut Microbiome in Kenyan Colorectal Cancer: Probiotic S. boulardii and Response to FOLFOX Chemotherapy. AACR 2021 (Virtual Po).
206. Sanjib Nilam Banerjee SN*, Bajpai P*, Elkholy A, Moore DW, Kim H-G, Agarwal S, Behring M, Diffalha SA, **Manne U**. Development of 3D organoid raft cultures as a model to screen the therapeutic efficacy of PRIMA-1Met (APR-246). AACR 2021 (Virtual).
207. Behring M, Nelson D, Vazin T, Alagan R, Aladuwaka S, Mishra M, Shafi T, Gutierrez O, **Manne U**. Characterizing colon and prostate cancers with comorbid chronic kidney disease in NHANES. AACR 2021 (Virtual Poster).
208. Agarwal S, Behring M, Bajpai P, Elkholy A, Kim H-G, Chandrashekar DS, Gupta N, Al Diffalha S, Varambally S, **Manne U.** TRIM29 mediates metastasis though hypoxia-

regulated proteins in microsatellite-stable and p53-mutated colorectal cancers. AACR 2021 (Virtual Poster).

209. Agarwal S, Behring M, Bajpai P, Elkholy A, Kim H-G, Chandrashekar DS, Gupta N, Al Diffalha S, Varambally S, **Manne U.** TRIM29 mediates metastasis though hypoxia-regulated proteins in microsatellite-stable and p53-mutated colorectal cancers. AACR 2021 (Virtual Poster).
210. **Manne U**. Interplay of Molecular Factors and Comorbid Conditions in Cancer Disparities. Research Symposium, International Conference on Cancer Health Disparities (ICCHD-2021). Abstract.
211. Al Diffalha S, Patel CR, Bajpai P, Elkholy A, Behring M, Wilk MB, Gajapathy M, Massicano F, Mamidi TKK, Brown DM, Kaur G, Shelton AK, Smithberger EJ, Netto GJ, Miller CR, Worthey E, **Manne U**. Unique Somatic Mutational Landscape in Cirrhotic-Like (Cirrhotomimetic) Hepatocellular Carcinoma, USCAP, 2022 Abstract ID 1209 (Accepted) Virtual Poster.
212. Zein-Sabatto B, Behring M, Mruthyunjayappa S, Dayana V, Lee G, Dhall D, **Manne U**, Al Diffalha S, Patel CR. Evaluation of the gray zone in staging between T3 and T4a colonic adenocarcinomas. USCAP, 2022 Abstract ID 1393 (Accepted) Virtual Poster.
213. Pesoli CC, Patel CR, Al Diffalha S, Dhall D, Varambally S, **Manne U**, Bart Rose J, Lee G. ERO1L Expression as a Novel Predictor of Poor Prognosis in Resected Pancreatic Ductal Adenocarcinomas. USCAP, 2022 Abstract ID 1182 (Accepted) Virtual Poster.
214. Alagan R, Aladuwaka S, Singh R, Manne U, Mishra MK. Implementing geospatial technology to understand the prostate cancer health burdens and socioeconomic status in Alabama. AACR-2022. Abstract ID 3687/26.
215. Martini R, Telesford K, Lord B, Ravichandran H, Elemento O, Manley N, Monteil M, Newman L, Manne U, Yates C, Davis MB. DARC/ACKR1 expression is associated with immune landscape changes among triple negative breast tumors. AACR-2022. Abstract ID 6165.
216. Khushman M, Toboni M, Zeng J, Xiu J, **Manne U**, El-Rayes B, Lou E, Shield A, Philip PA, Salem M, Abraham J, Spetzler D, Marshall J, Jayachandran P, Lenz H-J, Korn WM, Powell MA. The differential response to immune checkpoint inhibitors in colorectal and endometrial cancer patients according to different mismatch repair alterations. Abstract ID 371490, Publication 3625, ASCO – 2022.
217. Jacob R, Posey J, Grant WR, Reddy S, Gbolahan O, **Manne U**, Paluri R. Neoadjuvant Modified FOLFIRINOX or Gemcitabine-nab Paclitaxel followed by Stereotactic Body Radiotherapy for Patients with Locally Advanced Pancreatic Cancer and Borderline Pancreatic Inoperable Cancers. Abstract ID 384224, Publication #e16253, ASCO – 2022.
218. Khushman M, Gandhi N, Xiu, El-Rayes J, Seeber A, Lou E; Shields AF, Philip PA, El-Deiry W, Marshall JL, Jayachandran P, Lenz HJ, Oberley M, Korn M, **Manne U**. The prognostic significance of TP53 mutations in patients with right-sided and left-sided colorectal cancer. Abstract ID 377627, Publication 3589, ASCO – 2022.
219. Bajpai P, Agarwal S, Shimoga DC, Elkholy A, Kim H-G, Afaq F, Singh S, Shelton A, Ryan B, Singh R, Miller RC, Paluri R, Kushman M, Al Diffalha S, **Manne U**. Reducing regorafenib toxicity by combining with dual JAK-HDAC inhibitor in colorectal cancer. Abstract ID 377678, Publication #e15597, ASCO – 2022.
220. Khushman M, Gandhi N, Xiu, El-Rayes J, Seeber A, Lou E; Shields AF, Philip PA, El-Deiry W, Marshall JL, Jayachandran P, Lenz HJ, Oberley M, Korn M, **Manne U**. The molecular signature of gain-of-function (GOF) vs. non-GOF classification *TP53* mutations in colorectal cancer. Abstract ID#: 423522, ASCO, 2023.

221. Karthikeyan SK, Chandrashekar DS, **Manne U**, Creighton C, Qin ZS, Kumar S, Varambally S. Mammonc-DB: A web based user-friendly tool for comprehensive multi-omics data analysis in breast cancer. Abstract ID-6571, AACR-2023.
222. Khushman M, Afaq F, Bajpai P, Al Diffalha S, Outlaw D, Williams, GR, Jacob R, Baig KRKK, Ahmed A, Shajan P, Varambally S, **Manne U.** The prognostic significance of P4HA1 and the therapeutic efficacy of diethyl-pythiDC, its small molecule inhibitor, in pancreatic ductal adenocarcinoma. Abstract ID-1003, AACR-2023.
223. Afaq F, Agarwal S, Bajpai P, Kim H-G, Al Diffalha S, Shajan P, Kushman M, Varambally S, **Manne U.** Pharmacologic targeting or silencing of TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Abstract ID-1710, AACR-2023.
224. Agarwal S, Bajpai P, Afaq F, Behring M, Kim H-G, Chandrashekar DS, Shajan P, Al Diffalha S, Khushman M, Seeber A, Varambally S, **Manne U.** BZW2 a potential target to inhibit colorectal cancer growth and metastasis. Abstract ID-1292, AACR-2023.
225. **Manne U**, Scarinci IC, Rivers BM, Lillard JW, Carter V, Dean-Colomb W, Yates CC. Building a Successful Cancer Research Partnership – Morehouse School of Medicine, Tuskegee University, and University of Alabama at Birmingham O'Neal Comprehensive Cancer Center. Biennial Program Meeting, Partnerships to Advance Cancer Health Equity, CRCHD, National Cancer Institute, NIH, 2023 Abstract #10.
226. Bajpai P, Paluri R, Diffalha SA, Chandrashekar DS, Afaq F, Otali D, Bash R, Miller CR, Varambally S, Khushman M, Singh R, Samuel T, **Manne U**. African American Patient-Specific Novel Molecular Targets of Pancreatic Ductal Adenocarcinoma. AACR, PDAC Conference, Boston, MA, 2023.
227. Gillis A, Herring B, Srinivasasainagendra V, Chen W, Guenter R, Hemant T, Chen D, Chen H, Rose JB, Yates C, **Manne U**, Bhatia S. Differential gene expression in pancreatic neuroendocrine tumors by adverse social determinant of health status. The National Cancer Policy Forum workshop, Washington DC, March 20-21, 2024.
228. Gillis, A, Herring B, Guenter R, Chen, W, Chen D, Chen, H, Rose B, **Manne U**, Bhatia S. Influence of Social Determinants of Health on Pancreatic Neuroendocrine Tumor Stage at Presentation. The Annual Meeting of the North American Neuroendocrine Tumor Society 98 P8, DOI: 10.1530/endoabs.98.P8.
229. Khushman M, Seeber A, Iglesia M, Krysiak K, Sun L, Firwana B, **Manne U**. The association between variant of unknown significance neurotrophic tropomycin receptor kinase alterations and response to immune checkpoint inhibitors in solid tumors. Annual Meeting of the Society for Immunotherapy of Cancer (Abstract-164, 2023).
230. Gangnusa T, Kamal AHM, Daic J, Amara CS, Putluria, V, Piyarathnaa DWB, Kim H-G, Gandhi T, Ambatia CS, Parsaware K, Coarfa C, **Manne U**, Sreekumar A, Liuc S, Lotang Y, Putluri V. Metabolomics-based biomarker discovery and clinical validation for non-invasive diagnosis of bladder cancer. Munich Metabolomics Meeting 2023.
231. Ghandour F, Zein-Sabatto B, Lobo J, Manne U, Dhall D, Patel CR, Osme A, Goksel B, Diffalha SA. Exploring Fibronodular Hepatocellular Carcinoma: A Case Series Investigating Histopathological and Clinical Characteristics, and Its Potential Association with Cirrhosis. Abstract ID-1884, USCAP 2024.
232. Diffalha SA, Bajpai P, Patel CR, **Manne U**. B3GNT6: A Novel Marker to Identify Ganglion Cells Aiding in the Diagnosis of Hirschsprung's Disease. Abstract ID-2005, USCAP 2024.
233. Varambally S, Chandrashekar DS, Puli GC, Karthikeyan SK, **Manne U**, Creighton CJ, Kumar S. UALCAN Mobile, An app for cancer gene expression data analysis AACR 2024 Abstract-2270.

234. Dhasmana S, Dhasmana A, Rios S, Perez IA, Khan S, Afaq F, **Manne U**, Yallapu MM, Chauhan SC. TRIP13 augments pancreatic cancer progression- An integrated systems biology study AACR 2024, Abstract-6220.
235. Bajpai, P, Agarwal S, Afaq F, Diffalha SA, Kim H-G, Varambally S, Ganji PR, Manne A, Paluri R, Khushman M, **Manne U**. Regorafenib antitumor immune response is enhanced by a novel drug combination in a CRC syngeneic model. AACR, 2024. Abstract-585
236. Afaq F, Khushman M, Bajpai P, Al Diffalha S, Otali D, Varambally S, **Manne U**. Targeting prolyl 4-hydroxylase subunit alpha 1 with a small molecule inhibitor, diethyl-pythiDC, reduces pancreatic ductal adenocarcinoma growth and metastasis. AACR-2024 Abstract-5973.
237. Paluri RK, Su Y, Singh S, Williams G, **Manne U**, Deep G. Molecular characterization of small extracellular vesicles in the blood of pancreatic cancer patients treated with neoadjuvant chemotherapy regimens in combination with radiotherapy. ASCO GI (Submitted).
238. Maun BR, Abushukair H, Abdelrahim M, Abdullah E, Al Diffalha S, **Manne U**, Khushman M. The association between alterations in the Ataxia Telangectasia Mutated (ATM) gene and response to Immune Checkpoint Inhibitors. AACR GI, 2024 (Submitted).
239. Bandi DSR, Nagaraju GP, Foote JB, Keeton AB, Chen X, Berry KL, Maxuitenko YY, **Manne U**, Buchsbaum DJ, Piazza GA, El-Rayes BF. A novel pan-RAS inhibitor (ADT-1004) with superior efficacy over mutation-specific KRAS inhibitors in mouse models of pancreatic cancer. EORTC-AACR Molecular Targets (Submitted).
240. Bandi DSR, Nagaraju GP, Foote JB, Keeton AB, Chen X, Berry KL, Maxuitenko YY, **Manne U**, Buchsbaum DJ, Piazza GA, El-Rayes BF. Survival benefit and tumor regression with a dual RAS/β-catenin inhibitor, ADT-030, in murine models of pancreatic and lung cancer. EORTC-AACR Molecular Targets (Submitted).
241. Manne A, Puram H, Sherapally D, Jeepalyam S, **Manne U**. Protein-informed gene methylation signatures predict treatment response and outcomes in pancreatic ductal adenocarcinoma. AACR GI, 2024 (Submitted).

MAJOR INVITED LECTURES & SEMINARS:

1. 2001 *Invited Speaker* - Annual Meeting of Biologic Staining Commission, Birmingham, AL (8-10, June).
2. 2001 *Invited Speaker - 2nd Annual Scientific Workshop of Early Detection Research Network*, Fred Hutchinson Cancer Research Center, Seattle, WA (15th, Oct).
3. 2002 Invites Speaker - Validation of prognostic value of molecular markers of colorectal Adenocarcinoma (CRC) using data mining tools. M.D. Anderson Cancer Center, Houston TX (4th Feb).
4. 2002 *Invited Speaker* - Annual Alumni Meeting of Graduate Students- Osmania University, Hyderabad, India (18th Oct).
5. 2003 *Invited Speaker* - Molecular markers of colorectal adenocarcinoma (CRC) associated with aggressiveness phenotypic features. University of Pittsburgh Cancer Institute, Pittsburgh, PA (24th June).
6. 2003 *Seminar Speaker* – Biomarkers of Colorectal Cancers, Graduate student's seminar series of cell and molecular pathology, University of Alabama at Birmingham. AL. (16th Oct).
7. 2004 *Invited Speaker* - Mini-symposium on racial and ethnic minorities and the medically underserved, at Annual Meeting of AACR, Orlando, FL (30th March).

8. 2004 *Invited Speaker* - Clinical implications of molecular markers of colorectal cancer, Greene Baum Cancer Center, University of Maryland at Baltimore, Baltimore, MD., (30th August).
9. 2004 *Invited Speaker and Chair of Clinical Oncology/Molecular Oncology* - 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine, Crete, Greece (14-16th, Oct).
10. 2004 *Invited Speaker* – Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE (1st November).
11. 2005 *Invited Speaker* - Mini-symposium on "*Genetic Modulation in Unique Populations,*" held at Annual Meeting of American Association for Cancer Research, Anaheim, CA (4th April).
12. 2005 *Invited Faculty Lecture* - Clinical Implications of Molecular Markers of Colorectal Cancer- Alabama Association of Pathologists, Birmingham, AL (3rd Dec).
13. 2006 *Invited Speaker* – Molecular Markers of Colorectal Cancer – GI working group of the UAB-Comprehensive Cancer Center - (Feb 19th).
14. 2006 *Invited Speaker* – Prognostic Molecular Markers of Colorectal Cancer – 4th EDRN (NCI) Scientific Workshop – (20th March).
15. 2006 *Invited Speaker* - Mini-symposium on clinical research- prognostic and predictive factors, at Annual Meeting of AACR, Washington DC (April 5th).
16. 2006 *Invited speaker* - Prognostic Makers of Colorectal Cancer: Are they ready for multi-center validation. EDRN-NCI Scientific Workshop-University of Pittsburgh, Pittsburgh (19th Sept).
17. 2007 *Invited Speaker* – Novel Prognostic and Predictive Molecular Markers of Colorectal Cancer – Are they ready for pre-clinical validation? – University of Health Sciences Center, Denver, CO (13th March).
18. 2007 *Invited Speaker* – Rabphillin 3A-Like Gene: A Novel Tumor Suppressor in Colorectal Cancer. Graduate Student's Seminar Series of Cell and Molecular Pathology, University of Alabama at Birmingham. AL (22nd March).
19. 2007 *Invited Speaker* - Prognostic/Predictive Molecular Markers of Colorectal Cancer, Cancer Institute of Apollo Hospitals, Hyderabad, India (24th Aug).
20. 2007 *Invited Speaker* – Validation of potential prognostic molecular markers of colorectal cancer in a multi-institutional setting. Scientific Workshop of NCI-University of Michigan, Ann Harbor, Michigan (17th Sept).
21. 2007 *Invited Speaker* - Prognostic value of p53 in colorectal cancer varies with tumor location and patient race/ethnicity, at AACR-Cancer Health Disparity Conference, Atlanta GA (29th Nov).
22. 2008 *Guest Speaker* - The need to educate researchers and clinicians for improved patient care. International Symposium on Frontiers in Functional Genomics, Gujarat, India (8th Feb).
23. 2008 *Invited Speaker* – Preclinical Translational Cancer Research. International Symposium on Clinical Translational Biomedical Research, Department of Biotechnology, Osmania University, Hyderabad, India (13th Feb).
24. 2008 *Invited Speaker* – p53 and Race in Colorectal Cancer. UAB-Minority Summer Institute Seminar, Double Tree Hotel, UAB (7th April).
25. 2008 *Invited Speaker* – Strategies Cancer Disparity Research Cancer Education Training Program, Symposium on Health Disparity Research, Department of Preventive Medicine, UAB (17th June).

26. 2008 *Invited Speaker* – Preclinical Validation of Candidate Prognostic Markers of Colorectal Cancer – Fred Hutchinson Cancer Research Center, Seattle, WA (16th Sept).
27. 2008 *Invited Speaker* – Discovery and Preclinical Validation of Molecular Markers of Colorectal Cancer, Cancer Research Seminar Series, Southern Research Institute (SRI), Birmingham, AL (16th Dec).
28. 2009 *Invited Speaker* – Validation of Colorectal Cancer Markers, Confounders of Clinical Outcomes, UT M.D. Anderson Cancer Center, Houston, TX (March 31st).
29. 2009 *Invited Speaker* – microRNAs as Prognostic Markers of Colorectal Cancer. AACR-Annual Meeting at Denver, CO (20th April).
30. 2009 *Invited Speaker* – Colorectal Neoplasia-Graduate Students, Division of Preventive Medicine, UAB (16th June).
31. 2009 *Invited Speaker* – Prognostic and Predictive Molecular Markers of Colorectal Cancer. Surgery Grand Rounds, Morehouse School of Medicine, Atlanta, GA (9th Sep).
32. 2009 *Invited Speaker* – Translational Health Disparity Research, Minority Institution/Cancer Center Partnership Funded Investigator Workshop, NCI, Rockville, MD (17th Sept).
33. 2009 *Expert Speaker* – Race/Ethnicity Specific Molecular Markers Aid in Personalized Cancer Treatment, The US Presidents Cancer Panel, 2009, Los Angeles, CA (27th Oct).
34. 2009 *Invited Speaker* - Preclinical Evaluation of Molecular Biomarkers of Colorectal Cancer, 13th Annual UAB Cancer Center Retreat, Birmingham (28th Oct).
35. 2009 *Invited Speaker* – The NCI-Translational Science Meeting, Predictive Markers of Colon Cancer. Vienna, DC (5th Nov).
36. 2010 *Invited Speaker* – Discovery and Validation of Molecular Markers of Colorectal Cancer, UAB Pathology Departmental Seminar (11th March).
37. 2010 *Invited Speaker* – microRNAs as Prognostic Markers of Colorectal Cancer. AACR-Annual Meeting at Washington, DC (19th April).
38. 2010 *Grand Rounds Speaker* – Pre-Clinical Translational Studies of Colorectal Cancer, Department of Pathology, Yale University, New Haven, CT (6th May).
39. 2010 *Invited Speaker* - Determination of the Clinical Value of Molecular Markers in Predicting Survival of African American and non-Hispanic Caucasian Patients over the Period of 1982-2008, UAB-Tumor Board (11th May).
40. 2010 *Invited Lecture* – Basic Science Health Disparities Research: Pre-Clinical and Clinical Translational Studies for "Evidence Based Care" -Health Disparity Cancer Education, Division of Preventive Medicine, UAB (15th June).
41. 2010 *Invited Speaker* – 11th Annual Biomedical Research Symposium, Interdisciplinary Approaches in Health Disparity Research. "Role of Preclinical Cancer Disparity Research in Evidence Based Care." Tuskegee University, Tuskegee, AL (23-24, Sept).
42. 2010 *Invited Lecture* - Improving Your Health UA27, "Colorectal Cancer in Elders, What you need to know?" Osher Lifelong Learning Institute, University of Alabama, Tuscaloosa, AL (6th Oct).
43. 2011 *Invited Lecture* – Disparities in Molecular Profiles of Colorectal Cancer-Cancer Epidemiology, University Michigan, Ann Arbor, MI (21st Jan).
44. 2011 *Invited Speaker* - Effect of Pre-Clinical Research on Cancer Disparities to Evidence-Based Care. 3rd International Conference on Drug Discovery and Therapy, Dubai, UAE (7th -10th Feb).

45. 2011 *Invited Speaker* - Prognostic Value of miRNAs in Colorectal Cancer Cambridge Healthtech Institute, Cambridge, MA (28th March).
46. 2011 *Invited Lecture* – "Molecular Markers of Colorectal Cancer: What is New?" UAB GI Working Group (10th May).
47. 2011 *Invited Speaker* – "Racial Differences in MicroRNA in Colorectal Cancer." Annual Meeting of the Biological Staining Commission. Atlanta GA (3rd June).
48. 2011 *Invited Speaker* – "Basic Science Health Disparities Research: Pre-Clinical and Clinical Translational Studies for Evidence Based Care." Video Conference Seminar to Scholars of Five Institutions by the UAB-Health Disparity Research Center (31st May).
49. 2011 *Invited Lecturer* – "Biology of Colorectal Neoplasia and Translational Research." UAB/Tuskegee University/Morehouse School of Medicine/UA Tuscaloosa/Creighton University-Cancer Education Course (21st June).
50. 2011 *Invited Panelist* – "Translational Sciences and Accrual to Clinical Trials." Partnership to Reduce Cancer Health Disparities Investigators Workshop, National Cancer Institute, NIH, Bethesda, MD (12th July).
51. 2011 *Invited Speaker* – "Predictive modeling of colorectal cancer clinical outcomes."Research Triangle Institute (RTI) Atlanta, GA (18th Oct).
52. 2011 *Invited Speaker* – "Colorectal Cancer Biomarker Development: Collaborative Project on EMAST with CDFD." Center for DNA Fingerprinting and Diagnosis, Hyderabad, India (8th Dec).
53. 2011 *Invited Speaker* – "Colorectal Cancer Development and Progression: Molecular Profiling." Seminar Series of the Graduate Studies, Department of Zoology, Osmania University, Hyderabad, India (Dec 15th).
54. 2011 *Invited Speaker* – "Evidence-Based Care Requires Consideration of Cancer Disparities." International Conference of Society for Mitochondrial Research and Medicine, Center for Cellular and Molecular Biology, Hyderabad, India (9th Dec).
55. 2012 *Invited Speaker* – "Cancer Biomarker Discovery and Validate: Colorectal Cancer". Department of Physiology, Morehouse School of Medicine, Atlanta, GA (16th Feb).
56. 2012 *Invited Speaker* – "Colorectal Cancer Prognostic/Predictive Models". Research Triangle Institute, Atlanta, GA (6th April)
57. 2012 *Invited Lecture* – "Molecular Epidemiology and Cancer Biomarkers of Colorectal Cancer". Cancer Control and Prevention Division, Department of Epidemiology, School of Public Health, UAB (1st June).
58. 2012 *Invited Lecture* – "Basic Science Health Disparity Research Symposium, Health Disparity Research Center", Preventive Medicine, UAB (19th June).
59. 2012 *Invited Speaker* – "Epigenetics and miRNA in Colorectal Cancer." Epigenetics Symposium, Department of Genetics, UAB (11th July).
60. 2012 *Invited Speaker* – "Molecular Markers of Colorectal Cancer", Asian Institute of Gastroenterology, Hyderabad, India (30th Oct).
61. 2012 *Keynote Speaker of a Session* – "Evidence-Based Care Requires Global Mapping of the Cancer for Molecular Phenotypes," the 33rd Annual Conference of Indian Association of Biomedical Scientists, NITTE University, Mangalore, India (2nd Nov).
62. 2012 *Workshop Organizer* – Workshop on Biomarker Discovery and Development. 9th Annual Conference of the Society for Mitochondrial Research and Medicine-India, Gandhinagar, Gujarath, India (3rd Nov).
63. 2012 *Invited Speaker* – Role of Biomarkers in Evidence Based Care, Himalayan Institute Hospital Trust, Dehradun, India (7th Nov).

64. 2012 *Invited Speaker* - Molecular Phenotyping of Colorectal Cancer: Candidate Markers, Cancer Research Institute, Himalayan Institute Hospital Trust, Dehradun, India (8th Nov).
65. 2012 *Invited Speaker* – Colorectal Cancer Biomarkers: Development and Validation, Sanford Health, Sioux Falls, SD (6th Dec).
66. 2013 *Invited Speaker* - Molecular Disparities in Cancer, National Scientific Symposium on Minority Health Disparity Center, UAB (28th Feb).
67. 2013 *Invited Speaker* - Translational Research in Cancer, Howard Huge Fellows, Graduate School of UAB (18th Mar).
68. 2013 *Invited Speaker* - Cancer Heterogeneity and Biomarker Development, Department of Pathology, UAB (2nd April).
69. 2013 *Invited Speaker* - Biomarkers for Cancer: Translational Research, Department of Epidemiology, School of Public Health, UAB. (31st May).
70. 2013 *Invited Speaker* - Basic Science Health Disparities Research: Pre-Clinical and Clinical Translational Studies for "Evidence Based Care", South East Regional Work-Shop, Minority Health Disparity Center, UAB (18th June).
71. 2013 *Invited Speaker* - Biomarkers of Colorectal Cancer: Translational Research, Howard Huge Med-to-Grad Graduate Students Seminar, UAB. (26th June).
72. 2013 *Invited Speaker* - Preventing and Controlling Cancer through Research, Summer Research Interns, U54-Partnership for Cancer Disparity Research, UAB. (3rd July).
73. 2013 *Grand Rounds Speaker* - Cancer Heterogeneity and Biomarker Development, Grady Memorial Hospital, Atlanta, GA (23rd July).
74. 2013 *Invited Speaker* – Efforts to Eliminate Cancer Disparity through Collaborative Research, Alabama State University, Montgomery AL (23rd October).
75. 2013 *Invited Keynote Speaker & Workshop Organizer* - Workshop on Biomarker Discovery and Development. 10th Annual Conference of the Society for Mitochondrial Research and Medicine-India, NIMHANS, Bangalore, India (19th Dec).
76. 2014 *Invited Speaker* – "Clinical Translational Research: Tumor Heterogeneity" Graduate Student Seminar, Georgia State University, Atlanta, GA (14th March).
77. 2014 *Invited Lecture* - Translational Research in Cancer, UAB Graduate Students (17th March).
78. 2014 *Invited Speaker* – Effect of Patient Demographics on Cancer Biomarker Development and Validation, Alexandria University, Alexandria, Egypt (2nd April).
79. 2014 *Invited Lecture* – Biomarkers for Cancer: Translation Research, Graduate Student Seminar, UAB School of Public Health (28th May).
80. 2014 *Invited Seminar* – "Preventing and Controlling Cancer through Research", Research Experience for Undergraduate Students from Minority Institutions of Alabama, UAB Preventive Medicine (16th June).
81. 2014 *Invited Seminar* - Basic Science Health Disparities Research: Pre-Clinical and Clinical Translational Studies for "Evidence Based Care", Health Disparity Research Program for Faculty and Research Scholars, UAB Preventive Medicine (17th June).
82. 2014 *Invited Talk:* Partnerships to Advance Cancer Health Equity (PACHE) Investigators Workshop, "Race/Ethnicity-Specific Molecular Cancer Biomarkers: What's Next?" Conducted by the National Cancer Institute, NIH, Bethesda, MD, USA (28th July).
83. 2014 *Invited Talk*: "Potential Molecular Biomarkers of Colorectal Cancer," UAB Comprehensive Cancer Center, GI Collaborative Group (16th Sept).

84. 2014 *Workshop Organizer*: Conducted a workshop on Cancer Biomarkers. "Evidence-Based Cancer Care Requires Development of Patient Population-Specific Molecular Biomarkers." Athens, Greece (9th Oct).
85. 2014 *Invited Talk*: "Development of Patient Population-Specific Molecular Biomarkers: Colorectal Cancer." 4th Annual Conference of the Society for Mitochondrial Research and Medicine Mitochondrial Biology: from Molecules to Disease. Manipal, India (8th Dec).
86. 2014 *Invited Speaker*: "Importance of Population-Based Studies in Developing Cancer Molecular Biomarkers." Center for DNA Fingerprinting, Forensic Investigations and Molecular Medicine, Hyderabad, India (11th Dec).
87. 2015 *Keynote Speaker*: Key Note Address at a National Scientific Research Conference of Minority Institutions, "Role of Cancer Disparities Research in Evidence Based Care," Alabama State University, Montgomery, AL (18th March).
88. 2015 *Invited Speaker*: "Colorectal Cancer Biomarkers: Clinical Implications Based on Race and Ethnicity," Temple University, Philadelphia, PA (21st April).
89. 2015 *Invited Speaker*: "Cancer Heterogeneity and Biomarker Development," Medical University of South Carolina, SC (27th April).
90. 2015 *Invited Speaker*: "UAB-Egyptian Cancer Institute Collaboration: Colorectal Cancer," Alexandria University, Alexandria, Egypt (9th June).
91. 2015 *Invited Speaker*: "*Community-Based Biomarker Studies: Impact on Clinical Practice,*" Research Triangle Institute, Atlanta (31st July).
92. 2015 *Chair & Workshop Organizer*: *"Workshop on Cancer Biomarker Development and Validation,"* Dubai, UAE (28th August).
93. 2015 *Invited Speaker*: "*Molecular Epidemiology and Cancer Biomarker Development,"* Centre for Chronic Conditions & Injuries (CCCI), Public Health Foundation of India, New Delhi, India (3rd September).
94. 2015 *Invited Speaker*: "*Building Cancer Research Partnerships with Minority Institutions*," Mississippi Medical Center, Jackson, MI (11th September).
95. 2015 *Invites Speaker*: "*Molecular Biomarkers of Colorectal Cancer-Clinical Implications Based on Tumor Site, Stage and Patient Race/Ethnicity*." Grand Rounds of Surgery, Michigan State University, Lansing, MI (1st October).
96. 2015 *Invited Speaker*: "*Cancer Biomarker Development and Clinical Applications*," Markey Cancer Center, Lexington, KY (7th October).
97. 2015 *Speaker*: "*Molecular Insights of Colorectal Cancer*," UAB Pathology Departmental Seminar (3rd November).
98. 2016 *Keynote Speaker*: "*Translating Basic Research in the Biomedical Sciences to Address Health Disparities in Minority Communities,"* XULA-COP Ninth National Health Disparities Conference-RCMI Symposium of NIMHD/NIH. New Orleans, LA (29th Feb).
99. 2016 *Invited Speaker*: *"Development of Patient Population-Specific Cancer Molecular Biomarkers."* 13th International Symposium on Recent Advances in Environmental Health Research. Jackson, MS (12th Sept).
100. 2016 *Invited Lecture*: "*Clinical Implications of Cancer Mutations and Gene Amplifications*" UAB Graduate School, UAB (14th Sept).
101. 2016 *Invited Speaker:* "*Clinical Translation Research in Cancer-GI Malignancies,*" Department of Surgery, Michigan State University, Lansing, MI (23rd Sept).
102. 2016 *Invited Speaker*: *"Development of Patient Population-Specific Cancer Molecular Biomarkers,"* School of Medicine, ESIC Hospital, Hyderabad, India (29th Nov).

103. 2017 *Invited Speaker*: "*Big data initiatives and challenges in analytical approaches,*" Computer Technology Solutions, Inc (CTS), Birmingham, AL (27th Feb).

104. 2017 *Invited Speaker:* "*Evidence based cancer care: Translational research,*" Preventive Medicine Division, UAB, Birmingham, AL (28th Feb).

105. 2017 *Invited Speaker*: "Development of population based intervention studies in rural and urban areas," Pack Health Inc, Birmingham, AL (1st Mar).

106. 2017 *Invited Speaker*: *"Cancer biomarkers, epidemiology and prevention: Future perspectives,"* College of Public Health, University of Nebraska Medical Center, Omaha, NE (21st Mar).

107. 2017 *Invited Lecture*: *"Translational research in cancer,"* UAB Graduate School, Birmingham, AL (18th May).

108. 2017 *Invited Speaker*: *"Cancer biomarker development: Future perspectives,"* Department of Biomedical Sciences, East Tennessee State University, Johnson City, TN (22nd May).

109. 2017 *Invited Lecture*: *"Biomarkers of colorectal cancer,"* Department of Pathology, Temple University, *Philadelphia, PA* AL (30th May).

110. 2017 *Invited Speaker*: *"Integration of cancer molecular biomarkers in the era of precision medicine initiatives,"* Division of Hematology and Oncology, UAB School of Medicine, Birmingham, AL (5th June).

111. 2017 *Invited Lecture*: "*Cancer prevention and control,*" PSRTP, undergraduate students summer research program, UAB (July 12th).

112. 2017 *Invited Speaker*: "*miRNAs as biomarkers of colorectal cancer disparity: Current status and perspective,*" Emerging Cancer Biomarkers, 9th Cambridge Healthtech Annual Next Generation Summit, Philadelphia, PA (Aug 18th).

113. 2017 *Speaker*: "Development of strategies to use innovative technology in population based cancer survivor intervention studies," Pack Health Inc, Birmingham, AL (22nd Sept).

114. 2017 *Group Discussion Leader:* "*Translational research initiatives in cancer health disparities*". AACR-Minority Disparity Meeting, Atlanta, GA (27th Sept).

115. 2017 *Speaker*: "*Identifying opportunities for 'Big' grants*", Molecular and Cellular Pathology Division of UAB Pathology, Research Retreat, (10th Nov).

116. 2017 *Invited Speaker*: "*Round Table Discussion on Cancer Health Disparity."* Stephenson Cancer Center, Oklahoma University, Oklahoma City, OK (13th Nov).

117. 2017 *Invited Speaker*: "*Strategies to develop cancer research partnerships*," Stillman College, Tuscaloosa, AL (13th Dec).

118. 2018 *Invited Lecture: Basic Science Health Disparities Research: Pre-Clinical and Clinical Translational Studies for "Evidence Based Care"* UAB-HDRTP, Scholars Conference (Mar 6).

119. 2018 *Invited Lecture: Preventing and Controlling Cancer Through Research.* UAB Summer Research and Training Program for Undergraduate Students UAB CCC (June 6).

120. 2018 *Invited Lecture: Cancer Health Disparities Research: Future perspectives.* UAB Cancer Education Course for Graduate and Undergraduate Students MHRC (June 12).

121. 2018 *Invited Speaker: "Therapeutic Value of Navitoclax based on the Expression status of miR-181b and miR-21 in African American and Caucasian Colon Cancer Patients."* The Richard Elkus Eminent Scholars Program in GI Oncology Research at UAB (July 20).

122. 2018 *Lecture: Candidate Biomarkers of Colorectal Cancer: Translational Opportunities,* UAB Translational Cancer Research Group (Sept 27).

123. 2018 *Invited External Speaker: Cancer Biomarker Development:* A Multidisciplinary Approach. Distinguished Lecture Series, Georgia State University, Atlanta, GA (Oct 18).

124. 2018 *International Distinguished Speaker: Molecular Biomarkers of Colorectal Cancer: Translational Opportunities.* National Institute of Immunology, New Delhi, India (Dec 6)

125. 2018 *International Alumni Lecture: Lessons from the Integrative Approaches of Precision, Molecular Epidemiology & Population Sciences in Cancer Prevention and Control.* National Institute of Malaria Research, New Delhi, India (Dec 7).

126. 2019 *Invited Speaker: Clinical Translational Cancer Studies.* UAB HDRTP Scholars Conference (Feb 12).

127. 2019 *Invited Lecture: Molecular Biomarkers of Colorectal Cancer: Translational Opportunities.* The RCMI-U54 Seminar Series, School of Vetinerary Sciences, Tuskegee University, Al (Feb 13).

128. 2019 *Invited Speaker: Precision Targeting of p53 by PRIMA-1MET in Colorectal Cancer.* UAB Division of Hematology and Oncology (April 5).

129. 2019 *Invited Distinguished Lecture: Molecular Epidemiology of Colorectal Cancer: Translational Opportunities.* Distinguished Lecture Series, UAB School of Public Health (April 8).

130. 2019 *Chair & Organizer*: *Workshop on Cancer Biomarker Development and Validation*. Topic of the Lecture, *Development of Patient Population-Specific Molecular Biomarkers and Translational Opportunities*. 11th Annual Conference of the Alexandria Society for Cancer Patient Care, Alexandria, Egypt (May 1-4).

131. 2019 *Invited Lecture*, "*Cancer Control and Prevention*," the PRSTP Summer Research Program for undergraduate students, UAB Cancer Center (26th June).

132. 2019 *Invited Lecture, "Mutations, amplifications and deletions in cancer*". GBS/CRN, UAB graduate school (29th September).

133. 2019 *Invited Lecture,* "Targeting p53 in colon cancer." GBS/CRN, UAB graduate school (3rd October).

134. 2020 *Invited Lecture,* "*Targeting anti-apoptotic Bcl-2 proteins in colorectal cancer*", Mitochondria, Metabolism, and Epigenetics, WTI, UAB Cancer Center (13th Jan).

135. 2020 *Invited Talk,* "*Microbiome and gene expression studies of colorectal cancers of multiple race/ethnic populations*." US-Egyptian Collaborative Group, UAB Preventive Medicine (23rd Jan).

136. 2020 *Invited Speaker*, "*Predictive and prognostic molecular biomarkers of colorectal cancer*." MNH Cancer Hospital, Hyderabad, India (30th Jan).

137. 2020 *Distinguished International Speaker*, "*Cancer biomarkers for individualized cancer care*," Indo-American Cancer Institute, Hyderabad, India (31st Jan).

138. 2020 *Invited Lecture*, "*Cancer biomarker development and translational opportunities*," Dr. B. R. Ambedkar Center for Biomedical Research, Delhi University, Delhi, India (10th Feb).

139. 2020 *Invited Distinguished Lecture*, "*Cancer biomarker development for personalized cancer treatment*". Depart of Biotechnology, IIT Roorke, Roorke, India (12th Feb).

140. 2020 *Organizer*, "*Translational Research Symposium in Gastrointestinal Oncology*". School of Medicine, UAB (6th March).

141. 2020 *Invited Lecture*, "*Translational Research Strategies in Cancer*" Graduate Students of the Cancer Biology theme, UAB Graduate School (9th March).

142. 2020 *Invited Speaker*, *"Summary of K99 grant applications from submission to review"* the UAB Cancer Prevention and Control Training Program for Trainees, UAB School of Public Health and School of Health Professions (9th September) (Virtual).

143. 2020 *Distinguished Lecture*, *"Cancer Biomarker Development and Personalized Cancer Treatment,"* the Centennial Celebration of the University of Lucknow, Lucknow, UP, India (21st November) (Virtual).

144. 2020 *Invited International Scholar Webinar Lecture*, *"Translational Cancer Research: Molecular Biomarker Development,"* Mizoram University, a Central University of India, Aizawl, India (25th November) (Virtual).

145. 2021 *Invited Seminar Early Stage Faculty Development Discussion Video Conference, "Basic Science Health Disparities Research: Pre-Clinical and Clinical Translational Studies for 'Evidence Based Care'* Preventive Medicine, SOM, UAB (March 9th).

146. 2021 *Invited Lecture*, "*Cancer Translational Research: Opportunities and Challenges*" UAB Graduate School - Pathobiology of Cancer Program (March 10th).

147. 2021 *Invited Seminar,* "*Tumor Immune Cells and Obesity-Related Transcriptional Signature of TP53 Germline Alterations in African American and Caucasian Patients with Breast Cancer*." Obesity and Metabolism in Cancer Retreat, the O'Neal Comprehensive Cancer Center, UAB (June 16th).

148. 2021 *Invited Speaker*, Interplay of Molecular Factors and Comorbid Conditions in Cancer Disparities. 20201 Research Symposium, International Conference on Cancer Health Disparities (ICCHD-2021) (August 14th).

149. 2021 *Invited Speaker*, NIH/NCI- *Building Research Competitiveness*. Partnerships to Advance Cancer Health Equity (PACHE) National Workshop (Sept 20th).

150. 2021 *Invited Seminar*, *Building Cancer Research Partnerships*, Cancer Control and Prevention Program, O'Neal Comprehensive Cancer Research, UAB (Sept 22nd).

151. 2021 *Invited Seminar*, *UAB-Tissue Biorepository*, Translational Research Group, UAB (Sept 23rd)

152. 2021 *Invited Lecture*, *Population-Based Integrative Translational Cancer Research*, Global Cancer Consortium of Mayo Clinic, Manipal University, India and University of Kentucky Markey Cancer Center (Oct 1st).

153. 2021 Invited Lecture, Strategic Priorities, Action Plans, and Success of Cancer Research Partnerships with Minority Serving Institutions. Temple University/Fox Chase Cancer Center (Oct 14th).

154. 2021 Invited Speaker, *"Collaborations and Team Building, a Pathway for Career Development in STEM".* The Miles College ADVANCE Research and Education Program, NSF (Nov 19th).

155. 2021 *Invited International Speaker*, "*Application of Honey and Honey Bee Products in Cancer Research,*" International Honey Bee Conference, Haldwani, Uttarkhand, India (Dec 19th).

156. 2022 *Invited Lecture*, "*Translational Cancer Research*", Department of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH (Jan 4th).

157. 2022 *Invited Lecture, "Preclinical Molecular Cancer Research"* Graduate School of UAB, (March 7th).

158. 2022 *Invited Speaker,* "*Evidence Based Care"* Preventive Med, SOM, UAB (Mar 8th).

159. 2022 *Invited Speaker, "Translational and Implementation Cancer Research to Reduce Health Disparities and Enhance Equity*". University of Pittsburgh Medical Center, Hillman Cancer Center (March 21st).

160. 2022 *Invited Speaker,* "*Evaluating the Molecular Basis for Cancer Health Disparities to Reduce the Cancer Burden"*. University of Texas Health Science Center, Mays Cancer Center (May 2nd).

161. 2022 *Invited Lecture,* "*Preventing and Controlling Cancer Through Research*," Summer Training Program, UAB Pathology (June 15).

162. 2022 *Distinguished Lecture, "Molecular Basis for Cancer Health Disparities"* Stephenson Cancer Center Seminar Series, Oklahoma University, Oklahoma City, OK, (July 25th).

163. 2022 *Distinguished Lecture Series, "Evaluating the Molecular Basis for Cancer Health Disparities to Reduce the Cancer Burden in the Catchment Area." T*he Dan L Duncan Comprehensive Cancer Center, Baylor Medical Center, Texas (August 2).

164. 2022 *Meet the Expert-Session, "Strategies to Build the Cancer Health Disparity Research Program-CPACHE."* The Center for Cancer Health Disparities, Baylor Medical Center, Texas (August 3).

165. 2022 *Expert Lecture Series*, "*Use of Tissues in Basic, Translational, and Clinical Cancer Research*," Graduate Students of Cancer Prevention and Control Training Program, UAB Nutrition Sciences (November 16).

166. 2023 *Keynote Speaker, 'Based Integrative Translational Research in Breast Cancer'.* 2nd International Global Cancer Consortium Conference, Manipal Comprehensive Cancer Care Center, Kasturba Medical College, Manipal, India (Jan 7th).

167. 2023 *Distinguished International Expert, "Care Risk and Translational Cancer Research."* Osmania University, Hyderabad, India (Jan 13th).

168. 2023 *Invited Speaker, "Cancer Risk and Awareness in Rural Populations"* Telangana State Higher Education, Mandal Schools of Papannapet, India (Jan 18th Jan)

169. 2023 *Inaugural Lecture, "Career Development Strategies with Majoring in Zoology: Contributions to Advancement of Medicine",* School of Sciences, South Campus, Telangana University, Nizamabad, Telangana, India (Jan 19th)

170. 2023 *Meet the Expert, "Session with University Faculty and Students to Develop Next Generation of Scientist"* Biomedical Sciences, North Campus, Telangana University, Dichpally, Telangana, India (Jan 19th).

171. 2023 *Distinguished Lecture Series, "Integrative Approaches for Translational Cancer Research."* the National Institute of Pharmaceutical Education and Research, Hyderabad, India (Jan 20th).

172. 2023 *Expert Lecture and Discussion, "Cancer Research: Role of Pharmaceutical Sciences,"* Institute of Pharma Research, GLA University, Mathura, India (23 Jan).

173. 2023 *Meet the Expert Session*, *"Cancer control and prevention in the developing world"* Disease Control Consortium, Delhi, India (Jan 27th).

174. 2023 *Invited Lecture: Basic Science Health Disparities Research: Pre-Clinical and Clinical Translational Studies for "Evidence Based Care."* UAB-HDREP, Scholars Program. Virtual Presentation (Mar 7th).

175. 2023 *Expert Lecture and Discussion:* "*Cancer Health Disparities/Equity – Where we are at and what we need to do?*" Cancer Omics Training Workshop-Global Cancer Consortium. Virtual Presentation (Mar 13th).

176. 2023 I*nvited Seminar*, "*Translation cancer research and establishing community partnership*", Michigan State University, Lansing, MI (April 3rd).

177. 2023 *Invited lecture*, "Population-based Molecular Epidemiology and Cancer Biomarker Development", May's Cancer Center, UT San Antonio (virtual) (April 5th).

178. 2023 *Expert Panelist*: "*Fostering Knowledge Ecosystem-Role of Universities in India and USA-a Comparative Perspective,*" as part of G20 countries. Webinar (May 4th).

179. 2023 *External Speaker: "Establishing successful partnership for cancer research,"* Dept. Department of Urban Health and Population Science, Lewis Katz School of Medicine, Temple University, Philadelphia, PA (Virtual) (May 25th)
180. 2023 *Lecture/Seminar*: "Building career in cancer research and care," Research Summer Training Program, MSM/TU/UAB O'Neal CCC (May 31st).
181. 2023 *International Speaker, " Career Development and Transition to Cancer Research"* Dept. Microbiology, University of New South Wales, Sydney, Australia (Aug. 16th)
182. 2024 *Expert Lecture and Discussion*: *Opportunities and Challenges in Conducting the Preclinical and Clinical Translational Studies in Cancer*. Early-stage cancer investigators and faculty, UAB (March 5th).
183. 2024 *Invited Lecture: Translational and Implementation Cancer Research to Reduce Health Disparities and Enhance Equity.* College of Pharmacy, University of Arkansas for Medical Sciences (March 8th).
184. 2024 *Invited Lecture: Cancer Control and Prevention,* Undergraduate Student Research Program, HSOM, UAB (June 12th).

PROFESSIONAL SOCIETIES/ASSOCIATIONS MEMBERSHIPS

1992-2000 Australian Society for Parasitologists (ASP)
1995-Current American Association for Cancer Research (AACR)
2001-Current American Society of Clinical Oncology (ASCO)
2003-2005 American Society for Clinical Pathology (ASCP)
2004-2007 Federation of American Societies for Experimental Biology (FASEB)
2004-Current ASCO-Indo-American Cancer Congress (ASCO-IACC)

NATIONAL COUNCILS/COMMITTEES

NIH & Other Foundation Grant Application Review Committees:

2005 - 2011 *Reviewer,* Small Grants Program for Cancer Prevention of NCI/NIH
2006 – 2013 Reviewer, Susan G. Komen Breast Cancer Foundation, Research Grant Applications.
2007 – 2014 Reviewer, Small Grants Program for Cancer Epidemiology, NCI/NIH
2007 Apr/Oct *Reviewer*, ZRG1 ONC-P, Cancer Biomarkers Special Emphasis Panel of NCI/NIH.
2008 Apr/Dec *Reviewer,* Minority Center Grants P20-ZRG1 EMNR B51, Study Section, NIH/NCI.
2009 March *Reviewer,* Cancer Health Disparities P60-ZRG1 OBT-M 50S, NIH/NCI
2009 July *Reviewer,* Center for Excellence GO-ZMD1 PA131, Study Section, NIH/NCI.
2009 - 2011 Reviewer*,* ONC-P, Cancer Health Disparities (UO1-Grants), Special Emphasis Panel of NCI/NIH.
2009-2012 *Reviewer,* ZMD1 PA (05), National Center for Minority Health Disparities (RO1-Grants) Study Section, NIH.
2013 NIH Special Emphasis Panel on NCI's Minority Health Disparities (U54-Grants) Study Section
2013 *Reviewer,* ZMD1 PA Special Emphasis Panel Study Section (R01/R21), NCI NIH.
2014 *Reviewer,* Special Emphasis Panel Study Section (R01-Provocative Questions), NCI/NIH.
2014 *Reviewer,* Special Emphasis Panel Study Section (Omnibus R21/R03), NCI/NIH).
2014 *Reviewer, Ad hoc* Member of Study Section Panel (K-Awards), NCI/NIH.

2015	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (P01).
2015	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (R15).
2016	*Reviewer*, Member of the Department of Defense-CDMRP Special Emphasis Study Section Panel on Breast Cancer.
2015-2017	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (U54/P20).
2015-2017	*Reviewer*, Member of the NIH/NIA Special Emphasis Study Section Panel (P30).
2015-2017	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (P01).
2016-Current	*Reviewer*, Member of the Department of NIH/NCI Study Section Panel K99/K22-Series (permanent study section member, three times a year).
2017	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel, RCMI grants (U54-NCI).
2017	Reviewer, Harvard Catalyst – Grant Review Team member
2015-2019	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (Loan Repayment Program of NIH).
2017	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (U54-RCMI of NIMHD).
2017	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (U54-RCMI of NIA).
2017	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (U54 & P20 of PACHE of NCI).
2018	*Reviewer*, Member of the NIH/NCI Special Emphasis Study Section Panel (P20-NCI/SPORE Exploratory Grants).
2018	*Reviewer*, Member of the UAB Pathology Departmental Pilot Grant Panel.
2018	*Reviewer*, Member of the DoD Study Section Panel CSRA (CRC-1).
2018	*Reviewer*, Member of a Special Emphasis Panel of NCI/NIH to review P20-SPORE exploratory grants.
2018-2019	*Reviewer*, Member of a Panel of NCI/NIH to review P50-SPORE (ZCA1 RPRB-F (01) grant applications.
2018	Reviewer, Member of a MikeSliv Foundation grant review panel.
2018	*Chair of Review Committee*, UAB MHRC pilot grant review.
2019	*Reviewer*, Member of a Panel of NCI/NIH K22/K99R00- special review section
2019	*Reviewer*, Member of a Panel of NCI/NIH P01- ZCA1 RPRB-F (01) SEP
2020	*Reviewer*, Member of a Panel of NCI/NIH K22/K99- special review section (Feb, June, October)
2021	*Reviewer*, Member of a Panel of NCI/NIH K22 (January); P20 SEP- Exploratory SPORE grants NCI/CHCRD (Feb)
2019-Current	Reviewer, Member of a Panel of NCI/LRP-SEP (March/Sept)

Other Scientific Committees

1.	1999-2010	Member of Scientific Committee of GI group, Early Detection Research Network (EDRN), National Cancer Institute.
2.	2001-2008	Member of Systematic Review of the prognostic molecular markers of colorectal cancer: A global study, Department of Clinical Pharmacology, University of Oxford, London, UK.

UNIVERSITY ACTIVITIES

1. 2002-2010 Member of knowledge discovery group of UAB, Computer and Information Sciences.
2. 2007-Current Member of the Pathology Graduate/Postdoctoral Research Day competitions committee.
3. 2010-Current Member of the *Adams Grant* applications to fund research by residents and fellows of the UAB-Pathology
4. 2010-Current Chair the mock grant review sessions of the UAB Minority Health and Health Disparity Research Center, UAB

EDITORIAL BOARD MEMBERSHIPS:

1. 2004-Current Editorial Board member of Journal of *Disease Markers*
2. 2005-Current Editorial Board member of *Journal of Translational Medicine*
3. 2010-Current Editorial Board member of *J Gastrointestinal Oncology*
4. 2011-Current Editorial Board member of *J Cancer Therapy*
5. 2011-Current Editorial Board Member *of PLoS One*
6. 2011-Current Associate Editor *of Molecular Cancer Biology*
7. 2011-2019 Associate Editor of *BMC Cancer*
8. 2012-Current Editorial Board Member of *Case Reports of Pathology*
9. 2012-Current Editor of *Molecular Cancer Biology*
10. 2013-Current Editorial Board Member of *Journal Pathology Discovery*
11. 2013-2019 Editorial Board Member of *Frontiers of Preventive Medicine*
12. 2013 Editor of a *Special Issue* of the journal *Molecular Cancer Biology*, *Molecular Disparities in Cancer Biology,* and Published by the *eOpen Access* Publishing, Lithonia, GA, USA.
13. 2015-Current Editorial Board Member of the journal *Archives of Clinical Gastroenterology*
14. *2017-Current* Editorial Board Member of the journal *Digestive Medicine Research*
15. 2019-Current Editorial Board Member of the journal *Cancers*.
16. 2020-Current Editorial Board Member of the journal *Precision Cancer Medicine*.

Peer Reviewer of Research Journals:

1. 2001-Current Cancer Research
2. 2001-Current Clinical Cancer Research
3. 2001-Current Disease Markers
4. 2002-Current Cancer Epidemiology Biomarkers & Prevention
5. 2002-Current American Journal of Nutrition
6. 2002-Current American Journal Clinical Pathology
7. 2002-Current The Journal National Cancer Institute
8. 2002-Current Laboratory Investigation
9. 2002-Current Modern Pathology
10. 2004-Current Cancer (American Cancer Society)
11. 2004-Current Cancer Informatics of NCI
12. 2004-Current Journal of Biotechniques and Histochemistry
13. 2005-Current Cancer Biomarkers
14. 2005-Current Journal of Translational Medicine

15. 2007-Current Frontiers in Bioscience
16. 2007-Current British Journal of Cancer
17. 2008-Current Molecular Cancer
18. 2009-Current BMC Cancer
19. 2009-Current BMC Genetics
20. 2009-Current Journal of Histochemistry and Cytochemistry
21. 2009-Current Cancer Prevention Research (new AACR journal)
22. 2009-Current JAMA
23. 2010-Current Journal of Molecular Signaling
24. 2010-Current PLoS One
25. 2010-Current Journal of Gastrointestinal Oncology
26. 2011-Current Molecular Cancer Therapy
27. 2011-Current Journal Cancer Therapy
28. 2011-Current Journal Cancer Epidemiology
29. 2012-Current Cancer Biology and Therapy
30. 2012-Current Case Reports of Pathology
31. 2012-Current Journal Pharmacogenetics
32. 2012-Current Journal Cancer Biology and Therapy
33. 2012-Current BMC Gastroenterology
34. 2013-Current Advances in Med Sciences
35. 2013-Current International J Medical Sciences
36. 2013-Current Onkologie
37. 2017-Current JAMA Oncology
38. 2017-Current Hindawi- Biomarkers
39. 2018-Current Gastroenterology
40. 2019 Journal of Urology; Gastroenterology; Case Reports of Pathology; Mol. Can Therapy; JAMA; BMC Cancer; PLoS One
41. 2020 Molecular Therapy; Cancers; Trends in Cancer; J Cellular Mol Med; Neoplasia; Gastroenterology; and Cancers.
42. 2021 British Medical Journal, Gastroenterology, Indian J Med Res
43. 2022 BMC Cancer, Clin Can Res, Qeios
44. 2023 Cells, J Histochem and Cytochem, Nature Communications, Neoplasia, Dig Dis and Sciences
45. 2024 Cell Death and Diff,

TEACHING EXPERINCE:

RESEARCH TRAINING/EDUCATION PROGRAMS DEVELOPED

1. 1998-2008 **PTRN Journal Clubs**: Program of Translational Research in Neoplasia Program, developed together with Drs. Eltoum and Grizzle, in the Anatomic Pathology Division, presented research articles and participated in discussion related to basic and translational research and diagnostics in human cancers.
2. 2001-2009 **Training Fellows from Pathology, Surgery and OBGYN Oncology**: A research consortium was developed together with Drs. Grizzle, Martine Heslin, and Ronald Alvarez to train clinical fellows from these departments. At the end of their training, they present abstracts and publish papers.
3. 2008-2015 **GI Clinical Oncology Research Consortium** was formed together with Drs. Boris Pasche, James Posey, to t**rain Fellows from Hematology Oncology**.

The fellows at the end of training, will present abstracts and posters at national meetings and publish manuscript.

4. 2013-Current **Partnership Research Summer Training Program (PRSTP)**: This program is focused on providing hands-on summer research experience for undergraduate students from minority schools and UAB to conduct cancer research at UAB laboratories.
5. 2016-Current **GBSC-728- Cancer Genomics, Epigenetics & Therapeutics.** Together with Dr. Sooryanarayana Varambally, developed this graduate level course and serve as a ***co-Course Director***.

GRADUATE TEACHING:

1. 2000-2009 **IBS 703** – Graduate Students of Integrative Biomedical Sciences (IBS): as part of ***Molecular Genetics*** **course**.
2. 2000-2008 **Path 700** – Graduate students of Advances in Molecular and Cellular Pathology (MCP) as part of ***Biology of Disease*** **course**.
3. 2001-2009 **Rotating Student of IBS Graduate Program**: Students from this program rotate in my laboratory for Six months. At the end of the rotation the students present their studies to the graduate committee.
4. 2001-2009 **Rotating Student of MCP Graduate Program**: Students from this program rotate in my laboratory for Six months. At the end of the rotation the students present their studies to the graduate committee.
5. 2000-2009 **PREP Student of Pathology** – I have trained and mentored several students of the Pathology PREP Program for 9 years. During this period, students learn several laboratory techniques and work on a research topic and at the end of the 2 months period; they present their findings in the form of a poster.
6. 2002-Current **Graduate Students of Public Health**: Epidemiology and public health issues in cancer research. Course Master - Dr. John Waterbor of UAB-Public Health School.
7. 2010-2011 **UA27, Osher Lifelong Learning Institute**, University of Alabama, Tuscaloosa. Improving Your Health - Colorectal Cancer in Elders, What you need to know? Osher Lifelong Learning Institute, University of Alabama, Tuscaloosa, AL.
8. 2017-Current **GGCS 320** Undergraduate Students, Cancer Genetics
9. 2007-Current **Cancer Education** - Cancer Pathobiology & Clinical Translational Research, the UAB Minority Health Disparity Research Center.
10. 2011-Current **GBS-770** Cancer Biology Course. Graduate level course, UAB
11. 2011-Current **EPI-613/713** Cancer Epidemiology and Prevention, Graduate level course, UAB
12. 2011-Current **GBS 770-01** Pathogenesis and Biology, Graduate Level Course, UAB.
13. 2016-Current **GBSC 728**-Cancer Genomics, Epigenetics and Therapeutics (***Course Co-Director***)

MENTORING/TRAINING

***RESEARCH MENTOR FOR FACULTY MEMBERS*:**

1. 2008 – 2013 *Harvey L. Bumpers*, MD, FACS. Professor of Surgery, Michigan Stage University (*Mentor* for Career Development as part of a funded NIH-U54

	UAB-Tuskegee/Morehouse School of Medicine Partnership grant, when he was a Professor of Surgery, Morehouse School of Medicine, Atlanta, GA). Current Position : Professor of Surgery, Director of Breast Surgery, Michigan State University, Lansing, MI.
2. 2009 - 2012	*Jamie A. Cannon,* M.D., Assistant Professor of Surgery, UAB (*Co-Mentor* for studies funded by NIH-Deept South Network).
3. 2010 – 2013	*Leona Council*, M.D., Assistant Professor of Pathology, UAB (*Mentor* for studies funded by the *Charles Barkley Research Foundation*).
4. 2011 – 2013	*Shantel Hebert-Magee*, M.D., Assistant Professor of Pathology, UAB (*Mentor* for studies funded by the *Charles Barkley Research Foundation*). Current Position : Pathologist, Florida Hospital Laboratories, Orlando, FL.
5. 2012 – 2014	*Clarence Clark, MD*, Assistant Professor of Surgery, Morehouse School of Medicine, Atlanta, GA (as part of U54-Partnership grant).
6. 2011–2015	*Temesgen Samuel, DVM, PhD*, Assistant Professor of Pathology, School of Vetinerary Tuskegee University, Tuskegee, AL (Mentor for the studies included in U54-Full Project). Current Position : Associate Professor of Pathology, School of Vetinerary Tuskegee University, Tuskegee, AL.
7. 2012–2015	*Jesus Salazar, PhD*, Research Instructor, Department of Medicine, UAB. (*Mentor* on studies funded by the *Charles Barkley Research Foundation*). Current Position : Senior Molecular Virologist, Medical Research Council Uganda, Kampala, Uganda.
8. 2013–2015	*Amit Tiwary, PhD*, Assistant Professor of Anatomy, School of Vetinerary Medicine, Tuskegee University (U54-Partnership grant). Current Position : Associate Professor of Pharmacy and Pharmaceutical Sciences, University of Toledo, OH
9. 2012–2016	*Venkat R. Katkoori, PhD, Research Assistant Professor,* Michigan State University, Lansing, MI. (Current Position : Assistant Professor, Department of Surgery, Michigan State University, Lansing, MI)
10. 2016-2018	*Carlo Crotreras, MD*, Assistant Professor, Department of Surgery, UAB (Associate Professor of Surgery, Ohio State University, Columbus, OH).
11. 2013–2018	*Esther Azungwe Suswam, PhD,* Assistant Professor of Pathology, UAB.
12. 2014-2018	*Rongjun Guo MD*, Assistant Professor of Pathology, UAB (Associate Professor, at University of Toledo, OH).
13. 2017-2018	*Sabita Saldana, PhD*, Assistant Professor, Department of Biology, Alabama State University, Montogomery, AL.
14. 2013–2019	*Tiffany Carson PhD,* Assistant Professor, Preventive Medicine, UAB.
15. 2014-2020	*Ravi Paluri, MD*, Assistant Professor, Hematology & Oncology, UAB (Currently Associate Professor at Wake Forest, NC)
16. 2018-2020	*Bunyamin Ozaydin, PhD*, Assistant Professor, Department of Health Services Administration, UAB
17. 2021-2022	*Moh'd Khusham, MD*, Associate Professor, Hematology & Oncology, UAB. (Currently at WASU, St Luise)
18. 2019-2022	*Akin Ojesina, MD, PhD*, Assistant Professor, Department of Epidemiology, UAB (Currently Associate Professor at U. Wisconsin, Madison, WI)
19. 2017-Current	*Sameer Al Diffalha, MD*, Assistant Professor, Department of Pathology, UAB

20. 2019-Current *Goo Lee, MD, PhD*, Assistant Professor, Department of Pathology, UAB
21. 2021-Current *Paul Benson, MD*, Associate Professor, Department of Pathology, UAB
22. 2022-Current *Aishwarya Ravindran, M.D.* Assistant Professor, Hematopathology, UAB

MEDICAL STUDENTS, RESIDENTS, AND CLINICAL FELLOWS:

1. 1995 -1996 *Robert Poczantek* of UAB Medical School, currently Assistant Professor of Rehabilitation Medicine, UAB.
2. 1997-1999 *Omar Danner* of UAB Medical School, currently Associate Professor of Surgery, John Hopkins University.
3. 2002 – 2003 *John Steinhauer*, MD., Department of Pathology, UAB, a Fellow of GI Pathology, M.D. Anderson Cancer Center, Houston TX.
4. 2007 – 2008 *Kelly Mathew*, MD., Department of OBGYN, UAB
5. 2007 – 2010 *Supriya Koya*, MD, Fellow of GI Medical Oncology, Division Hematology & Oncology, UAB
6. 2013-2014 *Caleb Dulaney*, MD, Resident of Internal Medicine, Department of Medicine, UAB.
7. 2013-2015 *Ravikumar Paluri*, MD, Fellow of Medical Oncology, Division Hematology & Oncology, UAB.
8. 2019- 2020 *Anatoly Nikolaev*, MD, PhD., Resident/Fellow of Radiation Oncology, UAB
9. 2022-Current *Falone Amo*a, MD, Resident/Scientist-Track, Dept. Pathology, UAB

UNDER GRADUATE STUDENTS:

Undergraduate Research Training Program: In 2013 a Summer Research Experience Program for Undergraduate Students was developed and overseeing all activities. Till now over 123 undergraduate students are trained. Below list **does not** include these students.

1. 2000 – 2002 *Bernard Gary* of UAB Biology Department, currently working as a Research Assistant, Department of Pathology, UAB.
   Current Position: Research Associate, Southern Research Institute, Birmingham, AL
2. 2002 *Jason Kelly* of UAB Biology Department.
   Current Position: Medical graduate of George Washington University and currently he is a Family Practitioner in Huntsville, AL
3. 2002 *Courtney Lukens* of Auburn University Biomedical Sciences.
   Current Position: A Pediatrician at Childrens' of Alabama.
4. 2003-2004 *Anit Makhija* of UAB Health Related Profession (MSHA).
   Current Position: The Director of Performance Improvement at Children's National Health System, Washington DC.
5. 2003 – 2006 *Courtney Herring* of UAB Honors student.
   Current Position: A Pediatrician at Children's Minnesota.
6. 2004 – 2005 *Adam Carroll* of Biology Department, Samford University, is a PREP student of Pathology, UAB.
   Current Position: An Internist at St. Vincent's, Birmingham, AL
7. 2007-2008 *Rahul Goli* of Biomedical Sciences, University of Pennsylvania.
   Current Position: Cardiology Fellow at UCLA
8. 2008/2009 *Deron Davis* of UAB Biology major, worked for two years in the lab.

Current Position: Family Medicine Doctor, Graduated with MD degree from Uniformed Services University of the Health Sciences F. Edward Hebert School of Medicine, Uniformed Services University, Bethesda, MD.

9. 2009 *Swaroop Vitta*, Undergraduate student of Birmingham Southern College, Birmingham. Current Position: Gastroenterologist, Grandview Hospital, AL.

10. 2010 *Katheryne Bailey* of Mesa State College, Colorado, currently a PREP student of Pathology, UAB. Current Position: A Pediatrician at University of Washington, Washington

11. 2011 *Mohini Gupta*, Undergraduate USA, Mobile., AL.
Current Position: A Pediatrics, Pensacola, FL

12. 2012 *Rishi Gupta*, Undergraduate Emory, GA,
Current Position: Interventional Radiology, Minneapolis, MN

13. 2013 *Saksham Narang*, Summer Intern, Boston University, currently a sophomore at BU. Current Position: A Licensing Associate of UAB BLH Institute for Innovation and Entrepreneurship

14. 2013-2014 *Kevin Narang*, Summer Research Intern from Boston University.
Current Position: A Surgery Resident at University of Washington, St Louise.

15. 2013 *Brittany Holts,* Summer Intern, from Tuskegee University, AL
Current Position: A Postdoctoral fellow at Morehouse School of Medicine

16. 2014 *Helen Bae*, Summer Intern, UAB undergraduate.
Current Position: A Medical Student at UAB.

17. 2016-2017 *Kristen Rutledge,* Undergraduate Student, Department of Nursing, UAB
Current Position: A nurse in the department of surgery, UAB

18. 2015-2018 *Han Yu*, Undergraduate Student, Department of Chemistry, UAB.
Current Position: A DO Student of the New York College of Osteopathic Medicine.

19. 2017-2019 *Akshay Kumar Aluri*, Undergraduate Student, USA, Mobile, AL
Current Position: A Medical Student at UAB

20. 2019-2021 *Emily Tran,* Undergraduate Student, Honors Program, UAB
Current Position: A Clinical Research Specialist at UAB

21. 2019-2021 *Koriann Tiesi,* Undergraduate Student, College of Arts and Sciences, UAB
Current Position: Student, Master of Science, Clinical Laboratory Science/Medical Technologist at UAB

POSTDOCTORAL FELLOWS & THEIR CAREER DEVELOPMENT:

1. 2002 - 2003 *Gandham Mahendra*, Ph.D., Postdoctoral Fellow
Current Position: Associate Scientist, Department of Physiology, University of Utah, Salt Lake City, Utah.

2. 2002 – 2006 *Chakrapani Chatla*, MD, M.PH. Postdoctoral Fellow
Current Position: Senior Scientist of UNICEF and WHO, Pediatric AIDs care and HIV prevention of mother-to-child transmission, program, India.

3. 2002 - 2004 *Catalina Suarez-Cuervo*, MD. Postdoctoral Fellow
Current Position: Research Coordinator, Hem & Oncol, Johns Hopkins, MD.

4. 2003 – 2009 *Xu Jia*, MD, Postdoctoral Fellow
Current Position: Research Associate, University of New York, New York, NY.

5. 2009 – 2011 *Chura Salih*. DMD. Research Associate

Current Position: Research Associate, University of Kansas, KS

6. 2003 – 2012 *Venkat Katkoori*, MS, Ph.D. Research Associate
   Current Position: Assistant Professor, Michigan State University, Lansing, MI
7. 2005 – 2012 *Chandrakumar Shanmugam*, MD. Research Associate
   Current Position : Professor, Bhaskar Collage of Medicine, Hyderabad, India.
8. 2012 – 2013 *Liselle Bovell*, PhD, Postdoctoral Fellow
   Current Position: Science Writer, CDC, Atlanta, GA.
9. 2014–2015 *Samir Amer, MD*, Visiting Fellow, USAID Scholar, Associate Professor of Pathology, National University of Egypt, Cairo, Egypt.
10. 2012–2015 *Balananda Kumar Durjati Putcha*, *PhD*, Research Associate
    Current Position: Scientist III, BioProcess Science at Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO.
11. 2012–2015 *Trafina Jadhav*, *PhD*, Postdoctoral Fellow
    Current Position: Senior Manager, Clinical Development, Clinical Development, TSUMURA & CO., New York, NY.
12. 2014-2015 *Mohammad Abdel Gawwad, MD,* Research Assistant
    Current Position: Postdoctoral fellow, UAB Pathology
13. 2014-2016 *Gaurav Kumar*, *PhD*. Postdoctoral Fellow
    Current Position: Res Associate. University of Virginia, Charlottesville, VA.
14. 2016-2018 *Rajeshwer Singh, MD*, Research Associate
    Current Position: Resident, Family Practice, UAB Selma, AL
15. 2016-2018 *Fang Xiao, PhD*, Research Associate
    Current Position: Research Associate, the University of Toledo, Ohio
16. 2015-2018 *Mohamed Osman, DVM, Researcher I*
    Current Position: Biologist Roche Diagnostics, Bay Area, CA.
17. 2017-2021 *Sumit Agarwal, PhD*, Postdoctoral Fellow
    Current Position: Scientist, Gene Therapy, Cell and Molecular Biology, Immunoassay, Biopharmaceuticals. Thermo Fisher Scientific, St. Louise, MO
18. 2018-2019 *Alsubaie Abduljalil Mohammed, DVM,* Researcher I
    Current Position: Researcher II, UAB
19. 2018-2021 *Michael Behring*, *PhD*, Postdoctoral Fellow
    Current Position: Assistant Professor, Athens State University, Athens, AL
20. 2019-2022 *Amr Elkholy, MS,* Researcher I
    Current Position: Graduate Student, Cancer Biology, UAB

2021-2023 *Achyuth Reddy Dorasala,* Research Assistant (part-time)
Current Position: Researcher, Matrix-IFS, Jersey City, NJ.

21. 2015–2023 *Hyung-Gyoon Kim, PhD.* Researcher V – Retired from UAB
22. 2019-Current *Prachi Bajpai, PhD*, Researcher V
23. 2020-Current *Farrukh Afaq, PhD,* Researcher V
24. 2023-Current *Dennis Otali, PhD*, Researcher V
25. 2021-Current *Aakanksha Singh Parihar,* Research Assistant (part-time)

GRADUATE STUDENTS:

1. 2002 – 2006 *Danyu Lee* of Department of Computer & Information Sciences, UAB (Co-Mentor). PhD Scholar
   Current Position: Managing consultant at IBM Canada, Calgary, Canada Area

2. 2002 – 2005 *Dominik Alexander* of School of Public Health, Cancer Prevention Program, UAB (*Primary Mentor*). PhD Scholar
   Current Position: Principal Epidemiologist, MetaMethod. Ann Arbor, MI.
3. 2004 – 2006 *Qasim Ijaz* of Computer & Information Sciences, UAB (Co-Mentor).
   Current Position: Technology Leader at Amazon Alexa, Seattle. MS student
4. 2006 – 2008 *Dennis Ottali* of Department of Biology, UAB (Co-Primary Mentor).
   Current Position: Research Scientist, UAB Pathology, PhD Scholar
5. 2004 – 2009 *Robert Hines* of School of Public Health, Cancer Prevention Program, UAB (*Primary Mentor*). PhD Scholar
   Current Position: Associate Professor, Department of Population Health, College of Medicine, University Central Florida, Orlando, FL.
6. 2007 – 2012 *Chun Wei Wang* of Department of Physics, UAB (Co-Mentor), MS student
   Current Position: Postdoctoral Fellow, Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL.
7. 2009 - 2012 *Emily Vogtmann* of School of Public Health, Cancer Prevention Program, UAB (Co-Primary Mentor). PhD Scholar
   Current Position: Earl Stadtman Investigator, NCI, Division of Cancer Epidemiology and Genetics, Metabolic Epidemiology Branch, NIH
8. 2008 – 2012 *Liselle Bovell* of Molecular & Cellular Pathology, UAB (*Primary Mentor*). PhD Scholar
   Current Position: Science Writer and Editor, ApotheCom, USA.
9. 2012 – 2014 *Jing Xie,* Department of Genetics, UAB, Graduate Committee Member. MS student
   Current Position: Clinical Laboratory Director at PerkinElmer, Atlanta, GA.
10. 2014–2017 Southern Research Institute, Chair of the Graduate Committee, PhD Scholar.
    Current Position: Senior Clinical Fellow, School of Medicine, University of Washington, Seattle.
11. 2013–2018 *Trevor Carden*, Department of Genetics, UAB, and Graduate Committee Member.
    Current Position: Medical Writer, Teleflex Inc, Morrisville, NC
12. 2013-2018 *Michael P Behring*, School of Public Health, *Primary Mentor*, UAB PhD Scholar
    Current Position: T32 Postdoctoral Fellow, UAB Pathology.
13. 2015-2019 *Kevin Hale*, Post Baccalaureate Student of UAB.
    Current Position: Research Laboratory Assistant, LabCorp, Birmingham, AL
14. 2021-Current Falone Amoa, MD/PhD program, Department of Pathology, UAB

POST-BACCALAUREATE/POST-GRADUATE STUDENTS:

1. 2001 – 2003 *Vinodh Vasudevan, MD,* School of Public Health, UAB. Currently Pediatrician at Phoenix Children's.
2. 2001 – 2002 *Chakrapani Chatla, MD,* School of Public Health, UAB and a Postdoctoral Fellow of Pathology, UAB. Currently is a Public Health Specialist of Novartis
3. 2002 – 2003 *Rajinder Singh, MD* of Department of Pathology, and postdoctoral fellow at UAB. Currently, Professor of Dermatopathology, Mount Sinai St. Luke's and Mount Sinai West, NY

4. 2003 *Sameera Vohra, MD,* School of Public Health, UAB. Currently is an Internist at Baylor Scott & White Health, Austin, TX
5. 2003 – 2005 *Vanita Jain, MD,* School of Public Health, UAB. Currently is a Psychiatrist at University of Utah.
6. 2004 – 2006 *Ram Neelagiri, MD,* School of Public Health, UAB. Currently is a Family Medicine, UNC Primary and Specialty Care at Briercreek, NC
7. 2005 – 2007 *Harpreet Singh*, MD, School of Public Health, UAB
8. 2013 - 2015 *Mohammed Osman*, *DVM*, School of Health Related Professions, UAB. Biologist, Roche Diagnostics, Bay Area, CA.
9. 2017- 2018 *Abduljalil Alsubaie, DVM,* School of Health Related Professions, UAB. Currently a Graduate Student at UAB.

ROTATING GRADUATE STUDENTS:

1. 2003 *Pushkar Phadke* of Molecular and Cellular Pathology graduate program of UAB. Currently consulting pathologist, at Dermpath Diagnostics.
2. 2004 *Pritish Pawar* of Integrated Biomedical Sciences graduate program of UAB. Currenlty, a Neurologist at Foothills Neurology, Phoenix, AZ.
3. *2005* *Courtney L McGauley* of Molecular and Cellular Pathology graduate program of UAB.
4. 2007 *Liselle Bovell* of Integrated Biomedical Sciences graduate program. Currently a medical writer, Atlanta, GA.
5. 2008/2009 *Deron Davis* of Integrated Biomedical Sciences graduate program of UAB. Currenlty a Family Medicine doctor, Bethesda, MD.
6. 2012 *Monica Wielgos*, of Pathobiology and Molecular Medicine program of UAB. Currenlty a Translational Medicine Scientist at Genmab, Princeton, NJ
7. 2012 *Divya Devadasan* of Pathobiology and Molecular Medicine PhD program of UAB. Currently a Global Associate Product Manager, Thermo Fisher Scientific, Ontario, Canada
8. 2012 *Abhishek Gangrade*, of Cancer Biology PhD program of UAB. Research Associate, Biomedical
9. 2021 *Amr Hassanien Ahmed Elkholy,* Students of Can Biology PhD program, UAB.